Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

DOI: 10.1161/01.cir.0000111245.75752.c6
Circulation, 2004, 109, 433-8.

#	Paper	IF	Citations
2252	Characterization of blood pressure and morphological traits in cardiovascular-related organs in 13 different inbred mouse strains. **2004**, 97, 369-76		61
2251	Développement d'un cadre de travail pour comprendre et étudier la fragilité. **2004**, 27 / n° 109, 15		57
2250	Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension. **2004**, 89, 5377-81		27
2249	Targeting metabolic syndrome. **2004**, 13, 1203-6		3
2248	Immunosuppression and metabolic syndrome in renal transplant recipients. **2004**, 2, 263-73		7
2247	The metabolic syndrome: what to treat, how to treat, what are the goals?. **2004**, 2, 191-7		2
2246	Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. **2004**, 14, 443-6		65
2245	Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. **2004**, 24, e19-24		118
2244	Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. *Circulation* , **2004**, 110, 1507-12	16.7	149
2243	Etiology of the Metabolic SyndromeâReply. **2004**, 291, 1443		
2242	Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. *Circulation*, **2004**, 110, 3842-8	16.7	207
2241	Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action. **2004**, 1, 76-81		16
2240	Metabolic syndrome: a definition in progress. *Circulation*, **2004**, 110, e35; author reply e35	16.7	7
2239	Insulin-like growth factor-1 as a vascular protective factor. *Circulation*, **2004**, 110, 2260-5	16.7	203
2238	Screening of newborns for metabolic disorders with mass spectrometry. **2004**, 291, 1444; author reply 1444-5		
2237	Nonpeptide corticotropin-releasing hormone receptor type 1 antagonists and their applications in psychosomatic disorders. **2004**, 80, 111-23		15
2236	Management of type 2 diabetes mellitus: is it time for a paradigm shift?. **2004**, 2, 251-62		2

2235	Low-grade inflammation and microalbuminuria in hypertension. **2004**, 24, 2414-9		74
2234	Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes. **2004**, 58, 867-76		37
2233	Metabolic effects associated with atypical antipsychotic medications. **2004**, 40, 70-2		16
2232	Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. **2004**, 4, 579-91		2607
2231	The metabolic syndrome: diagnosis and treatment. **2004**, 6 Suppl 3, S5-13		12
2230	Metabolic syndrome and other factors associated with increased risk of diabetes. **2004**, 6 Suppl 3, S14-29		6
2229	Diabetes as a risk factor for death following endometrial cancer. **2004**, 94, 740-5		66
2228	Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. **2004**, 47, 1574-80		94
2227	Inflammation, insulin resistance, and obesity. **2004**, 6, 424-31		116
2226	Diabetes in African Americans: unique pathophysiologic features. **2004**, 4, 219-23		28
2225	Five polymorphisms in gene candidates for cardiovascular disease in Afro-Brazilian individuals. **2004**, 18, 309-16		27
2224	Session Summary. **2004**, 30, 851-853		
2223	Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. **2004**, 20, 1437-45		76
2222	Relationship between antihypertensive drugs and metabolic syndrome. **2004**, 2, 308-14		2
2221	Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. *Circulation*, **2004**, 109, 551-6	16.7	639
2220	Secondary prevention strategies in ischemic stroke: identification and optimal management of modifiable risk factors. **2004**, 79, 1330-40		30
2219	[Hypertension and metabolic syndrome]. **2004**, 123, 707-11		6
2218	Guías para el tratamiento de las dislipemias en el adulto: Adult Treatment Panel III (ATP-III). **2004**, 51, 254-265		5

2217	The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome. **2004**, 44, 2003-7	64
2216	What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. **2004**, 34, 371-418	201
2215	Increasing prevalence of the metabolic syndrome among u.s. Adults. **2004**, 27, 2444-9	1106
2214	AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. **2004**, 324, 1204-9	206
2213	Le syndrome mtabolique : comparaison des paramres biologiques dans diffrentes dfinitions. **2004**, 19, 188-194	1
2212	The metabolic syndrome: antecedent of adult cardiovascular disease in pediatrics. **2004**, 145, 427-30	25
2211	The triglyceride-high-density lipoprotein axis: an important target of therapy?. **2004**, 148, 211-21	71
2210	Increased oxidative stress in obesity and its impact on metabolic syndrome. **2004**, 114, 1752-61	3467
2209	The metabolic syndrome and inflammation: association or causation?. **2004**, 14, 228-32	145
2208	Can we identify metabolically healthy but obese individuals (MHO)?. **2004**, 30, 569-72	191
2207	Endocrinopathic laminitis in the horse. **2004**, 3, 45-56	35
2206	Sndrome metabco. **2004**, 9, 1131-1139	
2205	Varo de 49 aos remitido para estudio de hiperlipidemia mixta y elevacio de transaminasas. **2004**, 9, 1163-1165	
2204	L-arginine and hypertension. **2004**, 134, 2807S-2811S; discussion 2818S-2819S	87
2203	Whole grains and coronary heart disease: the whole kernel of truth. **2004**, 80, 1459-60	56
2202	Mirtazapine-Associated Rapid Weight Gain and Decreased Physical Activity. **2004**, 34, 308-309	1
2201	Importance and management of dyslipidemia in the metabolic syndrome. **2005**, 330, 295-302	24
2200	Metabolic syndrome: historical perspectives. **2005**, 330, 264-8	13

2199	The cardiometabolic syndrome as a cardiovascular risk factor. **2005**, 330, 311-8	61
2198	Management of the metabolic syndrome. **2005**, 330, 343-51	14
2197	Introduction to the metabolic syndrome. **2005**, 7, D3-D5	41
2196	The use of very-low-calorie diets (VLCDs) and meal replacements for weight control. **2005**, 379-411	
2195	Reduced glycemic index and glycemic load diets do not increase the effects of energy restriction on weight loss and insulin sensitivity in obese men and women. **2005**, 135, 2387-91	73
2194	Clustering of haemostatic variables and the effect of high cashew and walnut diets on these variables in metabolic syndrome patients. **2005**, 16, 429-37	16
2193	Kidney disease and the metabolic syndrome. **2005**, 330, 319-25	22
2192	CB1 Cannabinoid Receptor Antagonists. **2005**, 103-118	13
2191	Oral glucose tolerance test or metabolic syndrome criteria to predict risk in patients with coronary heart disease?: reply. **2005**, 26, 623-624	1
2190	Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population. **2005**, 6, 5-24	23
2189	Risk factor clusters for metabolic syndrome in coronary heart disease: state of the science. **2005**, 24, 64-9	4
2188	Metabolic syndrome is associated with extension of coronary artery disease in patients with non-ST segment elevation acute coronary syndromes. **2005**, 16, 287-92	18
2187	The metabolic syndrome in women: a growing problem for cardiac risk. **2005**, 20, 427-32	7
2186	Choosing our battles in the overweight/obesity crisis: targeting those who have the most to gain by losing. **2005**, 20, 294-5	
2185	C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: the Minoh Study. **2005**, 69, 386-91	57
2184	Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. **2005**, 68, 779-87	26
2183	Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. **2005**, 7, 430-8	60
2182	Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. **2005**, 7, 675-91	92

2181	Prevalence of the metabolic syndrome in the island of Gran Canaria: comparison of three major diagnostic proposals. **2005**, 22, 1751-6	21
2180	Type 2 diabetes mellitus: a cardiovascular perspective. **2005**, 59, 798-816	38
2179	Insulin resistance in children and adolescents with type 1 diabetes mellitus: relation to obesity. **2005**, 6, 3-4	3
2178	Diagnosis and management of the metabolic syndrome in obesity. **2005**, 6, 283-96	98
2177	Insulin resistance: more important to identify than quantify. **2005**, 10, 597-8	1
2176	Triglycerides + high-density-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the CArdiovascular STudy in the ELderly. **2005**, 35, 604-10	39
2175	Influence of metabolic syndrome on hypertension-related target organ damage. **2005**, 257, 503-13	99
2174	Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. **2005**, 183, 13-30	168
2173	Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. **2005**, 22, 267-71	28
2172	Factors predicting the development of metabolic syndrome and type II diabetes against a background of hypertension. **2005**, 35, 324-9	15
2171	Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. **2005**, 35, 369-74	86
2170	High-density lipoprotein apolipoprotein A-I kinetics in obesity. **2005**, 13, 1008-16	36
2169	Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. **2005**, 37, 243-53	432
2168	Diagnosis of impaired glucose tolerance in hypertensive patients in daily clinical practice. **2005**, 59, 632-8	10
2167	Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. **2005**, 125, 61-7	412
2166	Association of metabolic syndrome with exercise capacity and heart rate recovery in patients with coronary heart disease in the heart and soul study. **2005**, 95, 1175-9	39
2165	Approach to treatment of the patient with metabolic syndrome: lifestyle therapy. **2005**, 96, 15E-21E	52
2164	Functional capacity and cardiovascular assessment: submaximal exercise testing and hidden candidates for pharmacologic stress. **2005**, 96, 11J-19J	7

2163 Assessment of patients at intermediate cardiac risk. **2005**, 96, 2J-10J 17

2162 Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. **2005**, 96, 1674-80 24

2161 The metabolic basis of atherogenic dyslipidemia. **2005**, 7, 27-35 35

2160 A constellation of complications: the metabolic syndrome. **2005**, 7, 36-45 48

2159 Managing cardiovascular risk inpatients with metabolic syndrome. **2005**, 7, 46-51 4

2158 Temas de actualidad en cardiologÍa preventiva: el sÍndrome metabÓlico. **2005**, 5, 13A-23A

2157 PrevenciÓn y tratamiento del sÍndrome metabÓlico. **2005**, 5, 46D-52D

2156 Editorial: should we evaluate insulin sensitivity in rheumatoid arthritis?. **2005**, 35, 5-7 9

2155 Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. **2005**, 42, 1175-83 217

2154 [Metabolic syndrome: diagnosis and dietary intervention]. **2005**, 46, 57-67; quiz 68 6

2153 Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. **2005**, 48, 1359-65 234

2152 The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. **2005**, 48, 1684-99 307

2151 Current Treatment Options for the Metabolic Syndrome. **2005**, 7, 61-74 31

2150 Treatment of the metabolic syndrome: the impact of lifestyle modification. **2005**, 7, 95-102 36

2149 Metabolic syndrome: demographic features, etiology, and clinical management. **2005**, 7, 381-8 3

2148 Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome. **2005**, 7, 457-64 5

2147 Hypertrophy in the female heart. **2005**, 7, 173-7 1

2146 Erectile dysfunction: interrelationship with the metabolic syndrome. **2005**, 5, 64-9 32

2145	Dietary fats and membrane function: implications for metabolism and disease. **2005**, 80, 155-69		259
2144	Regulation of body mass and management of childhood overweight. **2005**, 44, 589-94		13
2143	Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. **2005**, 82, 146-54		2
2142	Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitorâ based or nonnucleoside reverse transcriptase inhibitorâ based antiretroviral therapy. **2005**, 82, 146-154		4
2141	INFLUENCE OF MENOPAUSE ON BLOOD PRESSURE DIPPING IN WOMEN WITH METABOLIC SYNDROME: A CASE-CONTROL STUDY. **2005**, 1, 9-13		
2140	Dynamic genetic architecture of metabolic syndrome attributes in the rat. **2005**, 21, 243-52		32
2139	Prevention of Metabolic Syndrome. **2005**, 48, 1188		1
2138	Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome. **2005**, 25, 2580-6		80
2137	Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. **2005**, 67, 705-13		174
2136	Belgian consensus on metabolic problems associated with atypical antipsychotics. **2005**, 9, 130-7		54
2135	Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. **2005**, 28, 873-7		40
2134	Point: the metabolic syndrome still lives. **2005**, 51, 1352-4		51
2133	Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. **2005**, 28, 132-7		188
2132	Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*, **2005**, 112, 819-27	16.7	81
2131	What a cardiologist needs to know about patients with human immunodeficiency virus infection. *Circulation*, **2005**, 112, 3947-57	16.7	38
2130	Revised Adult Treatment Panel III guidelines and cardiovascular disease mortality in men attending a preventive medical clinic. *Circulation*, **2005**, 112, 1478-85	16.7	19
2129	Diagnostic definitions â metabolic syndrome. **2005**, 5, 115-118		5
2128	Metabolic syndrome and cardiovascular disease. **2005**, 19, 84-93		70

2127	Our passive lifestyle, our toxic diet, and the atherogenic/diabetogenic metabolic syndrome: can we afford to be sedentary and unfit?. *Circulation*, **2005**, 112, 453-5	16.7	101
2126	The metabolic syndrome: requiescat in pace. **2005**, 51, 931-8		278
2125	The prevalence of the metabolic syndrome did not increase in Mexico City between 1990-1992 and 1997-1999 despite more central obesity. **2005**, 28, 2480-5		33
2124	Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. **2005**, 54, 2003-11		117
2123	Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. **2005**, 25, 1268-73		176
2122	Quantitative genetic analysis of the metabolic syndrome in Hispanic children. **2005**, 58, 1243-8		54
2121	Soy protein influences insulin sensitivity and cardiovascular risk in male lean SHHF rats. **2005**, 37, 309-15		19
2120	Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. **2005**, 36, 1366-71		135
2119	Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. **2005**, 353, 2121-34		1172
2118	Exercise, insulin resistance, and hypertension: a complex relationship. **2005**, 3, 60-5		16
2117	Beyond statin therapy: why we need new thinking. **2005**, 21 Suppl 6, S3-8		6
2116	Global risk stratification to improve cardiovascular prevention: integration of traditional risk factors, emerging risk factors, and new, noninvasive cardiovascular imaging. **2005**, 3, 265-8		
2115	Metabolic syndrome: therapeutic considerations. **2005**, 107-33		22
2114	Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. **2005**, 2, 536-43		638
2113	Elevated C-reactive protein augments increased arterial stiffness in subjects with the metabolic syndrome. **2005**, 45, 997-1003		75
2112	Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. **2005**, 54, 1914-25		181
2111	Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat. **2005**, 315, 1020-7		19
2110	Metabolic syndrome, subclinical coronary atherosclerosis, and cardiovascular risk. **2005**, 3, 105-10		9

2109	The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. **2005**, 28, 878-81		219
2108	Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. **2005**, 28, 2211-6		54
2107	Anti-atherogenic effect of insulin in vivo. **2005**, 42, 455-62		17
2106	Clinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension. **2005**, 42, 393-452		4
2105	Critical questions about the metabolic syndrome. *Circulation*, **2005**, 112, 3675-6	16.7	37
2104	Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. **2005**, 64, 1704-11		315
2103	Clinical research in primary stroke prevention: needs, opportunities, and challenges. **2005**, 25, 91-104		14
2102	Metabolic syndrome: is there a pathophysiological common denominator?. **2005**, 94, 75-83		7
2101	Ghrelin improves endothelial function in patients with metabolic syndrome. *Circulation*, **2005**, 112, 2986-92	16.7	158
2100	Haemorheological variables as risk factors of ischaemic heart diseases. **2005**, 26, 624-5; author reply 625		
2099	Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. **2005**, 26, 2032-8		66
2098	Renal manifestations of the metabolic syndrome. **2005**, 20, 861-4		19
2097	A psychodynamic approach to screening for the metabolic syndrome. **2005**, 33, 671-82; discussion 683-7		
2096	Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. **2005**, 39, 55-62		24
2095	Aetiology and consequences of the metabolic syndrome. **2005**, 7, D10-D13		16
2094	Definition of the metabolic syndrome: current proposals and controversies. **2005**, 330, 269-72		48
2093	S□ndrome metab□ico en j□enes: Diagn□tico y tratamiento. **2005**, 58, 3-13		2
2092	The metabolic syndrome. **2005**, 365, 1415-28		4380

2091	Evaluaci□n del riesgo cardiovascular y nuevos factores de riesgo de aterosclerosis. **2005**, 22, 195-203		2
2090	Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. **2005**, 25, 1045-50		285
2089	Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*, **2005**, 112, 2735-52	16.7	8005
2088	Manejo integral del s□ndrome metab□ico. **2005**, 12, 293-302		
2087	LDL cholesterol and global risk stratification in referred hypertensive patients. **2005**, 180, 137-43		12
2086	Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. **2005**, 181, 143-8		35
2085	[Diagnosing metabolic syndrome in primary care,too: Basal glucemia and glycosylated haemoglobin may not be sufficient]. **2005**, 36, 53		
2084	Ultrasonography for the evaluation of visceral fat and the metabolic syndrome. **2005**, 54, 1230-5		31
2083	Place des glitazones dans de futures recommandations cliniques. **2005**, 66, 59-70		0
2082	Polycystic ovary syndrome in adolescence. **2005**, 34, 677-705, x		83
2081	Evaluaci□n del riesgo cardiovascular y nuevos factores de riesgo de aterosclerosis. **2005**, 22, 195-203		
2080	Plasma triglyceride level is an independent predictor of altered left ventricular relaxation. **2005**, 18, 1285-91		34
2079	Le syndrome mtabolique : quelle(s) dfinition(s) pour quel(s) objectif(s) ?. **2005**, 66, 32-44		4
2078	Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. **2005**, 21, 113-9		23
2077	Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. *Circulation*, **2005**, 111, 369-76	16.7	706
2076	Therapy insight: heart disease and the insulin-resistant patient. **2005**, 2, 252-60		9
2075	Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. **2005**, 21, 299-306		18
2074	How to Manage Metabolic Syndrome. **2005**, 12, 231-238		2

2073	Retinoid x receptor heterodimers in the metabolic syndrome. **2005**, 353, 604-15		318
2072	Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. **2005**, 28, 1769-78		1287
2071	A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. **2005**, 25, 2062-8		821
2070	Adipose tissue, inflammation, and cardiovascular disease. **2005**, 96, 939-49		1539
2069	Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. **2005**, 25, 2243-4		177
2068	Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. *Circulation*, **2005**, 112, 3066-72	16.7	1379
2067	Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. *Circulation*, **2005**, 112, 505-12	16.7	361
2066	Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. **2005**, 9, 267-81		95
2065	Probing depth but not attachment level may be associated with the development of impaired glucose tolerance among (40- to 79-year-old) Hisayama residents. **2005**, 5, 231-3		
2064	Smoking and development of type 2 diabetes in patients with decreased functional capacity. **2005**, 104, 275-81		7
2063	Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. **2005**, 105, 319-21		54
2062	Brief review and critical examination of the use of hs-CRP for cardiac risk assessment with the conclusion that it is premature to use this test. **2005**, 356, 1-8		14
2061	Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. **2005**, 27, 1930-41		41
2060	Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis. **2005**, 68 Suppl1, S2-9		33
2059	The metabolic syndrome: a vascular perspective. **2005**, 16, 314-20		11
2058	Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. **2005**, 72, 203-9		42
2057	New therapeutic options for the metabolic syndrome: what's next?. **2005**, 16, 254-60		18
2056	AMPK, the metabolic syndrome and cancer. **2005**, 26, 69-76		355

2055	Interleukin-15 in hypertension: further insights into inflammation and vascular disease. **2005**, 18, 1017-8	7
2054	Low HDL-C: a secondary target of dyslipidemia therapy. **2005**, 118, 1067-77	58
2053	[Metabolic syndrome: a modern variant of stress-related disease?]. **2005**, 58, 768-71	3
2052	[Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia]. **2005**, 125, 481-6	56
2051	An evaluation of the metabolic syndrome in the HyperGEN study. **2005**, 2, 2	34
2050	The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. **2005**, 2, 3	190
2049	Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction. **2005**, 2, 31	143
2048	Clinical utility of extended-release niacin: update and summary. **2005**, 1, 571-8	
2047	The Metabolic Syndrome: a Modern Variant of StressâRelated Disease?. **2005**, 58, 768-771	2
2046	Prevalencia del s□ndrome metab□co en una poblaci□ de pacientes con sobrepeso y obesidad. **2005**, 52, 391-398	0
2045	Transgenic animal models for the study of adipose tissue biology. **2005**, 19, 605-23	31
2044	Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. **2005**, 80, 19-32	885
2043	The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. **2005**, 80, 9-18	157
2042	Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. **2005**, 28, 2745-9	805
2041	The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. **2005**, 28, 2289-304	1574
2040	Oxidative stress in insulin-resistant conditions: cardiovascular implications. **2005**, 4, 343-51	26
2039	Drug Treatment in the Metabolic Syndrome. **2005**, 431-461	1
2038	The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. **2006**, 5, 24	52

2037	Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome. **2006**, 5, 89-99		15
2036	Physical activity and the metabolic syndrome in Canada. **2006**, 31, 40-7		54
2035	The Role of Cardiac Rehabilitation in the Treatment and Secondary Prevention of Cardiovascular Disease. **2006**, 13, 21-27		1
2034	Metabolic Syndrome. **2006**, 13, 185-198		15
2033	Definition of the Metabolic Syndrome: What's New and What Predicts Risk?. **2006**, 4, 237-51		18
2032	[4G/5G polymorphisms of PAI-1 in the metabolic syndrome]. **2006**, 126, 234		
2031	The metabolic syndrome: A high-risk state for cancer?. **2006**, 169, 1505-22		326
2030	Metabolic syndrome and morphofunctional characteristics of the left ventricle in clinically hypertensive nondiabetic subjects. **2006**, 19, 199-205		38
2029	Prevalence of metabolic abnormalities in the Tunisian adults: a population based study. **2006**, 32, 215-21		37
2028	Metabolic syndrome: a marker of patients at high cardiovascular risk. **2006**, 22 Suppl B, 85B-90B		35
2027	ndice tobillo-brazo y riesgo cardiovascular estimado mediante la funci SCORE en sujetos no diabticos en prevenci primaria. **2006**, 18, 45-50		2
2026	Diagnstico de sndrome metabco. Adecuaci de los criterios diagnsticos en nuestro medio. **2006**, 18, 244-260		0
2025	Physical activity and clustered cardiovascular risk in children: a cross-sectional study (The European Youth Heart Study). **2006**, 368, 299-304		1024
2024	Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. *Circulation*, **2006**, 113, 2943-6	16.7	194
2023	Is visceral obesity the cause of the metabolic syndrome?. **2006**, 38, 52-63		443
2022	Tu-W16:8 A structural model for apolipoprotein A-I Milano (A-IM) in its heterodimeric form with apolipoprotein A-II (A-II). **2006**, 7, 154		
2021	Tu-W17:1 Metabolic syndrome in non-diabetic Europeans: Relation to cardiovascular mortality. **2006**, 7, 154		1
2020	Is hyperuricemia another facet of the metabolic syndrome?. **2006**, 69, 104-9		21

2019	Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. **2006**, 186, 345-53	76
2018	Components of the metabolic syndrome and incidence of diabetes in elderly Italians: the Italian Longitudinal Study on Aging. **2006**, 187, 385-92	25
2017	Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. **2006**, 189, 198-205	172
2016	Optimal care of cardiovascular disease and type 2 diabetes patients: shared responsibilities between the cardiologist and diabetologist. **2006**, 7, 37-42	9
2015	Diabetes: assessing the pipeline. **2006**, 7, 43-9	11
2014	Case and care complexity in the medically ill. **2006**, 90, 679-92	59
2013	Hyperlipidemic mice present enhanced catabolism and higher mitochondrial ATP-sensitive K+ channel activity. **2006**, 131, 1228-34	34
2012	El eslabñ perdido del sndrome metablco: hiperlipemia posprandial y estrš oxidativo. **2006**, 53, 345-352	7
2011	[Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population]. **2006**, 126, 406-9	21
2010	[Geographical differences in metabolic syndrome prevalence. The case of Canary Islands (Spain)]. **2006**, 127, 357	
2009	[Classification criteria and clinical significance of the metabolic syndrome]. **2006**, 206, 447-50	1
2008	[Clustering of cardiovascular risk factors and prevalence of metabolic syndrome in subjects with resistant hypertension]. **2006**, 127, 241-5	7
2007	Concurrent presence of metabolic syndrome in obstructive sleep apnea syndrome exacerbates the cardiovascular risk: a sleep clinic cohort study. **2006**, 29, 433-41	45
2006	The effects of changes in the metabolic syndrome detection status on arterial stiffening: a prospective study. **2006**, 29, 673-8	45
2005	Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. **2006**, 47, 2229-36	127
2004	The effects of diet on inflammation: emphasis on the metabolic syndrome. **2006**, 48, 677-85	495
2003	Distribution and metabolic syndrome correlates of plasma C-reactive protein in biracial (black-white) younger adults: the Bogalusa Heart Study. **2006**, 55, 699-705	49
2002	Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. **2006**, 55, 940-5	62

2001	High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome. **2006**, 55, 1014-21		30
2000	Hypothalamic-pituitary-adrenal activity in type 2 diabetes mellitus: role of autonomic imbalance. **2006**, 55, 1135-40		36
1999	Leptin and adiponectin levels in middle-aged postmenopausal women: associations with lifestyle habits, hormones, and inflammatory markers--a cross-sectional study. **2006**, 55, 1630-6		28
1998	A critical reflection on the definition of metabolic syndrome. **2006**, 53, 449-56		16
1997	The metabolic syndrome. Beyond the insulin resistance syndrome. **2006**, 53, 457-68		11
1996	Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE. **2006**, 88, 222-6		53
1995	Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. *Circulation*, **2006**, 113, 898-918	16.7	1889
1994	Diabetes and arterial stiffening. **2007**, 44, 245-251		19
1993	Calcium in Human Health. **2006**,		31
1992	Diet and inflammation: a link to metabolic and cardiovascular diseases. **2006**, 27, 15-20		152
1991	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). **2007**, 28, 88-136		889
1990	Oxidative stress in the metabolic syndrome. **2006**, 29, 791-5		61
1989	A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione scoring. **2006**, 151, 754.e7-754.e17		21
1988	Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. **2006**, 7, 7-11		51
1987	The metabolic syndrome in Spanish migrants to Brazil: unexpected results. **2006**, 72, 75-80		7
1986	Coexistence of insulin resistance and inflammation effectively predicts cardiac disease but not stroke in Japanese patients with type 2 diabetes mellitus. **2006**, 74, 316-21		8
1985	Metabolic syndrome and prediabetes. **2006**, 52, 55-144		15
1984	The metabolic syndrome and its relationship to hypertensive target organ damage. **2006**, 8, 195-201		27

1983	Drug-induced metabolic syndrome. **2006**, 8, 114-9	24
1982	Hypertension--a treatable component of the cardiometabolic syndrome: challenges for the primary care physician. **2006**, 8, 12-20	7
1981	Prevalence of the metabolic syndrome in the United States National Health and Nutrition Examination Survey 1999-2002 according to different defining criteria. **2006**, 8, 562-70	49
1980	Insulin resistance, diabetes, hypertension, and renin-angiotensin system inhibition: reducing risk for cardiovascular disease. **2006**, 8, 713-20; quiz 721-2	22
1979	Managing multiple cardiovascular risk factors: state of the science. **2006**, 8, 12-22	13
1978	Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. **2006**, 45, 299-305	98
1977	Dairy products and the risk to develop type 2 diabetes or cardiovascular disease. **2006**, 16, 1001-1004	18
1976	Elevated circulating levels of markers of oxidative-nitrative stress and inflammation in a genetic rat model of metabolic syndrome. **2006**, 15, 380-6	51
1975	Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients. **2006**, 16, 54-9	44
1974	Normal weight obese (NWO) women: an evaluation of a candidate new syndrome. **2006**, 16, 513-23	138
1973	Retinal vascular manifestations of metabolic disorders. **2006**, 17, 262-8	130
1972	The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation. **2006**, 38, 1440-4	8
1971	The significance of carotid artery atheromas on panoramic radiographs in the diagnosis of occult metabolic syndrome. **2006**, 101, 95-101	17
1970	[Nationwide multicenter study on the prevalence of overweight and obesity in type 2 diabetes mellitus in the Brazilian population]. **2006**, 50, 136-44	22
1969	Severity of Coronary Atherosclerosis; Influence of Metabolic Syndrome Risk Factor Clustering and hs-CRP. **2006**, 36, 802	7
1968	Fatores dietticos na prevenß e tratamento de comorbidades associadas ˆs□ndrome metab□ica. **2006**, 19, 389-401	10
1967	Analysis of the factors contributing to serum retinol binding protein and transthyretin levels in Japanese adults. **2006**, 13, 209-15	34
1966	Nutritional risk and the metabolic syndrome in women: opportunities for preventive intervention from the Framingham Nutrition Study. **2006**, 84, 434-441	62

1965	Obesity: A complication or an opportunity?. **2006**, 17, 125-129	
1964	Type 2 Diabetes. **2006**,	
1963	Effects of etanercept in patients with the metabolic syndrome. **2006**, 166, 902-8	190
1962	Fibrinolysis and diabetic vascular disease: roles of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. **2006**, 1, 429-440	5
1961	Burnout and risk of cardiovascular disease: evidence, possible causal paths, and promising research directions. **2006**, 132, 327-53	545
1960	Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction. **2006**, 110, 673-81	32
1959	Nutritional risk and the metabolic syndrome in women: opportunities for preventive intervention from the Framingham Nutrition Study. **2006**, 84, 434-41	59
1958	Metabolic findings from the CATIE trial and their relation to tolerability. **2006**, 11, 32-9	45
1957	Obesity, Metabolic Syndrome, and the Benefits of Citrus. **2006**, 211-218	
1956	Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). **2006**, 43, 458-66	120
1955	Type 2 diabetes mellitus and its effect on vascular disease. **2006**, 21, 485-92	2
1954	Eating, vascular biology, and atherosclerosis: a lot to chew on. **2006**, 27, 13-4	11
1953	The metabolic syndrome: risk factors and management. **2006**, 21, 306-13	18
1952	Prevalence of the metabolic syndrome in veterans with schizophrenia. **2006**, 12, 5-10	35
1951	Metabolic syndrome negatively impacts early patency of saphenous vein grafts. **2006**, 17, 41-4	28
1950	Identification of the metabolic syndrome and imaging of subclinical coronary artery disease: early markers of cardiovascular risk. **2006**, 21, 291-7	5
1949	Metabolic syndrome increases the risk of significant coronary artery involvement in patients with peripheral artery disease. **2006**, 17, 529-32	10
1948	What is the metabolic syndrome? Prediabetes and cardiovascular risk. **2006**, 21, 285-90	7

1947	The metabolic syndrome: a glance at its history. **2006**, 24, 621-6	108
1946	Medication-induced weight gain and dyslipidemia in patients with schizophrenia. **2006**, 163, 1697-704; quiz 1858-9	29
1945	Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. **2006**, 82, 763-70	19
1944	Is reduced baroreflex gain a component of the metabolic syndrome? Insights from the LINOSA study. **2006**, 24, 361-70	29
1943	Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. **2006**, 17, 431-9	12
1942	The obesity epidemic and its cardiovascular consequences. **2006**, 21, 353-60	72
1941	Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. **2006**, 24, 837-43	64
1940	Nutrition and metabolism: race, sex and the metabolic syndrome. **2006**, 17, 82-4	2
1939	Definitions and mechanisms of the metabolic syndrome. **2006**, 5, 252-259	
1938	Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. **2006**, 1, 129-47	42
1937	Metabolic Syndrome. **2006**,	
1936	[Diagnosis of metabolic syndrome]. **2006**, 95, 1731-6	
1935	Diabetes, gender, and left ventricular structure in African-Americans: the atherosclerosis risk in communities study. **2006**, 4, 43	10
1934	Degradation in insulin sensitivity with increasing severity of the metabolic syndrome in obese postmenopausal women. **2006**, 8, 336-41	15
1933	The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy. **2006**, 8, 365-80	5
1932	Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. **2006**, 8, 603-10	91
1931	Prevalence of silent myocardial ischaemia in new-onset middle-aged Type 2 diabetic patients without other cardiovascular risk factors. **2006**, 23, 775-9	21
1930	Abnormal glucose metabolism and features of the metabolic syndrome are common in patients presenting for elective cardiac catheterization. **2006**, 36, 759-64	7

1929	Vitamin D status and the metabolic syndrome. **2006**, 64, 479-86	132
1928	Association between hormones and metabolic syndrome in older Italian men. **2006**, 54, 1832-8	72
1927	The metabolic syndrome in China. **2006**, 62, 260-3	8
1926	Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. **2006**, 5, 295-309	195
1925	Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. **2006**, 14, 2127-31	162
1924	The effect of moderate alcohol consumption on fat distribution and adipocytokines. **2006**, 14, 60-6	72
1923	Cholesteryl ester transfer protein in metabolic syndrome. **2006**, 14, 812-8	36
1922	Abdominal obesity and metabolic syndrome. **2006**, 444, 881-7	2900
1921	Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes. **2006**, 60, 1376-83	22
1920	Reactive oxygen species production by circulating monocytes: insights from pathophysiology to clinical hypertension. **2006**, 20, 307-9	6
1919	Association of hypertension with single nucleotide polymorphisms in the quantitative trait locus for abdominal obesity-metabolic syndrome on chromosome 17. **2006**, 20, 419-25	7
1918	Prevalence and correlates of metabolic syndrome (MS) in older adults. **2006**, 42, 35-45	28
1917	Metabolic syndrome: screening, diagnosis, and management. **2006**, 51, 141-51	6
1916	Do risk factors influence the diagnostic accuracy of noninvasive coronary angiography with multislice computed tomography?. **2006**, 13, 635-41	16
1915	Women's health and the metabolic syndrome. **2006**, 1092, 33-48	8
1914	Gender differences in the metabolic syndrome and their role for cardiovascular disease. **2006**, 95, 136-47	306
1913	Gender differences in the metabolic syndrome and their role for cardiovascular disease. **2006**, 95, 147-147	12
1912	Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. **2006**, 298, 321-8	458

1911	Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. **2006**, 49, 49-55	72
1910	Genotype of galectin 2 (LGALS2) is associated with insulin-glucose profile in the British Women's Heart and Health Study. **2006**, 49, 673-7	12
1909	Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. **2006**, 49, 1169-74	37
1908	Impact of parental smoking on diabetes, hypertension and the metabolic syndrome in adult men and women in the San Antonio Heart Study. **2006**, 49, 2291-8	16
1907	3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: Part 1. **2006**, 16, 4376-80	26
1906	Surgical risk in patients with metabolic syndrome: focus on lipids and hypertension. **2006**, 8, 433-8	5
1905	Metabolic syndrome in the elderly. **2006**, 6, 64-71	36
1904	Microalbuminuria and proximal tubule remodeling in the cardiometabolic syndrome. **2006**, 1, 107-14	6
1903	Myocardial myocyte remodeling and fibrosis in the cardiometabolic syndrome. **2006**, 1, 326-33	24
1902	Atherogenic dyslipidemia in the cardiometabolic syndrome. **2006**, 1, 153-5	2
1901	Metabolic syndrome and coronary heart disease equivalent conditions in predicting cardiovascular events in young to middle-aged adults. **2006**, 1, 173-7	3
1900	Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). **2006**, 1, 295-300	2
1899	Cardiorespiratory fitness, macronutrient intake, and the metabolic syndrome: the Aerobics Center Longitudinal Study. **2006**, 106, 673-9	58
1898	Position of the American Dietetic Association: the roles of registered dietitians and dietetic technicians, registered in health promotion and disease prevention. **2006**, 106, 1875-84	23
1897	The metabolic syndrome and erectile dysfunction: multiple vascular risk factors and hypogonadism. **2006**, 50, 426-7	27
1896	Physiological dysregulation and changes in health in an older population. **2006**, 41, 862-70	50
1895	Relation of coronary collateral vessel development in patients with a totally occluded right coronary artery to the metabolic syndrome. **2006**, 97, 636-9	34
1894	Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). **2006**, 97, 1332-6	52

1893	Lowered criterion for normal fasting plasma glucose: impact on the detection of impaired glucose tolerance and metabolic syndrome. **2006**, 37, 140-4	5
1892	Association of increased cardiorespiratory fitness with low risk for clustering of metabolic syndrome components in asymptomatic men. **2006**, 37, 522-8	19
1891	Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome. **2006**, 25, 581-7	42
1890	Managing cardiovascular risk in patients with metabolic syndrome. **2006**, 8 Suppl 1, S7-14	6
1889	Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. **2006**, 48, 897-904	101
1888	The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. **2006**, 1, 29-35	38
1887	The cardiometabolic syndrome and cardiovascular disease. **2006**, 1, 25-8	9
1886	Anthropometric features and cardiovascular risk in young Latin Americans with type 2 diabetes mellitus. **2006**, 20, 69-74	3
1885	The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. **2006**, 20, 343-8	28
1884	Evaluating and treating cardiometabolic risk factors: a case discussion. **2006**, 26, 32S-41S	
1883	The metabolic syndrome and cardiometabolic risk: scope of the problem and current standard of care. **2006**, 26, 3S-12S	13
1882	A central role of eNOS in the protective effect of wine against metabolic syndrome. **2006**, 24, 291-8	32
1881	Insulin resistance and impaired beta cell function in rheumatoid arthritis. **2006**, 54, 2765-75	155
1880	Tissue-specific glucocorticoid excess in the metabolic syndrome: 11HSD1 as a therapeutic target. **2006**, 67, 567-569	7
1879	New generation angiotensin II type 1 receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-**2006**, 67, 687-697	4
1878	Insulin resistance in diabetic nephropathy--cause or consequence?. **2006**, 22, 401-10	25
1877	The great metabolic syndrome debate. **2006**, 3, 125-125	
1876	Using endophenotypes for pathway clusters to map complex disease genes. **2006**, 30, 143-54	25

1875	Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH. **2006**, 43, 1169-70	9
1874	Nasobiliary drainage for cholestatic pruritus. **2006**, 43, 1170-1	16
1873	High-sensitivity C-reactive protein, adiposity, and blood pressure in the Yakut of Siberia. **2006**, 18, 766-75	15
1872	How effective is rimonabant at promoting and maintaining weight loss in patients with obesity?. **2006**, 2, 428-429	
1871	Endothelial nitric oxide synthase as a mediator of the positive health effects of Mediterranean diets and wine against metabolic syndrome. **2007**, 97, 33-51	4
1870	The role of lifestyle modification in dysmetabolic syndrome management. **2006**, 11, 197-206	11
1869	Treatment of obesity: a challenging task. **2006**, 151, 212-220	3
1868	Association between the metabolic syndrome and parental history of premature cardiovascular disease. **2006**, 27, 722-8	23
1867	New approaches to atherosclerotic cardiovascular disease. the potentialities of torcetrapib. **2006**, 1, 109-14	2
1866	Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome. **2006**, 91, 3878-84	61
1865	Metabolic syndrome and prediabetes identify overlapping but not identical populations. **2006**, 114, 377-83	14
1864	Lipoproteine und Zielwerte bei Diabetes mellitus. **2006**, 1, 181-186	
1863	Incremental prescription and drug costs during the years preceding diabetes diagnosis in primary care practices in Germany. **2006**, 114, 348-55	11
1862	Metabolic risk factors, drugs, and obesity. **2006**, 354, 974-5; author reply	2
1861	Comparison of metabolic syndrome prevalence using six different definitions in overweight pre-pubertal children enrolled in a weight management study. **2006**, 30, 853-60	80
1860	Preventive Cardiology. **2006**,	
1859	Contribution of CB1 blockade to the management of high-risk abdominal obesity. **2006**, 30 Suppl 1, S44-52	33
1858	The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management. **2006**, 12, 1567-79	10

1857	The Metabolic Syndrome (Emperor) Wears No Clothes. **2006**, 29, 1693-1696		71
1856	The evaluation of the role of beta-hydroxy fatty acids on chronic inflammation and insulin resistance. **2006**, 2006, 64980		6
1855	The etiology of hypertension in the metabolic syndrome part one: an introduction to the history, the concept and the models. **2006**, 4, 293-304		4
1854	Relationship between inflammation, insulin resistance and type 2 diabetes: 'cause or effect'?. **2006**, 2, 195-211		92
1853	Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats. **2006**, 291, H1780-7		105
1852	Statins for diabetic cardiovascular complications. **2006**, 4, 245-51		28
1851	Characteristics and prevalence of the metabolic syndrome among three ethnic groups in Canada. **2006**, 30, 669-76		52
1850	Renal manifestations in the metabolic syndrome. **2006**, 17, S81-5		106
1849	Mutations in the hereditary hemochromatosis gene are not associated with the increased body iron stores observed in overweight and obese women with polycystic ovary syndrome. **2006**, 29, 2556		12
1848	Metabolic Syndrome and Asymptomatic Peripheral Artery Disease in Subjects Over 60 Years of Age. **2006**, 29, 148-150		32
1847	Aortic stiffness, living donors, and renal transplantation. **2006**, 47, 216-21		48
1846	Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. *Circulation*, **2006**, 113, 20-9	16.7	239
1845	Insulin signalling in human adipose tissue. **2006**, 112, 82-8		28
1844	Synergistic acceleration of arterial stiffening in the presence of raised blood pressure and raised plasma glucose. **2006**, 47, 180-8		76
1843	Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. **2006**, 2, 635-46		
1842	Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. *Circulation*, **2006**, 113, 867-75	16.7	100
1841	Polycystic ovary syndrome and the postmenopausal woman. **2006**, 12, 143-8		5
1840	Metabolic abnormalities and risk for colorectal cancer in the physicians' health study. **2006**, 15, 2391-7		102

1839	Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome. **2006**, 29, 1071-1076	103
1838	A UK audit of screening for the metabolic side effects of antipsychotics in community patients. **2007**, 33, 1397-403	103
1837	Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. **2006**, 29, 1697-9	71
1836	Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. **2006**, 29, 625-30	96
1835	Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women. **2006**, 26, 189-93	34
1834	Dyslipidaemia, hypercoagulability and the metabolic syndrome. **2006**, 4, 175-83	37
1833	Role of atherosclerosis assessment and other novel markers in the metabolic syndrome. **2006**, 4, 261-9	
1832	New concepts in dyslipidemia in the metabolic syndrome and diabetes. **2006**, 4, 299-314	2
1831	Hyperlipidemia guideline adherence and association with patient gender. **2006**, 15, 1009-13	4
1830	A high-throughput microfluidic assay for SH2 domain-containing inositol 5-phosphatase 2. **2006**, 4, 175-83	11
1829	Cardiovascular risk and the metabolic syndrome. **2006**, 4, 252-60	13
1828	Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. **2006**, 55, 530-7	138
1827	The metabolic syndrome: recognition and management. **2006**, 9, 16-33	13
1826	Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling. A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells. **2006**, 281, 7727-36	120
1825	A Proposal for the Cutoff Point of Waist Circumference for the Diagnosis of Metabolic Syndrome in the Japanese Population. **2006**, 29, 1123-1124	146
1824	The Metabolic Syndrome (Emperor) Wears No Clothes: Response to Oda. **2006**, 29, 2566-2567	3
1823	Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the Edinburgh Artery Study. **2006**, 29, 637-42	84
1822	Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. **2006**, 29, 685-91	75

1821	The Metabolic Syndrome: How to Approach Differing Definitions. **2006**, 2, 58-62		
1820	The Epidemiology of Alimentary Diseases. **2006**,		
1819	Associations of chronic kidney disease with the metabolic syndrome in non-diabetic elderly. **2006**, 21, 3608-9		10
1818	Background and treatment of metabolic syndrome: a therapeutic challenge. **2006**, 10, 206-14		4
1817	The Metabolic Syndrome: Some Second Thoughts?. **2006**, 24, 38-39		1
1816	Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. **2007**, 20, 41-51		34
1815	Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. **2007**, 30, 1851-6		107
1814	Insulin resistance: link to the components of the metabolic syndrome and biomarkers of endothelial dysfunction in youth. **2007**, 30, 2091-7		83
1813	Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. **2007**, 27, 2043-9		83
1812	Metabolic syndrome, or What you will: definitions and epidemiology. **2007**, 4, 32-8		194
1811	Costs of the metabolic syndrome in elderly individuals: findings from the Cardiovascular Health Study. **2007**, 30, 2553-8		30
1810	Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. **2007**, 30, 113-9		228
1809	Metabolic syndrome: is it a syndrome? Does it matter?. *Circulation*, **2007**, 115, 1806-10; discussion 1811	16.7	126
1808	Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. **2007**, 21, 625-32		43
1807	Pulse hypertension: a new component of the metabolic syndrome in elderly women?. **2007**, 21, 934-41		5
1806	Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study. **2007**, 32, 2369-74		17
1805	Association of metabolic syndrome and insulin resistance with congestive heart failure: findings from the Third National Health and Nutrition Examination Survey. **2007**, 61, 67-73		39
1804	The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. **2007**, 30, 1248-54		116

1803	Contribution of the metabolic syndrome to sudden death risk in asymptomatic men: the Paris Prospective Study I. **2007**, 28, 1149-54		30
1802	Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. **2007**, 28, 2028-40		107
1801	Medical costs of obese Japanese: a 10-year follow-up study of National Health Insurance in Shiga, Japan. **2007**, 17, 424-9		22
1800	The metabolic syndrome and the carotid artery structure in noninstitutionalized elderly subjects: the three-city study. **2007**, 38, 893-9		52
1799	Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study. **2007**, 38, 2063-9		150
1798	Relationship between arterial stiffness and the risk of coronary artery disease in subjects with and without metabolic syndrome. **2007**, 30, 243-7		26
1797	The prevalence of metabolic syndrome in various populations. **2007**, 333, 362-71		153
1796	HIV and metabolic syndrome: a comparison with the general population. **2007**, 45, 426-31		79
1795	Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. **2007**, 46, 283-90		95
1794	Waist-to-hip ratio is associated with pulmonary gas exchange in the morbidly obese. **2007**, 131, 362-7		49
1793	Body composition, metabolic syndrome and testosterone in ageing men. **2007**, 19, 448-57		52
1792	Adiponectin and hypertension: a putative link between adipocyte function and atherosclerotic risk?. **2007**, 21, 1-4		19
1791	The future of metabolic syndrome and cardiovascular disease prevention: polyhype or polyhope? Tales from the polyera. **2007**, 39, 627-31		2
1790	Ceramide and adenosine 5'-monophosphate-activated protein kinase are two novel regulators of 11beta-hydroxysteroid dehydrogenase type 1 expression and activity in cultured preadipocytes. **2007**, 148, 5268-77		24
1789	Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. *Circulation*, **2007**, 115, 1004-11	16.7	130
1788	Chapter 1: Introduction. **2007**, 14, S2-S113		
1787	Poor specificity of fasting plasma glucose cut-off values in ruling out glucose intolerance: the complementary usefulness of OGTT. **2007**, 115, 112-7		7
1786	High capacity homogeneous non-radioactive cortisol detection assays for human 11beta-hydroxysteroid dehydrogenase type 1. **2007**, 5, 105-15		1

1785	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). **2007**, 9, C3-C74		25
1784	Fueling the Heart: Multiple Roles for Cardiac Metabolism. **2007**, 1157-1175		3
1783	Associations between body mass index, cardiorespiratory fitness, metabolic syndrome, and impaired fasting glucose in young, urban native american women. **2007**, 5, 45-54		10
1782	The evolving definitions and increasing prevalence of the metabolic syndrome. **2007**, 32, 23-32		87
1781	The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?. **2007**, 1, 7-26		17
1780	Metabolic syndrome. *Circulation*, **2007**, 115, e32-5	16.7	51
1779	Impact of metabolic syndrome definitions on prevalence estimates: a study in a Portuguese community. **2007**, 4, 320-7		31
1778	Nonfatal acute myocardial infarction in Costa Rica: modifiable risk factors, population-attributable risks, and adherence to dietary guidelines. *Circulation*, **2007**, 115, 1075-81	16.7	36
1777	Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. **2008**, 61, 238-45		43
1776	Insulin resistance, metabolic syndrome, and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). **2007**, 30, 2951-6		78
1775	Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. *Circulation*, **2007**, 116, 2119-26	16.7	73
1774	Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. **2007**, 56, 735-42		57
1773	Local adipose tissue depots as cardiovascular risk factors. **2007**, 75, 690-701		113
1772	Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. **2007**, 44, 726-34		158
1771	Social gradient in the metabolic syndrome not explained by psychosocial and behavioural factors: evidence from the Copenhagen City Heart Study. **2007**, 14, 405-12		35
1770	A case series: evaluation of the metabolic safety of aripiprazole. **2007**, 33, 823-30		52
1769	Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. **2007**, 10, 508-26		47
1768	Ultrasonographic measurement of intra-abdominal fat thickness in HIV-infected patients treated or not with antiretroviral drugs and its correlation to lipid and glycemic profiles. **2007**, 51, 35-41		14

1767	The metabolic syndrome and cerebrovascular disease: suspicion and evidence. **2007**, 24 Suppl 1, 64-75	9
1766	The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. **2007**, 104, 12587-94	490
1765	Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study. **2007**, 14, 192-9	23
1764	Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome. **2007**, 45, 1133-9	22
1763	Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. **2007**, 49, 40-7	194
1762	Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. **2007**, 41, 1345-51	8
1761	Development of diabetes in Chinese with the metabolic syndrome: a 6-year prospective study. **2007** , 30, 1430-6	83
1760	Television viewing is associated with prevalence of metabolic syndrome in Hispanic elders. **2007**, 30, 694-700	61
1759	Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions. **2007**, 30, 872-7	212
1758	Effective cut-off values of waist circumference to detect the clustering of cardiovascular risk factors of metabolic syndrome in Japanese men and women. **2007**, 4, 340-5	28
1757	TRB2, a mouse Tribbles ortholog, suppresses adipocyte differentiation by inhibiting AKT and C/EBPbeta. **2007**, 282, 24075-82	70
1756	Apple Polyphenol Improves Lipid Metabolism and Insulin Independence in Obese Rats. **2007**, 54, 287-294	6
1755	Plasma cytokines, metabolic syndrome, and atherosclerosis in humans. **2007**, 55, 26-35	32
1754	Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. **2007**, 22, 252-60	171
1753	Metabolic syndrome in adolescents with spinal cord dysfunction. **2007**, 30 Suppl 1, S127-39	76
1752	Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. **2007**, 20, 519-27	30
1751	PPAR□its role in the human metabolic syndrome. **2007**, 2, 31-53	10
1750	High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. **2007**, 71, 252-5	53

1749	Metabolic syndrome increases the risk of ischemic stroke in women. **2007**, 46, 643-8	31
1748	Hyperlipidemia in chronic kidney disease. **2007**, 30, 987-92	37
1747	Normal-weight obese syndrome: early inflammation?. **2007**, 85, 40-5	168
1746	Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. **2007**, 25, 833-9	34
1745	Metabolic syndrome: treatment of hypertensive patients. **2007**, 14, 386-402	37
1744	Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication. **2007**, 25, 883-9	10
1743	The metabolic syndrome, the Guy syndrome and the hypofit syndrome. **2007**, 8, 397-8	1
1742	Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. **2007**, 18, 633-7	51
1741	A 74-year-old woman with diabetes. **2007**, 297, 196-204	12
1740	Etiology of the Metabolic Syndrome. **2007**, 3, 232-239	6
1739	Blood pressure control in Italy: results of recent surveys on hypertension. **2007**, 25, 1491-8	103
1738	Managing cardiometabolic risk: an evolving approach to patient care. **2007**, 6, 5-14	6
1737	Does the prevalence of the metabolic syndrome improve by applying the International Diabetes Federation criteria?. **2007**, 10, 1173-80	5
1736	La psoriasis, ¿una enfermedad sistmica?. **2007**, 98, 396-402	24
1735	GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women. **2007**, 142, 138-45	31
1734	Atherothrombosis at a distance: contributing role of existing large-burden vascular disease, circulating biosignals and modulating extravascular tissues. **2007**, 119, 761-8	1
1733	Metabolic syndrome in a multiethnic sample of school children: implications for the pediatric nurse. **2007**, 22, 43-58	4
1732	Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: role of tumor necrosis factor-alpha. **2007**, 17, 274-9	41

1731	Aminotransferase activity in morbid and uncomplicated obesity: predictive role of fasting insulin. **2007**, 17, 442-7	19
1730	Metabolic syndrome is associated with coronary artery calcium in asymptomatic white Brazilian men considered low-risk by Framingham risk score. **2007**, 10, 141-6	11
1729	Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension. **2007**, 9, 530-7	13
1728	2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1. **2007**, 50, 429-32	50
1727	Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk?. **2007**, 153, 67-73	32
1726	Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. **2007**, 20, 784-91	78
1725	Prevalence of the metabolic syndrome in individuals with hyperuricemia. **2007**, 120, 442-7	418
1724	Body weight changes with beta-blocker use: results from GEMINI. **2007**, 120, 610-5	70
1723	Multiple risk factors for cardiovascular disease and diabetes mellitus. **2007**, 120, S3-S11	171
1722	Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. **2007**, 120, S12-8	209
1721	Introduction. **2007**, 120, S1-S2	
1720	Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?. **2007**, 120, S3-8; discussion S9	30
1719	The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: the San Antonio Heart Study. **2007**, 17, 870-7	28
1718	A guideline-driven assessment of need for cardiovascular disease risk intervention in persons with chronic paraplegia. **2007**, 88, 751-7	68
1717	PPARalpha in atherosclerosis and inflammation. **2007**, 1771, 972-82	148
1716	A research and discussion note: The macrostructure of consensus statements. **2007**, 26, 79-89	18
1715	Molecular mechanisms of insulin resistance and associated diseases. **2007**, 375, 20-35	202
1714	The S447X variant of lipoprotein lipase gene is associated with metabolic syndrome and lipid levels among Turks. **2007**, 383, 110-5	24

1713	Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: an Asian-Pacific perspective. **2007**, 75, 255-66	21
1712	In addition to obesity and insulin resistance, microalbuminuria and diminished insulin secretion are linked with the metabolic syndrome in community-dwelling nondiabetic Taiwanese subjects. **2007**, 76, 102-10	1
1711	FABP2 Ala54Thr polymorphism and diabetes in Chilean elders. **2007**, 77, 245-50	21
1710	Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives. **2007**, 104, 312-20	21
1709	Angiotensin II, corticosteroids, type II diabetes and the metabolic syndrome. **2007**, 68, 1200-7	13
1708	Metabolic syndrome, abdominal obesity, and cardiovascular risk in elderly women. **2007**, 114, 224-9	39
1707	Nutritional status, socio-economic status, heart rate, and blood pressure in African school children and adolescents. **2007**, 121, 171-7	26
1706	The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. **2007**, 190, 167-73	84
1705	Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. **2007**, 191, 182-90	114
1704	A low level of C-reactive protein in Japanese adults and its association with cardiovascular risk factors: the Japan NCVC-Collaborative Inflammation Cohort (JNIC) study. **2007**, 194, 238-44	45
1703	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. **2007**, 194, 1-45	190
1702	Understanding essential hypertension from the perspective of the cardiometabolic syndrome. **2007**, 1, 120-34	7
1701	Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. **2007**, 60, 525.e1-525.e64	7
1700	Parámetros antropométricos asociados al riesgo cardiovascular en España. Estudio DORICA. **2007**, 19, 61-69	1
1699	[Treatment of type 2 diabetes: revision of current therapeutical options and priorities]. **2007**, 129, 746-57	
1698	Discovery of acetyl-coenzyme A carboxylase 2 inhibitors: comparison of a fluorescence intensity-based phosphate assay and a fluorescence polarization-based ADP Assay for high-throughput screening. **2007**, 5, 225-35	17
1697	Obstructive Sleep Apnea: Pathophysiology, Comorbidities and Consequences. **2007**,	4
1696	Prevalence and independent predictors of insulin resistance in children from Crete, Greece: the Children Study. **2008**, 25, 65-72	25

1695	Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. **2007**, 14, 133-40	26
1694	Analyzing the frequency and significance of the metabolic syndrome in patients with systemic lupus erythematosus. **2007**, 3, 121-4	
1693	Cardiovascular morbidity and mortality of the metabolic syndrome. **2007**, 91, 1169-84, x	62
1692	Gene expression profile in obesity and type 2 diabetes mellitus. **2007**, 6, 35	37
1691	The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health. **2007**, 6, 20	12
1690	The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress. **2007**, 6, 4	43
1689	Gender differences in dementia risk factors. **2007**, 4, 120-9	120
1688	Medical Treatment of Stable Angina. **2007**, 911-936	
1687	Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. **2007**, 30, 83-8	146
1686	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). **2007**, 14 Suppl 2, E1-40	309
1685	The metabolic syndromeâ□oes it exist?. **2007**, 12, 52-54	
1684	Metabolic syndrome and its association with morbidity and mortality. **2007**, 32, 33-45	26
1683	The metabolic syndrome using the National Cholesterol Education Program and International Diabetes Federation definitions among urbanised black South Africans with established coronary artery disease. **2007**, 12, 6-12	4
1682	Short-term effects of a non-dieting lifestyle intervention program on weight management, fitness, metabolic risk, and psychological well-being in obese premenopausal females with the metabolic syndrome. **2007**, 32, 125-42	46
1681	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). **2007**, 28, 2375-414	1029
1680	Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. **2007**, 50, 204-11	183
1679	National Cholesterol Educational Program and International Diabetes Federation diagnostic criteria for metabolic syndrome in an Italian cohort: results from the FIBAR Study. **2007**, 30, 925-30	8
1678	Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. **2007**, 27, 84-91	619

1677	Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. *Circulation*, **2007**, 115, 2526-32	16.7	343
1676	Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. **2007**, 56, 1010-3		912
1675	Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. **2007**, 4 Suppl B, S162-77		138
1674	Roles of lipid mediators in kidney injury. **2007**, 27, 338-51		29
1673	[Blood screening of glucose and lipid disorders as coronary atherosclerosis risks factors in French adolescents 16 to 19-20 years old]. **2007**, 68, 372-83		1
1672	Controversy in diagnosis and management of the metabolic syndrome. **2007**, 91, 1041-61, vii-viii		14
1671	The metabolic syndrome: how to approach differing definitions. **2007**, 91, 1025-40, vii		29
1670	Management of mental illness in patients with diabetes. **2007**, 34, 713-30, v		3
1669	Chemerin is a novel adipokine associated with obesity and metabolic syndrome. **2007**, 148, 4687-94		600
1668	Geographic and Demographic Variation in the Prevalence of the Metabolic Syndrome in Canada. **2007**, 31, 34-46		6
1667	Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study. **2007**, 56, 348-56		40
1666	Prevalence and cardiovascular disease risk of the metabolic syndrome using National Cholesterol Education Program and International Diabetes Federation definitions in the Korean population. **2007**, 56, 552-8		62
1665	Cardiovascular risk factor levels and their relationships with overweight and fat distribution in children: the Fleurbaix Laventie Ville Sant'Il study. **2007**, 56, 614-22		84
1664	Nuclear magnetic resonance-determined lipoprotein abnormalities in nonhuman primates with the metabolic syndrome and type 2 diabetes mellitus. **2007**, 56, 838-46		26
1663	Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples. **2007**, 56, 969-76		27
1662	Serum sex hormone-binding globulin, a determinant of cardiometabolic disorders independent of abdominal obesity and insulin resistance in elderly men and women. **2007**, 56, 1356-62		35
1661	Maternal smoking-A contributor to the obesity epidemic?. **2007**, 1, I-II		17
1660	Interleukin-1 (IL-1) receptor antagonist gene polymorphism in normal weight obese syndrome: relationship to body composition and IL-1 alpha and beta plasma levels. **2007**, 55, 131-8		52

1659	[Sensitivity and specificity of metabolic syndrome criteria for insulin resistance diagnosis in Spanish population]. **2007**, 128, 168-71	4
1658	Prevalencia del s□ndrome metab□ico en la provincia de Albacete. **2007**, 207, 64-68	23
1657	[Effect of a global intervention in the integral control of multiple risk factors in patients at high or very high cardiovascular risk. CIFARC 2 project]. **2007**, 207, 112-20	7
1656	[Identification, diagnosis and control of patients with abdominal obesity and cardiovascular and metabolic risk factors]. **2007**, 128, 429-37	6
1655	Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. **2007**, 67, 121-53	110
1654	The ESHRE/ASRM consensus on polycystic ovary syndrome (PCOS)--an extended critical analysis. **2007**, 14, 522-35	34
1653	Psoriasis, a Systemic Disease?. **2007**, 98, 396-402	3
1652	Mechanisms by which diabetes increases cardiovascular disease. **2007**, 4, 131-140	60
1651	Glucocorticoid antagonists and 11□HSD1 inhibitors. **2007**, 4, 117-122	2
1650	High frequency of diabetes in early post-partum assessment of women with gestational diabetes mellitus. **2007**, 1, 159-165	5
1649	Metabolic syndrome in rural Bangladesh: Comparison of newly proposed IDF, modified ATP III and WHO criteria and their agreements. **2007**, 1, 251-257	12
1648	CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. **2007**, 49, 442-9	121
1647	High dietary glycemic load and glycemic index increase risk of cardiovascular disease among middle-aged women: a population-based follow-up study. **2007**, 50, 14-21	125
1646	Severe acquired (secondary) high-density lipoprotein deficiency. **2007**, 1, 41-56	20
1645	Prognostic relevance of metabolic syndrome in hypertensive patients at low-to-medium risk. **2007**, 20, 1291-6	27
1644	Inflammation and schizophrenia. **2007**, 7, 789-96	88
1643	The epidemiology of the metabolic syndrome. **2007**, 2, 132-138	
1642	Prevalence of Metabolic Syndrome in Rural Populace: A Study of Its Association With Adipocytokines. **2007**, 55, 449-458	1

1641	The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. **2007**, 29, 330-6	72
1640	[Insulin resistance and secretion assessment across a range of glucose tolerance from normal individuals through diabetes]. **2007**, 51, 1498-505	4
1639	GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES. **2007**, 3, 71-99	1
1638	Association of hormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study. **2007**, 292, E353-8	52
1637	Association between proinsulin, insulin, proinsulin/insulin ratio, and insulin resistance status with the metabolic syndrome. **2007**, 51, 1128-33	9
1636	Prevalence of metabolic syndrome in a rural area of Brazil. **2007**, 125, 155-62	29
1635	[Prevalence and characteristics associated with metabolic syndrome in Japanese-Brazilians with and without periodontal disease]. **2007**, 23, 657-68	26
1634	[Corporal fat distribution and lipidic and glicemic profiles of HIV-infected patients]. **2007**, 51, 42-51	17
1633	The Anti-Obesity Effect of the Palatinose-Based Formula Inslow is Likely due to an Increase in the Hepatic PPAR-alpha and Adipocyte PPAR-gamma Gene Expressions. **2007**, 40, 234-41	25
1632	Type 2 diabetes and cardiovascular disease: reducing the risk. **2007**, 13, S2-15; quiz S16-7	10
1631	Hypertension and Diabetes Mellitus. **2007**, 406-417	2
1630	Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. **2007**, 57, 109-15	316
1629	Metabolic syndrome and mitochondrial function: molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function. **2007**, 100, 1352-69	85
1628	Small, dense low-density-lipoproteins and the metabolic syndrome. **2007**, 23, 14-20	48
1627	Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?. **2007**, 45, 1097-107	95
1626	The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology. **2008**, 47, 361-2	5
1625	Mediterranean diet and the metabolic syndrome. **2007**, 51, 1268-74	52
1624	Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. **2007**, 13, 1109-14	237

1623	Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation. **2007**, 17, 750-5	41
1622	Calpain-5 gene variants are associated with diastolic blood pressure and cholesterol levels. **2007**, 8, 1	26
1621	Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare: The German Metabolic and Cardiovascular Risk Project (GEMCAS). **2007**, 6, 22	55
1620	Effect on hematologic risk factors for coronary heart disease of a cholesterol reducing diet. **2007**, 61, 483-92	18
1619	Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. **2007**, 31, 784-90	50
1618	Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. **2007**, 31, 1119-25	75
1617	Does using ethnic specific criteria improve the usefulness of the term metabolic syndrome? Controversies and suggestions. **2007**, 31, 1340-9	16
1616	Trans fat diet induces abdominal obesity and changes in insulin sensitivity in monkeys. **2007**, 15, 1675-84	154
1615	Deep subcutaneous adipose tissue: a distinct abdominal adipose depot. **2007**, 15, 1933-43	84
1614	Integrin expression and H2O2 production in circulating and splenic leukocytes of obese rats. **2007**, 15, 2209-16	11
1613	Effects of aerobic exercise on metabolic syndrome improvement in response to weight reduction. **2007**, 15, 2478-84	51
1612	Volumetric assessment of epicardial adipose tissue with cardiovascular magnetic resonance imaging. **2007**, 15, 870-8	129
1611	Minimal versus umbilical waist circumference measures as indicators of cardiovascular disease risk. **2007**, 15, 753-9	49
1610	Intake of dietary magnesium and the prevalence of the metabolic syndrome among U.S. adults. **2007**, 15, 1139-46	65
1609	MICRONUTRIENTS, INFLAMMATION AND CONGESTIVE HEART FAILURE AMONG THE ELDERLY: NUTRITIONAL PERSPECTIVES ON PRIMARY PREVENTION AND CLINICAL TREATMENT. **2007**, 34, S14-S16	5
1608	Prevalence of metabolic markers of insulin resistance in offspring of gestational diabetes pregnancies. **2008**, 9, 53-9	23
1607	The prevalence of metabolic syndrome in Japanese renal transplant recipients. **2007**, 12, 413-7	13
1606	Application of classification tree and logistic regression for the management and health intervention plans in a community-based study. **2007**, 13, 741-8	13

1605	Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-alpha receptors, C-reactive protein and adiponectin in morbidly obese patients. **2007**, 67, 679-86	63
1604	Specialist health visitor-led weight management intervention in primary care: exploratory evaluation. **2007**, 58, 23-34	11
1603	Predicting the Prevalence of Cardiometabolic Risk Factors When Clinical Data Are Limited. **2007**, 10, S4-S11	5
1602	Metabolic Syndrome and Employer Sponsored Medical Benefits: An Actuarial Analysis. **2007**, 10, S21-S28	14
1601	Features of metabolic syndrome in non-diabetic Italians and Brazilians: a discriminant analysis. **2007**, 61, 32-8	12
1600	Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. **2008**, 62, 287-99	14
1599	The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. **2007**, 99, 208-12	52
1598	Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome. **2007**, 99, 667-72	29
1597	Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. **2007**, 99, 27B-40B	109
1596	Combined effect of high low-density lipoprotein cholesterol and metabolic syndrome on subclinical coronary atherosclerosis in white men without clinical evidence of myocardial ischemia. **2007**, 100, 840-3	13
1595	Metabolic syndrome: an evolving threat in the genesis of coronary artery disease. **2007**, 2, 190-7	4
1594	Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity. **2007**, 17, 35-43	18
1593	Racial and Ethnic Differences in the Presentation of Metabolic Syndrome. **2007**, 3, 229-239	5
1592	GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. **2007**, 50, 552-8	25
1591	High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. **2007**, 8 Suppl 6, S14-23	17
1590	Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes. **2007**, 8 Suppl 7, S7-18	32
1589	Metabolic consequences of hyperglycemia and insulin resistance. **2007**, 8 Suppl 7, S30-42	64
1588	Frequency of Pro12Ala-polymorphism of the gene PPAR in the Ukrainian population and its possible relation to the development of the metabolic syndrome. **2007**, 41, 298-302	4

1587	Calcifications in the abdominal aorta predict fractures in men: MINOS study. **2008**, 23, 95-102	79
1586	Metabolic syndrome and cardiovascular disease: challenges and opportunities. **2007**, 30, 593-7	25
1585	Prepregnancy body mass index, hypertensive disorders of pregnancy, and long-term maternal mortality. **2007**, 197, 490.e1-6	43
1584	Vinegar-processed ginseng radix improves metabolic syndrome induced by a high fat diet in ICR mice. **2007**, 30, 587-95	27
1583	[Assessment of the natural history of coronary artery calcification and identification of its determinants. Rationale of the 2nd part of the Heinz Nixdorf Recall Study]. **2007**, 32, 108-20	11
1582	Gender and genetic differences in bladder smooth muscle PPAR mRNA in a porcine model of the metabolic syndrome. **2007**, 302, 43-9	14
1581	Obstructive sleep apnea syndrome is associated with metabolic syndrome rather than insulin resistance. **2007**, 11, 23-30	33
1580	Assessing obesity and other related health problems of mentally ill Hispanic patients in an urban outpatient setting. **2007**, 78, 171-81	19
1579	Insulin resistance in children and adolescents. **2006**, 7, 141-7	39
1578	Un Corazñ Saludable: factors influencing outcomes of an exercise program designed to impact cardiac and metabolic risks among urban Latinas. **2007**, 32, 401-12	27
1577	Clinical usefulness of quantitative evaluation of visceral fat by ultrasonography. **2007**, 34, 151-7	3
1576	Favorable effects of non-instrumental resistance training on fat distribution and metabolic profiles in healthy elderly people. **2007**, 99, 549-55	35
1575	Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. **2007**, 26, 1495-8	169
1574	Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislauferkrankungen (DLL-KardReha). **2007**, 2, 1-54	24
1573	The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications. **2007**, 4, 126-34	16
1572	The metabolic syndrome in hypertension: diagnostic and therapeutic implications. **2007**, 9, 305-13	6
1571	Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. **2007**, 22 Suppl 3, 391-5	735
1570	Resolution of diabetes mellitus and metabolic syndrome following Roux-en-Y gastric bypass and a variant of biliopancreatic diversion in patients with morbid obesity. **2007**, 17, 176-84	70

1569	Effects of dietary fibers on disturbances clustered in the metabolic syndrome. **2008**, 19, 71-84	324
1568	Relation of morning serum cortisol to prothrombotic activity in women with stable coronary artery disease. **2008**, 25, 165-72	24
1567	Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. **2008**, 25, 207-13	21
1566	Metabolic syndrome in sub-Saharan Africa: "smaller twin" of a region's prostatic diseases?. **2008**, 40, 909-20	12
1565	Do statins reduce events in patients with metabolic syndrome?. **2008**, 10, 39-44	7
1564	HIV therapy, metabolic syndrome, and cardiovascular risk. **2008**, 10, 61-70	52
1563	Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. **2008**, 10, 131-7	121
1562	Remission of metabolic syndrome: a study of 140 patients six months after Roux-en-Y gastric bypass. **2008**, 18, 601-6	16
1561	Preoperative gender differences in pulmonary gas exchange in morbidly obese subjects. **2008**, 18, 1587-98	18
1560	Management of the metabolic syndrome in cardiovascular disease. **2008**, 10, 27-38	1
1559	Assessment of minerals in obesity-related diseases in the Chandigarh (India) population. **2008**, 121, 106-23	5
1558	Relation between central adiposity and cognitive function in the Maine-Syracuse Study: attenuation by physical activity. **2008**, 35, 341-50	63
1557	The cardiometabolic syndrome and chronic kidney disease. **2008**, 2, 95-100	
1556	Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. **2008**, 22, 2670-8	60
1555	Investigating the association between K198N coding polymorphism in EDN1 and hypertension, lipoprotein levels, the metabolic syndrome and cardiovascular disease. **2008**, 123, 307-13	15
1554	Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. **2008**, 7, 35	62
1553	Dietary procyanidins lower triglyceride levels signaling through the nuclear receptor small heterodimer partner. **2008**, 52, 1172-81	61
1552	Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with insulin sensitivity: a population-based study. **2008**, 24, 378-83	28

1551	Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. **2008**, 47, 1118-27	46
1550	Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. **2008**, 47, 1158-66	105
1549	Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. **2008**, 48, 2085; author reply 2085-6	3
1548	Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling. **2008**, 18, 1340-5	44
1547	Importancia del runoff distal en la revascularizaci endoluminal de la arteria femoral superficial en claudicantes. **2008**, 22, 862-871	
1546	Implicaciones funcionales de la lesi parenquimatosa tras angioplastia de la arteria renal. **2008**, 22, 854-861	
1545	Resultados del tratamiento endoluminal para la enfermedad ostial de las ramas principales del cayado a tico. **2008**, 22, 423-430	
1544	Discussion: â lactation and midlife metabolic syndromeâ by Ram et al. **2008**, 198, e1-e6	1
1543	Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. **2008**, 118, 26-33	54
1542	An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?. **2008**, 62, 799-809	53
1541	Self-reported prevalence and awareness of metabolic syndrome: findings from SHIELD. **2008**, 62, 1168-76	37
1540	Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant. **2008**, 32, 1363-72	23
1539	Longitudinal preventive-screening cutoffs for metabolic syndrome in adolescents. **2008**, 32, 1506-12	15
1538	The metabolic syndrome and cardiovascular risk in the British Regional Heart Study. **2008**, 32 Suppl 2, S25-9	22
1537	Relationship between sleep duration and the metabolic syndrome: Korean National Health and Nutrition Survey 2001. **2008**, 32, 1091-7	127
1536	Threshold values of high-risk echocardiographic epicardial fat thickness. **2008**, 16, 887-92	178
1535	SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. **2008**, 40, 437-42	563
1534	Metabolic syndrome. **2008**, 21, 362-75	5

1533	Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. **2008**, 10, 617-25	14
1532	Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. **2008**, 8, 30	7
1531	Protective effects of a compound herbal extract (Tong Xin Luo) on free fatty acid induced endothelial injury: implications of antioxidant system. **2008**, 8, 39	15
1530	Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. **2008**, 101, 193-8	34
1529	Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. **2008**, 101, 1599-1605	49
1528	Relation of epicardial and pericoronary fat to coronary atherosclerosis and coronary artery calcium in patients undergoing coronary angiography. **2008**, 102, 380-5	206
1527	Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance. **2008**, 53, 1272-80	32
1526	Editorial comment on: daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance. **2008**, 53, 1280-1	
1525	The evidence for dietary prevention and treatment of cardiovascular disease. **2008**, 108, 287-331	230
1524	Complementary and alternative medicine and the management of the metabolic syndrome. **2008**, 108, 495-509	34
1523	Serum folate is associated with coronary heart disease independently of homocysteine in Turkish men. **2008**, 27, 732-9	7
1522	Association of metabolic syndrome with cognitive function: the role of sex and age. **2008**, 27, 747-54	46
1521	Impact of obesity on the pathogenesis and prognosis of coronary heart disease. **2008**, 3, 162-7	36
1520	The metabolic syndrome adds incremental value to the Framingham risk score in identifying asymptomatic individuals with higher degrees of inflammation. **2008**, 3, 7-11	3
1519	Postpartum adiponectin concentration, insulin resistance and metabolic abnormalities among women with pregnancy-induced disturbances. **2008**, 11, 106-15	10
1518	Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002. **2008**, 152, 165-70	244
1517	Risk factors associated with different stages of atherosclerosis in Colombian patients with rheumatoid arthritis. **2008**, 38, 71-82	36
1516	Exercise for preventing childhood obesity. **2008**, 19, 205-16, vii	25

1515	Dietary Interventions. **2008**, 39-71		
1514	Intra-abdominal fat and metabolic syndrome are associated with larger infrarenal aortic diameters in patients with clinically evident arterial disease. **2008**, 48, 114-20		13
1513	The long-term outcomes of percutaneous therapy for renal artery fibromuscular dysplasia. **2008**, 48, 865-71		73
1512	Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. **2008**, 57, 207-14		52
1511	Endothelial dysfunction and serum fatty acid composition in patients with type 2 diabetes mellitus. **2008**, 57, 1167-72		17
1510	Uric acid and the development of metabolic syndrome in women and men. **2008**, 57, 845-52		223
1509	Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. **2008**, 57, 1278-85		19
1508	Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome. **2008**, 57, 1539-44		52
1507	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. **2008**, 101, 273-86		222
1506	Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. **2008**, 61, 82.e1-82.e49		14
1505	[Definition and current situation of cardiometabolic risk]. **2008**, 208, 63-5		3
1504	[Comparison of the definitions of the metabolic syndrome according to ATP III and IDF]. **2008**, 208, 333-8		4
1503	Prevalencia de obesidad, diabetes, hipertensión, hipercolesterolemia y síndrome metabólico en adultos mayores de 50 años de Sanlúcar de Barrameda. **2008**, 61, 1150-1158		25
1502	The underlying mechanisms for development of hypertension in the metabolic syndrome. **2008**, 7, 10		93
1501	Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. *Circulation*, **2008**, 118, 346-54	16.7	778
1500	Blockade of glucocorticoid excess at the tissue level: inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes. **2008**, 51, 4851-7		47
1499	Prevalence of Obesity, Diabetes, Hypertension, Hypercholesterolemia, and Metabolic Syndrome in Over 50-Year-Olds in Sanlúcar de Barrameda, Spain. **2008**, 61, 1150-1158		1
1498	Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. **2008**, 51, 1775-83		263

1497	Metabolic syndrome and dyslipidemia in youth. **2008**, 2, 147-55	5
1496	The rat as a model for cardiovascular disease. **2008**, 5, 173-178	5
1495	The comparison of the metabolic syndrome between Chinese vegetarians and omnivores. **2008**, 2, 99-104	3
1494	Wild-Type Food in Health Promotion and Disease Prevention. **2008**,	5
1493	Cigarette smoking associates with body weight and muscle mass of patients with rheumatoid arthritis: a cross-sectional, observational study. **2008**, 10, R59	28
1492	Metabolic syndrome in permanent night workers. **2008**, 25, 443-54	139
1491	Rŝultats du traitement endovasculaire des lŝions ostiales des troncs supra-aortiques. **2008**, 22, 419-426	
1490	Implications of acute functional injury following percutaneous renal artery intervention. **2008**, 22, 783-9	19
1489	Percutaneous superficial femoral artery interventions for claudication--does runoff matter?. **2008**, 22, 790-8	36
1488	Antipsychotic Medicationâ□nduced Weight Gain and Risk for Diabetes and Cardiovascular Disease. **2007**, 223-245	1
1487	Hyperlipidemia Management for Primary Care. **2008**,	3
1486	Physical Activity: Physical Activity and the Metabolic Syndrome: A Review of the Evidence. **2008**, 2, 118-125	26
1485	HIV and the menopause. **2008**, 14, 163-8	19
1484	[Abdominal obesity: a health threat]. **2008**, 37, 1407-14	5
1483	Huang-Lian-Jie-Du-Tang inhibits myocardial remodeling in a rat model of metabolic syndrome. **2008** , 119, 259-65	11
1482	The relative value of metabolic syndrome and cardiovascular risk score estimates in premature acute coronary syndromes. **2008**, 155, 534-40	11
1481	Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. **2008**, 121, 149-157.e2	175
1480	A prospective study of determinants of the metabolic syndrome in adults. **2008**, 18, 567-73	44

1479	The role of urotensin II in the metabolic syndrome. **2008**, 29, 859-67	45
1478	The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. **2008**, 94, 206-18	370
1477	Metabolic syndrome and cancer risk. **2008**, 44, 293-7	155
1476	Diabetes exacerbates angiographic coronary lesion progression in subjects with metabolic syndrome independent of CRP levels. **2008**, 388, 41-5	20
1475	Visceral fat thickness in overweight men correlates with alterations in serum fatty acid composition. **2008**, 398, 57-62	20
1474	Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. **2008**, 7, 125-34	337
1473	Clinical significance of the metabolic syndrome in the absence of established hypertension and diabetes: A community-based study. **2008**, 79, 461-7	24
1472	Impaired early insulin secretion in Japanese type 2 diabetes with metabolic syndrome. **2008**, 79, 482-9	14
1471	Prevalence of type 2 diabetes among women with a previous history of gestational diabetes mellitus. **2008**, 81, 124-9	45
1470	Fatty liver and chronic inflammation in Chinese adults. **2008**, 81, 202-8	12
1469	No correlation and low agreement of imaging and inflammatory atherosclerosis' markers in familial hypercholesterolemia. **2008**, 200, 83-8	34
1468	High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection. **2008**, 201, 434-9	32
1467	Impaired coronary flow reserve in patients with metabolic syndrome. **2008**, 201, 112-6	42
1466	Metabolic syndrome, haemostasis and thrombosis. **2008**, 99, 995-1000	134
1465	[Association of age, inflammatory markers and subclinical atherosclerosis in subjects free from cardiovascular disease]. **2008**, 131, 361-6	1
1464	Consquences des lsions fonctionnelles aigus aprs revascularisation rhale percutane. **2008**, 22, 853-860	
1463	Outcomes of endoluminal therapy for ostial disease of the major branches of the aortic arch. **2008**, 22, 388-94	13
1462	Serum urate, metabolic syndrome, and cardiovascular risk factors. A population-based study. **2008**, 27, 620-3	27

1461	The metabolic syndrome--from insulin resistance to obesity and diabetes. **2008**, 37, 559-79, vii	59
1460	Traitement endovasculaire pour claudication intermittente des lésions de l'artère fémorale superficielle: le lit d'aval joue-t-il un rôle?. **2008**, 22, 861-870	
1459	Relationship between the metabolic syndrome and physical activity energy expenditure: a MONET study. **2008**, 33, 309-14	13
1458	Cardiovascular Risk Management in Clinical Practice. **2008**, 15, 9-16	3
1457	2008 white paper for implementing strategies and interventions for cardiovascular prevention in Italy. **2008**, 15, 63-73	3
1456	Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. **2008**, 17, 849-59	62
1455	Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort. **2008**, 22, 941-5	30
1454	Psoriasis comorbidities. **2008**, 19, 5-21	183
1453	Asymptomatic hyperuricemia: impact of ultrasonography. **2008**, 27, 592-5	104
1452	Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults. **2008**, 46, 778-84	31
1451	Obesity: effects on cardiovascular disease and its diagnosis. **2008**, 21, 562-8	56
1450	Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). **2008**, 168, 207-17	80
1449	Relationship between brachial artery flow-mediated dilatation, hyperemic shear stress, and the metabolic syndrome. **2008**, 13, 263-70	31
1448	Is schizophrenia a syndrome of accelerated aging?. **2008**, 34, 1024-32	195
1447	The Metabolic Syndrome in Clinical Practice. **2008**,	17
1446	Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol. **2008**, 158, 53-60	31
1445	Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. **2008**, 57, 340-7	198
1444	Metabolic syndrome and incident diabetes: current state of the evidence. **2008**, 31, 1898-904	385

1443	Themed Review: Lifestyle Treatment of the Metabolic Syndrome. **2008**, 2, 99-108	7
1442	Gender differences in cardiovascular disease prevention. **2008**, 14, 13-7	7
1441	Trends in metabolic syndrome and gene networks in human and rodent models. **2008**, 8, 198-207	14
1440	The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity. **2008**, 63, 414-9	78
1439	Cardiovascular disease risk profiles in women with histories of gestational diabetes but without current diabetes. **2008**, 112, 875-83	37
1438	Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. **2009**, 30, 107-15	81
1437	From individual risk factors and the metabolic syndrome to global cardiometabolic risk. **2008**, 10, B24-B33	27
1436	Mediterranean food and diets, global resource for the control of metabolic syndrome and chronic diseases. **2008**, 98, 150-73	10
1435	Pulse wave velocity is associated with metabolic syndrome components in CAPD patients. **2008**, 28, 641-6	23
1434	Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. **2009**, 24, 710-7	91
1433	Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. **2008**, 103, 3005-10	100
1432	Nodular glomerulosclerosis in a patient with metabolic syndrome without diabetes. **2008**, 4, 639-42	13
1431	The metabolic syndrome: definitions, prevalence and management. **2008**, 1, 100-8	38
1430	Metabolic syndrome in the Philippine general population: prevalence and risk for atherosclerotic cardiovascular disease and diabetes mellitus. **2008**, 5, 36-43	35
1429	Optimal cutoff point of waist circumference and use of home blood pressure as a definition of metabolic syndrome: the Ohasama study. **2008**, 21, 514-20	21
1428	Dairy product consumption and the metabolic syndrome. **2008**, 21, 148-57	89
1427	Platelet counts and platelet activation markers in obese subjects. **2008**, 2008, 834153	57
1426	Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. **2008**, 47, 1567-70	140

1425	Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. **2008**, 294, E52-60		60
1424	Biological specificity of visceral adipose tissue and therapeutic intervention. **2008**, 114, 277-86		38
1423	Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. **2008**, 28, 2195-201		112
1422	Adaptations to climate in candidate genes for common metabolic disorders. **2008**, 4, e32		204
1421	Comparison of two point-of-care lipid analyzers for use in global cardiovascular risk assessments. **2008**, 42, 633-9		59
1420	Does diagnosis of metabolic syndrome predict the likelihood of peripheral arterial disease as defined by a low ankle-brachial index?. **2008**, 15, 693-7		5
1419	Lower extremity vein graft failure: a translational approach. **2008**, 13, 63-74		50
1418	Obesity and the lung: 5. Obesity and COPD. **2008**, 63, 1110-7		196
1417	Short-term high fat-feeding results in morphological and metabolic adaptations in the skeletal muscle of C57BL/6J mice. **2008**, 32, 360-9		102
1416	Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. *Circulation*, **2008**, 118, 277-83	16.7	282
1415	Nutrition Review: Diet and Metabolic Syndrome. **2008**, 2, 113-117		5
1414	Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. **2008**, 28, 1039-49		1009
1413	Oxidized LDL and the metabolic syndrome. **2008**, 3, 637-649		83
1412	Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). **2008**, 31, 353-60		87
1411	Obesity and non-insulin-dependent diabetes mellitus in Swiss-Webster mice associated with late-onset hepatocellular carcinoma. **2008**, 199, 21-32		15
1410	Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. **2008**, 116, 184-9		23
1409	Management of new-onset diabetes mellitus after transplantation. **2008**, 120, 60-6		3
1408	Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. **2008**, 93, 139-46		224

1407	Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. **2008**, 168, 1568-75	306
1406	Relationship between metabolic syndrome and its components with coronary heart disease in Iranian men and women. **2008**, 116, 525-31	10
1405	Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. **2008** , 40, 383-94	14
1404	Prioritization of candidate disease genes for metabolic syndrome by computational analysis of its defining phenotypes. **2008**, 35, 55-64	21
1403	Gene expression profiling of skeletal muscle in exercise-trained and sedentary rats with inborn high and low VO2max. **2008**, 35, 213-21	24
1402	Hyperglycemia management in the hospital: about glucose targets and process improvements. **2008**, 120, 38-50	9
1401	Nonalcoholic fatty liver disease: from clinical recognition to treatment. **2008**, 2, 59-79	10
1400	Predictive value of prehypertension for metabolic syndrome, diabetes, and coronary heart disease among Turks. **2008**, 21, 890-5	35
1399	Metabolic syndrome status changes with fitness level change: a retrospective analysis. **2008**, 6, 8-14	9
1398	Does prevalence of the metabolic syndrome in women with coronary artery disease differ by the ATP III and IDF criteria?. **2008**, 17, 841-7	17
1397	Metabolic syndrome: prevalence among American Indian and Alaska native people living in the southwestern United States and in Alaska. **2008**, 6, 267-73	32
1396	Comparison of body fat estimation using waist:height ratio using different 'waist' measurements in Australian adults. **2008**, 100, 1135-41	31
1395	Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. **2008**, 48, 272-80	63
1394	Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. **2008**, 114, 611-24	194
1393	Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. **2008**, 115, 1-12	57
1392	Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. **2008**, 111, 4456-62	73
1391	Association between socioeconomic status and metabolic syndrome in women: testing the reserve capacity model. **2008**, 27, 576-83	91
1390	Polychlorinated biphenyl-77 induces adipocyte differentiation and proinflammatory adipokines and promotes obesity and atherosclerosis. **2008**, 116, 761-8	222

1389	Non-high-density lipoprotein cholesterol in patients with metabolic syndrome. **2008**, 56, 931-6	12
1388	The Roles of Abnormal Renal Sodium Handling in Hypertension Associated with Metabolic Syndrome. **2008**, 4, 197-202	1
1387	The metabolic syndrome in hypertension: European society of hypertension position statement. **2008**, 26, 1891-900	92
1386	Effect of exercise training intensity on abdominal visceral fat and body composition. **2008**, 40, 1863-72	216
1385	The role of increased gastrointestinal alcohol production in patients with the metabolic syndrome: Implications for the pathogenesis of non-alcoholic fatty liver disease. **2008**, 13, 48-56	1
1384	Is Metabolic Syndrome X a Disorder of the Brain?. **2008**, 4, 73-108	9
1383	Impact of metabolic syndrome in patients with acute coronary syndrome. **2008**, 45, 114-126	8
1382	Is the metabolic syndrome a disease of the foregut? Yes, excessive foregut. **2008**, 247, 1074-5	9
1381	Evidence for no global effect of metabolic syndrome per se on early hypertensive sequelae. **2008**, 26, 773-9	12
1380	Impact of metabolic syndrome on the outcome of patients with stable coronary artery disease: 2-year follow-up of the MASS II study. **2008**, 19, 383-8	8
1379	Management of metabolic syndrome in young population. **2008**, 15, 356-61	7
1378	Aerobic exercise and postprandial lipemia in men with the metabolic syndrome. **2008**, 40, 2105-11	29
1377	Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. **2008**, 22, 849-56	24
1376	Giving dietary advice. **2008**, 19, 602-606	
1375	Lipodystrophic syndrome in children and adolescents infected with the human immunodeficiency virus. **2008**, 12, 342-8	19
1374	Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction. **2008**, 87, 1932-8	15
1373	Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. **2008**, 4, 443-51	5
1372	Metabolic Regulation of Nuclear Receptors. **2008**, 23, 155	

1371	White coat hypertension in definition of metabolic syndrome. **2008**, 49, 449-57	9
1370	. **2008**,	7
1369	Effects of chromosome 17 on features of the metabolic syndrome in the Lyon hypertensive rat. **2008**, 33, 212-7	14
1368	Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease. **2008**, 4, 825-36	42
1367	Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy. **2009**, 5, 801-10	11
1366	Marcadores de aterosclerosis temprana y s□ndrome metab□ico en ni□s. **2009**, 137,	6
1365	[Sodium intake and metabolic syndrome: a systematic review]. **2009**, 53, 608-16	6
1364	Empirical evidence for "syndrome Z": a hierarchical 5-factor model of the metabolic syndrome incorporating sleep disturbance measures. **2009**, 32, 615-22	56
1363	[A multidimensional exploration of metabolic syndrome components]. **2009**, 25, 1073-82	2
1362	Association of Diabetes Mellitus and Metabolic Syndrome with Idiopathic Pulmonary Fibrosis. **2009**, 67, 113	5
1361	Metabolic syndrome and cardiovascular disease in South Asians. **2009**, 5, 731-43	78
1360	Vibration disrupts vascular function in a model of metabolic syndrome. **2009**, 47, 533-42	25
1359	Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. **2009**, 23, 273-8	24
1358	A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. **2009**, 94, 4414-22	55
1357	Artificial selection for whole animal low intrinsic aerobic capacity co-segregates with hypoxia-induced cardiac pump failure. **2009**, 4, e6117	11
1356	Metabolic syndrome and polycystic ovary syndrome... and vice versa. **2009**, 53, 227-37	40
1355	Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen. **2009**, 64, 415-20	10
1354	Glycemic Index and Glycemic Load: Effects on Glucose, Insulin, and Lipid Regulation. **2009**, 49-64	

1353	Metabolic syndrome and non-alcoholic fatty liver disease. **2009**, 8, S18-S24		108
1352	Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. **2009**, 11, 353-9		23
1351	Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy. **2009**, 18, 2041-7		44
1350	Prevalence of the metabolic syndrome among obese adolescents enrolled in a multidisciplinary weight management program: clinical correlates and response to treatment. **2009**, 7, 179-86		36
1349	Relationship of postprandial nonesterified fatty acids, adipokines, and insulin across gender in human immunodeficiency virus-positive patients undergoing highly active antiretroviral therapy. **2009**, 7, 199-204		
1348	Dietary carotenoid intake is associated with lower prevalence of metabolic syndrome in middle-aged and elderly men. **2009**, 139, 987-92		87
1347	Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. **2009**, 29, 416-23		162
1346	Genetic variations in peroxisome proliferator-activated receptor gamma expression affect blood pressure. **2009**, 106, 19084-9		16
1345	Fetuses of obese mothers develop insulin resistance in utero. **2009**, 32, 1076-80		481
1344	Opposite effects of metabolic syndrome and calorie restriction on thrombotic disease: heads and tails of the same coin--resveratrol's role. **2009**, 7, 397-400		4
1343	Fasting blood glucose and the risk of stroke and myocardial infarction. *Circulation*, **2009**, 119, 812-9	16.7	60
1342	Ability of lipid accumulation product to identify metabolic syndrome in healthy men from Buenos Aires. **2009**, 32, e85		26
1341	Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. **2009**, 106, 18745-50		130
1340	The association between masked hypertension and waist circumference as an obesity-related anthropometric index for metabolic syndrome: the Ohasama study. **2009**, 32, 438-43		31
1339	TaqIB polymorphism in cholesterol ester transfer protein (CETP) gene predicts future cardiovascular death in patients experiencing an acute coronary syndrome. **2009**, 47, 1039-46		4
1338	Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. **2009**, 53, 605-10		93
1337	Impaired anti-inflammatory function of apolipoprotein A-II concentrations predicts metabolic syndrome and diabetes at 4 years follow-up in elderly Turks. **2009**, 47, 1389-94		16
1336	ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. **2009**, 169, 832-42		81

1335	Preheparin serum lipoprotein lipase mass interacts with gender, gene polymorphism and, positively, with smoking. **2009**, 47, 208-15	6
1334	Hyperuricemia and incident heart failure. **2009**, 2, 556-62	74
1333	Treatment Considerations for Diabetes: A Pharmacistâ Guide to Improving Care in the Elderly. **2009**, 22, 575-587	1
1332	Metabolic syndrome and serum fatty acid patterns in serum phospholipids in hypertriglyceridemic persons with human immunodeficiency virus. **2009**, 89, 1180-7	11
1331	Gene-gene interaction between APOA5 and USF1: two candidate genes for the metabolic syndrome. **2009**, 2, 235-42	12
1330	New insights into lipid metabolism in chronic kidney disease: what are the practical implications?. **2009**, 27, 86-91	7
1329	Pleiotropic effects of rimonabant: clinical implications. **2009**, 15, 553-70	24
1328	Mediterranean diets are associated with a lower incidence of metabolic syndrome one year following renal transplantation. **2009**, 76, 1199-206	23
1327	Association of the metabolic syndrome with pulmonary venous hypertension. **2009**, 136, 31-36	137
1326	Location of arterial stiffening differs in those with impaired fasting glucose versus diabetes: implications for left ventricular hypertrophy from the Multi-Ethnic Study of Atherosclerosis. **2009**, 58, 946-53	32
1325	Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey. **2009**, 23, 316-24	16
1324	Metabolic syndrome and obstructive sleep apnoea: two circumferences in the same individual. **2009**, 23, 836	
1323	Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes. **2009**, 41, 116-22	15
1322	Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. **2009**, 35, 313-24	74
1321	Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. **2009**, 150, 1662-9	91
1320	Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors. **2009**, 19, 1477-83	1
1319	Mineralocorticoid receptor activation in obesity hypertension. **2009**, 32, 649-57	37
1318	Insulin-like growth factor-binding protein-1: serum levels, promoter polymorphism, and associations with components of the metabolic syndrome in short subjects born small for gestational age. **2009**, 94, 1386-92	17

1317	Mediterranean diets: are they practical in the Western world?. **2009**, 76, 1127-9		
1316	Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans. **2009**, 76, 72-80		40
1315	Genome-wide association study for empirically derived metabolic phenotypes in the Framingham Heart Study offspring cohort. **2009**, 3 Suppl 7, S53		9
1314	Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults: the cardiovascular risk in young Finns study. *Circulation*, **2009**, 120, 229-36	16.7	126
1313	How to save a life during a clinic visit for erectile dysfunction by modifying cardiovascular risk factors. **2009**, 21, 327-35		16
1312	Stroke Prevention. **2009**, 581-604		
1311	Effects of exercise training intensity on nocturnal growth hormone secretion in obese adults with the metabolic syndrome. **2009**, 94, 1979-86		28
1310	Insulin increases reendothelialization and inhibits cell migration and neointimal growth after arterial injury. **2009**, 29, 1060-6		41
1309	Lifestyle and metabolic determinants of incident hypertension, with special reference to cigarette smoking: a longitudinal population-based study. **2009**, 22, 156-62		26
1308	Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. **2009**, 32, 702-7		172
1307	Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. **2009**, 5, 453-65		3
1306	Components of metabolic syndrome and metachronous colorectal neoplasia. **2009**, 18, 1134-43		24
1305	The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. **2009**, 37, 65-77		63
1304	Effect of a dietary intervention and n-3 fatty acid supplementation on measures of serum lipid and insulin sensitivity in persons with HIV. **2009**, 90, 1566-78		22
1303	Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. **2009**, 94, 255-60		51
1302	Depressive symptoms and metabolic syndrome: selective association in older women. **2009**, 22, 215-22		28
1301	Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. **2009**, 18, 1019-25		50
1300	Activating transcription factor 3 constitutes a negative feedback mechanism that attenuates saturated Fatty acid/toll-like receptor 4 signaling and macrophage activation in obese adipose tissue. **2009**, 105, 25-32		81

1299	Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*, **2009**, 119, e21-181	16.7	1705
1298	Homeostasis model assessment of insulin resistance*body mass index interactions at ages 9 to 10 years predict metabolic syndrome risk factor aggregate score at ages 18 to 19 years: a 10-year prospective study of black and white girls. **2009**, 58, 290-5		13
1297	Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. **2009**, 58, 1743-6		101
1296	Clinical insights from the Treating to New Targets trial. **2009**, 51, 487-502		5
1295	Stability of the factor structure of the metabolic syndrome across pubertal development: confirmatory factor analyses of three alternative models. **2009**, 155, S5.e1-8		20
1294	The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. **2009**, 43, 1106-11		38
1293	Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes. **2009**, 23, 143-52		6
1292	1H-magnetic resonance spectroscopy for quantifying myocardial lipid content in humans with the cardiometabolic syndrome. **2009**, 11, 528-32		6
1291	Impaired cavernous reinnervation after penile nerve injury in rats with features of the metabolic syndrome. **2009**, 6, 3032-44		12
1290	Neck circumference as a measure of central obesity: associations with metabolic syndrome and obstructive sleep apnea syndrome beyond waist circumference. **2009**, 28, 46-51		181
1289	[Long term effect of autoadjusting positive airway pressure on C-reactive protein and interleukin-6 in men with obstructive sleep apnoea syndrome]. **2009**, 45, 577-84		11
1288	Mitochondrial ATP-sensitive K(+) channels as redox signals to liver mitochondria in response to hypertriglyceridemia. **2009**, 47, 1432-9		29
1287	Laparoscopic adjustable gastric banding for morbidly obese adolescents affects android fat loss, resolution of comorbidities, and improved metabolic status. **2009**, 209, 638-44		56
1286	Ethnic differences in hepatic steatosis: an insulin resistance paradox?. **2009**, 49, 791-801		252
1285	Fasting hyperinsulinemia associates with increased sub-clinical inflammation in first-degree relatives normal glucose tolerant women independently of the metabolic syndrome. **2009**, 25, 639-46		2
1284	Diabetes self-care maintenance, comorbid conditions and perceived health. **2009**, 6, 65-68		2
1283	Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat content. **2009**, 30, 444-8		59
1282	Posttransplant metabolic syndrome: an epidemic waiting to happen. **2009**, 15, 1662-70		122

1281	Long-term temporal trends in cardiovascular and metabolic risk factors. **2009**, 121, 623-30	8
1280	The influence of dietary fibre source and gender on the postprandial glucose and lipid response in healthy subjects. **2009**, 48, 395-402	35
1279	Metabolic syndrome increases the risk of stroke: a 5-year follow-up study in a Chinese population. **2009**, 256, 1493-9	24
1278	Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart. **2009**, 331, 89-116	42
1277	Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. **2009**, 20, 1181-92	86
1276	Metabolic syndrome: perception or reality?. **2009**, 11, 264-71	10
1275	Effects of resistin on insulin signaling in endothelial cells. **2009**, 3, 136-140	
1274	The WOMEN study: what is the optimal method for ischemia evaluation in women? A multi-center, prospective, randomized study to establish the optimal method for detection of coronary artery disease (CAD) risk in women at an intermediate-high pretest likelihood of CAD: study design. **2009**, 16, 105-12	9
1273	Design, synthesis, and docking studies of novel telmisartanâglitazone hybrid analogs for the treatment of metabolic syndrome. **2009**, 18, 589-610	9
1272	Design, synthesis, and docking studies of telmisartan analogs for the treatment of metabolic syndrome. **2009**, 18, 611-628	10
1271	Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. **2009**, 9, 80	19
1270	Association of the TLR4 Asp299Gly polymorphism with lung function in relation to body mass index. **2009**, 9, 46	6
1269	Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis. **2009**, 8, 26	20
1268	Glycemic load is associated with HDL cholesterol but not with the other components and prevalence of metabolic syndrome in the third National Health and Nutrition Examination Survey, 1988-1994. **2009**, 2, 3	25
1267	Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. **2009**, 34, 140-4	62
1266	Androgenic alopecia and insulin resistance: are they really related?. **2009**, 34, 694-7	31
1265	Severe psoriasis, morbid obesity and bariatric surgery. **2009**, 34, e421-2	22
1264	Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. **2009**, 70, 870-5	78

1263	Prognostic significance of FTO genotype in the development of obesity in Japanese: the J-SHIPP study. **2009**, 33, 1243-8	34
1262	High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. **2009**, 43, 49-54	105
1261	Loss of total and visceral adipose tissue mass predicts decreases in oxidative stress after weight-loss surgery. **2009**, 17, 439-46	61
1260	Serum adiponectin confers little protection against diabetes and hypertension in Turkish men. **2009** , 17, 564-70	13
1259	Abdominal obesity, insulin resistance, and the metabolic syndrome: contribution of physical activity/exercise. **2009**, 17 Suppl 3, S1-2	25
1258	The utility of physical activity in the management of global cardiometabolic risk. **2009**, 17 Suppl 3, S3-S14	43
1257	Characterization of obese phenotypes in a small nonhuman primate, the common marmoset (Callithrix jacchus). **2009**, 17, 1499-505	65
1256	Metabolic syndrome: a picture of health?. **2009**, 21, 197-199	1
1255	Waist circumference percentile thresholds for identifying adolescents with insulin resistance in clinical practice. **2009**, 10, 336-42	29
1254	The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. **2009**, 11, 559-95	125
1253	Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks. **2009**, 26, 981-8	47
1252	Mediterranean food pattern and the primary prevention of chronic disease: recent developments. **2009**, 67 Suppl 1, S111-6	127
1251	Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: a hospital-based case-control study in China. **2009**, 23, 132-7	46
1250	Optimization and validation of a SPE-HPLC-PDA-fluorescence method for the simultaneous determination of drugs used in combined cardiovascular therapy in human plasma. **2009**, 50, 630-9	29
1249	Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. **2009**, 42, 1331-46	291
1248	Structure-based virtual screening for identification of novel 11beta-HSD1 inhibitors. **2009**, 44, 1167-71	41
1247	Thyrotropin levels and their relationship with cardiovascular risk factors in the island of Gran Canaria, Spain. Implications of lowering the upper reference limit of thyrotropin stimulating hormone. **2009**, 32, 102-6	3
1246	Cardiorespiratory fitness and the metabolic syndrome in firefighters. **2009**, 59, 487-92	81

1245	Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. **2009**, 58, 2731-40	271
1244	Metabolic syndrome and periodontitis: is oxidative stress a common link?. **2009**, 88, 503-18	153
1243	Relationship between uric acid and hepatic steatosis among Koreans. **2009**, 35, 447-51	27
1242	Impaired left ventricular systolic and diastolic function in patients with metabolic syndrome as assessed by strain and strain rate imaging. **2009**, 83, 300-7	53
1241	Metabolic syndrome and risk of cancer mortality in men. **2009**, 45, 1831-8	80
1240	Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study. **2009**, 19, 98-104	41
1239	Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men. **2009**, 19, 401-8	110
1238	Cardiometabolic comorbidities and the approach to patients with psoriasis. **2009**, 100 Suppl 2, 14-21	22
1237	Impact of metabolic syndrome on left ventricular mass: is the same in all ethnic groups and in men and women?. **2009**, 131, 395-6; author reply 396-7	1
1236	Impact of metabolic syndrome on left ventricular mass: Is the same in all ethnic groups and in men and women? Reply. **2009**, 131, 396-397	
1235	Independent prediction of metabolic syndrome by plasma fibrinogen in men, and predictors of elevated levels. **2009**, 135, 211-7	17
1234	The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism. **2009**, 131, 305-12	7
1233	[Erectile dysfunction as a marker of silent cardiovascular disease in type-2 diabetic patients in Spain. The DIVA (DIabetes and VAscular disease) study]. **2009**, 132, 291-7	12
1232	HIV infection and obesity: a review of the evidence. **2009**, 20, 260-74	32
1231	Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. **2009**, 158, 860-6	34
1230	Central corneal thickness and its associations with ocular and systemic factors: the Singapore Malay Eye Study. **2009**, 147, 709-716.e1	65
1229	Long-term C-reactive protein variability and prediction of metabolic risk. **2009**, 122, 53-61	19
1228	Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patients. **2009**, 3, 195-200	2

1227	Serum 25-hydroxyvitamin D is independently associated with high-density lipoprotein cholesterol and the metabolic syndrome in men and women. **2009**, 3, 289-96	68
1226	Importance of metabolic syndrome for South Asians. **2009**, 2, 93-4	1
1225	Early onset of proteinuria and focal segmental glomerulosclerosis in obese, hyperinsulinemic adolescents developing metabolic syndrome. **2009**, 3, 169-174	2
1224	Metabolic syndrome: A review of emerging markers and management. **2009**, 3, 240-254	14
1223	Modern cardiovascular risk management in clinical practice. **2009**, 26, 275-279	
1222	Resistin gene variations are associated with the metabolic syndrome in Japanese men. **2009**, 3, I-II	17
1221	Outcomes of endoluminal reintervention for restenosis after percutaneous renal angioplasty and stenting. **2009**, 49, 946-52	16
1220	Endovascular revascularization of renal artery stenosis in the solitary functioning kidney. **2009**, 49, 953-60	12
1219	Metabolic syndrome: A predictor of adverse outcomes after carotid revascularization. **2009**, 49, 1172-80.e1; discussion 1180	34
1218	The hypertriglyceridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify high-risk men with an altered cardiometabolic risk profile. **2009**, 58, 1123-30	70
1217	Point-of-care testing of cholesterol and triglycerides for epidemiologic studies: evaluation of the multicare-in system. **2009**, 153, 71-6	41
1216	Influence of exercise intensity on abdominal fat and adiponectin in elderly adults. **2009**, 7, 363-8	46
1215	Long Term Effect of Autoadjusting Positive Airway Pressure on C-Reactive Protein and Interleukin-6 in Men With Obstructive Sleep Apnoea Syndrome. **2009**, 45, 577-584	3
1214	Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. **2009**, 94, 2558-64	113
1213	Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome. **2009**, 52, 1172-9	8
1212	Insulin Resistance. **2009**,	
1211	Metabolic syndrome and cardiometabolic risk: an update. **2009**, 18, 7-16	11
1210	Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. **2009**, 11, R36	91

1209	Heritabilities of the metabolic syndrome phenotypes and related factors in Korean twins. **2009**, 94, 4946-52	36
1208	Vascular biomarkers in the metabolic syndrome. **2009**, 9, 209-15	3
1207	Impact of treating the metabolic syndrome on chronic kidney disease. **2009**, 5, 520-8	41
1206	Metabolic syndrome and its associated risk factors in Brazilian postmenopausal women. **2009**, 12, 431-8	35
1205	Circulating levels of adiponectin, leptin, and tumour necrosis factor alpha in hypertension. **2009**, 41, 291-300	18
1204	The not-so-sweet side of fructose. **2009**, 20, 457-9	12
1203	Successful Internet-Based Lifestyle Change Program on Body Weight and Markers of Metabolic Health. **2009**, 5, 167-173	3
1202	Lifestyle modification decreases the mean platelet volume in prehypertensive patients. **2009**, 20, 58-63	49
1201	Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. **2009**, 203, 563-8	108
1200	Elevated C-reactive protein levels and metabolic syndrome in the elderly: The role of central obesity data from the InChianti study. **2009**, 203, 626-32	42
1199	Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. **2009**, 204, 509-14	78
1198	Association of C-reactive protein (CRP) gene allelic variants with serum CRP levels and hypertension in Turkish adults. **2009**, 206, 474-9	26
1197	Diabetes Mellitus. **2009**, 9-16	
1196	Prevalencia de factores de riesgo cardiovascular y de s□ndrome metab□ico en una cohorte de pacientes con infecci□ por el virus de la inmunodeficiencia humana del sur de Espaâ. Estudio PREGO. **2009**, 21, 62-67	
1195	Metabolic consequences of hyperglycemia and insulin resistance. **2009**, 4, 2-14	7
1194	Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women. **2009**, 17, 1124-8	30
1193	[Cardiovascular risk factors associated with antiretroviral therapy]. **2009**, 27 Suppl 1, 24-32	2
1192	S□ndrome metab□ico, la obesidad y el sedentarismo. **2009**, 10, 2688-2696	

1191	Dietary carbohydrates and dental-systemic diseases. **2009**, 88, 490-502	84
1190	Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: a multicenter, randomized, double-blind clinical trial. **2009**, 203, 479-82	6
1189	Relationship between adiposity and cardiovascular risk factors in prevalent hemodialysis patients. **2009**, 19, 357-64	25
1188	Percentage of excess BMI lost correlates better with improvement of metabolic syndrome after Roux-en-Y gastric bypass in morbidly obese subjects: anthropometric indexes and gastric bypass. **2009**, 5, 11-8	13
1187	Obesity, metabolic syndrome, and the surgical patient. **2009**, 27, 705-19	5
1186	Obesity, metabolic syndrome, and the surgical patient. **2009**, 93, 1049-63	17
1185	2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. **2009**, 27, S3-11	26
1184	Prevalence of metabolic syndrome in patients with psychotic disorders in the Netherlands. **2009**, 29, 399-402	11
1183	Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. **2009**, 50, 499-505	119
1182	How sweet it is? Susceptibility to diabetes mellitus in HIV-1 treatment. **2009**, 3, 613-624	
1181	Cardiovascular manifestations of insulin resistance. **2009**, 16, e14-28	10
1180	Multivariate therapeutic approach to binge-eating disorder: combined nutritional, psychological and pharmacological treatment. **2009**, 24, 312-7	21
1179	Independent and combined influence of physical activity and perceived stress on the metabolic syndrome in male law enforcement officers. **2009**, 51, 46-53	35
1178	Mechanisms of hypertension in the cardiometabolic syndrome. **2009**, 27, 441-51	55
1177	Waist circumference and waist-to-height ratio as predictors of cardiovascular disease risk in Korean adults. **2009**, 73, 1643-50	120
1176	[The metabolic syndrome and the risks of unfavourable outcome of pregnancy]. **2009**, 150, 1361-5	8
1175	Detectable HIV viral load is associated with metabolic syndrome. **2009**, 52, 459-64	24
1174	Effects of insulin resistance on endothelial progenitor cells and vascular repair. **2009**, 117, 173-90	58

1173	Pro12Ala polymorphism of the peroxisome proliferatoractivated receptor-gamma gene is associated with metabolic syndrome and surrogate measures of insulin resistance in healthy men: interaction with smoking status. **2009**, 73, 2118-24	27
1172	Criteria of waist circumference according to computed tomography-measured visceral fat area and the clustering of cardiovascular risk factors. **2009**, 73, 1881-6	50
1171	A proposal of combined evaluation of waist circumference and BMI for the diagnosis of metabolic syndrome. **2009**, 56, 1079-82	20
1170	The metabolic syndrome and pulmonary vascular disease. **2009**, 136, 3-4	3
1169	Components of the metabolic syndrome among a sample of overweight and obese Costa Rican schoolchildren. **2009**, 30, 161-70	17
1168	Dietary phylloquinone intakes and metabolic syndrome in US young adults. **2009**, 28, 369-79	28
1167	Role of Sympathetic Nerve Activity in Obesity, Hypertension and Metabolic Syndrome. **2010**, 6, 83-91	2
1166	Demographic and clinical determinants of moderate to vigorous physical activity during home-based cardiac rehabilitation: the home-based determinants of exercise (HOME) study. **2010**, 30, 240-5	30
1165	Metabolic syndrome, inflammation, and nonamnestic mild cognitive impairment in older persons: a population-based study. **2010**, 24, 11-8	65
1164	Aesthetic cardiology: adipose-derived stem cells for myocardial repair. **2010**, 5, 145-52	18
1163	Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD. **2010**, 6, 112-8	16
1162	Pharmacological Treatments for Obesity-Related Hypertension. **2010**, 6, 92-99	
1161	Prevalence of Obesity, Hypertension, Diabetes, and Metabolic Syndrome and Its Cardiovascular Complications. **2010**, 6, 73-82	7
1160	Effects of low-fat dairy consumption on markers of low-grade systemic inflammation and endothelial function in overweight and obese subjects: an intervention study. **2010**, 104, 1523-7	57
1159	Insulin Resistance in the Metabolic Syndrome. 13-21	
1158	High-intensity aerobic exercise training improves the heart in health and disease. **2010**, 30, 2-11	96
1157	Comparison of rival metabolic syndrome classifications against pathophysiological markers in renal transplant recipients. **2010**, 89, 347-52	13
1156	Metabolic syndrome? A critical look from the viewpoints of causal diagrams and statistics. **2010**, 11, 772-9	5

1155	Influence of commonly employed resistance exercise protocols on circulating IL-6 and indices of insulin sensitivity. **2010**, 24, 1091-101	34
1154	Prevalence of the metabolic syndrome among overweight and obese college students in Korea. **2010**, 25, 61-8	7
1153	C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients. **2010**, 30, 512-7	21
1152	Ambulatory blood pressure monitoring in type 2 diabetes and metabolic syndrome: a review. **2010**, 15, 1-7	28
1151	The impact of vitamin D deficiency on diabetes and cardiovascular risk. **2010**, 17, 113-9	87
1150	Rapidly worsening hypertriglyceridemia during treatment with risperidone. **2010**, 17, 216-8	5
1149	Metabolic syndrome: anesthesia for morbid obesity. **2010**, 23, 375-83	31
1148	Metabolic syndrome and bone metabolism: the Camargo Cohort study. **2010**, 17, 955-61	71
1147	Body mass index can similarly predict the presence of multiple cardiovascular risk factors in middle-aged Japanese subjects as waist circumference. **2010**, 49, 977-82	30
1146	Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. **2009**, 118, 231-40	26
1145	The relationship between serum uric acid level and metabolic syndrome: differences by sex and age in Taiwanese. **2010**, 20, 219-24	49
1144	Impact of blood pressure and other components of the metabolic syndrome on the development of cardiovascular disease. **2010**, 74, 456-61	12
1143	Metabolic syndrome and carotid artery parameter in Koreans aged 50 years and older. **2010**, 74, 560-6	10
1142	The "Senobi" breathing exercise is recommended as first line treatment for obesity. **2010**, 31, 259-62	4
1141	Differences in the body composition and biochemistry in women grouped as normal-weight, overweight and obese according to body mass index and their relation with cardiometabolic risk. **2010**, 5, 724-732	2
1140	[Obesity: ectopic fat distribution and the heart]. **2010**, 35, 198-205	3
1139	The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. **2010**, 53, 600-5	312
1138	LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. **2010**, 878, 2685-92	53

1137	Lower BMI cutoff for assessing the prevalence of metabolic syndrome in Thai population. **2010**, 47 Suppl 1, 91-6	13
1136	Alanine-aminotransferase levels predict impaired glucose tolerance in a worksite population. **2010**, 47, 161-5	10
1135	Prevalence of metabolic syndrome with International Diabetes Federation Criteria and ATP III Program in patients 65 years of age or older. **2010**, 14, 400-4	14
1134	Personality and metabolic syndrome. **2010**, 32, 513-9	77
1133	Clustering of leptin and physical activity with components of metabolic syndrome in Iranian population: an exploratory factor analysis. **2010**, 38, 206-13	12
1132	Metabolic syndrome associated with schizophrenia and atypical antipsychotics. **2010**, 10, 209-16	84
1131	Metabolic syndrome and insulin resistance in subjects with morbid obesity. **2010**, 20, 295-301	28
1130	Prevalence of diabetes, metabolic syndrome, and cardiovascular risk factors in US Asian Indians: results from a national study. **2010**, 24, 145-53	105
1129	Birth weight, family history of diabetes, and metabolic syndrome in children and adolescents. **2010**, 156, 719-23, 723.e1	54
1128	Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population. **2010**, 59, 628-34	50
1127	A functional nonsynonymous toll-like receptor 4 gene polymorphism is associated with metabolic syndrome, surrogates of insulin resistance, and syndromes of lipid accumulation. **2010**, 59, 711-7	25
1126	Serum uric acid and metabolic syndrome in Taiwanese adults. **2010**, 59, 802-7	54
1125	Visceral adipose tissue and body fat mass: predictive values for and role of gender in cardiometabolic risk among Turks. **2010**, 26, 382-9	27
1124	Apolipoprotein A-I positively associated with diabetes in women independently of apolipoprotein E genotype and apolipoprotein B levels. **2010**, 26, 975-80	12
1123	The characteristics of impaired fasting glucose associated with obesity and dyslipidaemia in a Chinese population. **2010**, 10, 139	22
1122	Relation of B-type natriuretic peptide levels to body mass index after comprehensive lifestyle changes. **2010**, 105, 1570-6	33
1121	Comparison of rates of progression of coronary atherosclerosis in patients with diabetes mellitus versus those with the metabolic syndrome. **2010**, 105, 1735-9	25
1120	Effect of total knee arthroplasty on metabolic syndrome. **2010**, 25, 1110-4	5

1119	Metabolic syndrome and its components after liver transplantation: incidence, prevalence, risk factors, and implications. **2010**, 29, 175-9	22
1118	Glycemic index, glycemic load, and prevalence of the metabolic syndrome in the cooper center longitudinal study. **2010**, 110, 1820-9	44
1117	Metabolic syndrome and solid-organ transplantation. **2010**, 10, 12-7	25
1116	Vasculogenic erectile dysfunction and metabolic syndrome. **2010**, 7, 3997-4002	16
1115	The vicious circle between oxidative stress and inflammation in atherosclerosis. **2010**, 14, 70-8	168
1114	Effect of obesity on platelet reactivity and response to low-dose aspirin. **2010**, 13, 56-62	54
1113	Cardiometabolic syndrome and its association with education, smoking, diet, physical activity, and social support: findings from the Pennsylvania 2007 BRFSS Survey. **2010**, 12, 556-64	6
1112	US trends in glycemic control, treatment, and comorbidity burden in patients with diabetes. **2010**, 12, 826-32	20
1111	Overactive bladder: Is there a link to the metabolic syndrome in men?. **2010**, 29, 1360-4	48
1110	The Mediterranean Diets: Nutrition and Gastronomy. **2010**, 322-343	1
1109	Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. **2010**, 62, 3173-82	114
1108	Amino acids stimulate Akt phosphorylation, and reduce IL-8 production and NF-B activity in HepG2 liver cells. **2010**, 54, 1568-73	25
1107	Short-term weight loss in overweight/obese low-income women improves plasma zinc and metabolic syndrome risk factors. **2010**, 24, 271-6	15
1106	Predictive value of serum apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk: population-based cohort study. **2010**, 43, 1381-6	15
1105	The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. **2010**, 43, 1399-404	41
1104	Total and high molecular weight adiponectin have similar utility for the identification of insulin resistance. **2010**, 9, 26	49
1103	Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome - A cross-sectional study. **2010**, 9, 34	40
1102	Early alterations in vascular contractility associated to changes in fatty acid composition and oxidative stress markers in perivascular adipose tissue. **2010**, 9, 65	29

1101	High-sensitivity C-reactive protein and gamma-glutamyl transferase levels are synergistically associated with metabolic syndrome in community-dwelling persons. **2010**, 9, 87	28
1100	Omega-3 polyunsaturated acids and cardiovascular disease: notable ethnic differences or unfulfilled promise?. **2010**, 8, 2095-104	20
1099	Psoriasis and body mass index. **2010**, 23, 152-4	35
1098	The difference of heart rate recovery between males with and without erectile dysfunction. **2010**, 15, 223-9	8
1097	Metabolic syndrome, insulin resistance, and periodontitis: a cross-sectional study in a middle-aged French population. **2010**, 37, 601-8	80
1096	Association of salivary lysozyme and C-reactive protein with metabolic syndrome. **2010**, 37, 805-11	15
1095	What men should know about metabolic syndrome, adiposopathy and 'sick fat'. **2010**, 64, 1735-9	4
1094	Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. **2010**, 73, 602-12	254
1093	Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. **2010**, 40, 887-92	129
1092	Exploring the components of metabolic syndrome with respect to gender difference and its relationship to health-promoting lifestyle behaviour: a study in Taiwanese urban communities. **2010**, 19, 3031-41	23
1091	The chronic effects of whey proteins on blood pressure, vascular function, and inflammatory markers in overweight individuals. **2010**, 18, 1354-9	144
1090	Associations between gender, age and waist circumference. **2010**, 64, 6-15	163
1089	A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. **2010**, 34, 919-35	62
1088	Metabolic or bariatric surgery? Long-term effects of malabsorptive vs restrictive bariatric techniques on body composition and cardiometabolic risk factors. **2010**, 34, 1404-14	30
1087	Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. **2010**, 2, 180-93	303
1086	Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. **2010**, 1193, 153-9	100
1085	Decreased high-density lipoprotein cholesterol is associated with inflammation and insulin resistance in non-diabetic haemodialysis patients. **2010**, 15, 692-9	6
1084	Prevalence of metabolic syndrome in bipolar patients initiating acute-phase treatment: a 6-month follow up. **2010**, 64, 625-33	20

1083	The discrimination of dyslipidaemia using anthropometric measures in ethnically diverse populations of the Asia-Pacific Region: the Obesity in Asia Collaboration. **2010**, 11, 127-36	26
1082	High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipients. **2010**, 14, 52-60	65
1081	Metabolic syndrome in pediatric renal transplant recipients: comparing early discontinuation of steroids vs. steroid group. **2010**, 14, 351-7	17
1080	Digestive and metabolic physiology of obesity. 28-43	
1079	Day/Night rhythm of hemostatic factors in obstructive sleep apnea. **2010**, 33, 371-7	35
1078	Association between elevated aminotransferase levels and the metabolic syndrome in Northern Turkey. **2010**, 9, 161-165	1
1077	Metabolic side effects and risk of cardiovascular disease. 173-188	
1076	Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. **2010**, Volume 3, 197-213	3
1075	Impact of having one cardiovascular risk factor on other cardiovascular risk factor levels in adolescents. **2010**, 17, 1167-75	6
1074	C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. **2010**, 17, 219-28	71
1073	Metformin Improves Insulin Signaling in Obese Rats via Reduced IKKbeta Action in a Fiber-Type Specific Manner. **2010**, 2010,	20
1072	Effects of dietary fiber intake on inflammation in chronic diseases. **2010**, 8, 254-8	11
1071	Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome-an open label pilot study. **2010**, 46, 140-9	193
1070	Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: the ARIC Study. **2010**, 5, e11690	47
1069	Glycaemic control, dyslipidaemia and metabolic syndrome among recently diagnosed diabetes mellitus patients in Tamale Teaching Hospital, Ghana. **2010**, 29, 8-11	9
1068	Prognostic role of metabolic syndrome in the elderly is not greater than the sum of its components. **2010**, 6, 217-228	3
1067	[Prevalence of metabolic syndrome among Chilean adults]. **2010**, 138, 707-14	9
1066	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. **2010**, Volume 3, 373-385	38

1065	Evaluation of Clustering Patterns using Singular Value Decomposition (SVD). **2010**, 1, 69-80	1
1064	Estimation of insulin resistance in non-diabetic normotensive Saudi adults by QUICKI, HOMA-IR and modified QUICKI: a comparative study. **2010**, 30, 257-64	9
1063	Cardiovascular physiology. 1-18	
1062	Acute coronary syndromes amongst type 2 diabetics with ischaemic electrocardiograms presenting to accident and emergency department of a Kenyan tertiary institution. **2009**, 86, 463-8	4
1061	A study of standardized extracts of Picrorhiza kurroa Royle ex Benth in experimental nonalcoholic fatty liver disease. **2010**, 1, 203-10	34
1060	Antipsychotics and metabolics in the post-CATIE era. **2010**, 4, 23-42	26
1059	Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). **2010**, 30, 953-61	130
1058	Surrogate markers of insulin resistance: A review. **2010**, 1, 36-47	292
1057	Associations of visceral and subcutaneous fat areas with the prevalence of metabolic risk factor clustering in 6,292 Japanese individuals: the Hitachi Health Study. **2010**, 33, 2117-9	60
1056	Is the whole greater than the sum of its parts?. **2010**, 37, 1794-6	0
1055	Drinking caloric beverages increases the risk of adverse cardiometabolic outcomes in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. **2010**, 92, 954-9	132
1054	The relationship between glucose tolerance and severity of coronary artery disease using the Gensini score. **2010**, 61, 751-5	24
1053	FABP4 plasma levels are increased in familial combined hyperlipidemia. **2010**, 51, 1173-1178	10
1052	Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. **2010**, 28, 4649-57	276
1051	Macronutrient Intakes and Waist Circumference. **2010**, 25, 9-19	
1050	Anaesthetic considerations with the metabolic syndrome. **2010**, 105 Suppl 1, i24-33	24
1049	Interaction of HDL cholesterol concentrations on the relationship between physical function and inflammation in community-dwelling older persons. **2010**, 39, 74-80	14
1048	High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. **2010**, 201, 285-92	75

1047	Prevalence of metabolic syndrome in patients with intermittent claudication and its correlation with the segment of arterial obstruction. **2010**, 61, 784-8	11
1046	Insulin inhibits and oral sucrose increases neointimal growth after arterial injury in rats. **2010**, 47, 412-22	11
1045	Exposure to a high-fat diet alters leptin sensitivity and elevates renal sympathetic nerve activity and arterial pressure in rabbits. **2010**, 55, 862-8	126
1044	Metabolic syndrome: an occupational perspective. **2010**, 35, 122-4	7
1043	TLR4 and Insulin Resistance. **2010**, 2010,	114
1042	Serum fetuin A/2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. **2010**, 47, 549-53	49
1041	A methodological reappraisal of total and high molecular weight adiponectin determination in human peripheral circulation: comparison of four immunometric assays. **2010**, 48, 561-8	12
1040	A 'complexity' of urate transporters. **2010**, 78, 446-52	87
1039	Metabolic syndrome and angiographic coronary artery disease prevalence in association with the Framingham risk score. **2010**, 8, 201-8	9
1038	Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. **2010**, 105, 2093-102	126
1037	Recent advances in hydrogen research as a therapeutic medical gas. **2010**, 44, 971-82	220
1036	Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. **2010**, 70, 541-6	31
1035	Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. **2010**, 6, 657-91	93
1034	Independent metabolic syndrome variants predict new-onset coronary artery disease. **2010**, 33, 1376-8	7
1033	Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. **2010**, 33, 1618-24	141
1032	Using glycosylated hemoglobin to define the metabolic syndrome in United States adults. **2010**, 33, 1856-8	28
1031	Postprandial insulin and triglycerides after different breakfast meal challenges: use of finger stick capillary dried blood spots to study postprandial dysmetabolism. **2010**, 4, 236-43	7
1030	Metabolic syndrome, independent of its components, is a risk factor for stroke and death but not for coronary heart disease among hypertensive patients in the ASCOT-BPLA. **2010**, 33, 1647-51	30

1029	Nuclear receptors linking circadian rhythms and cardiometabolic control. **2010**, 30, 1529-34	60
1028	Metabolic syndrome characteristics in gout patients. **2010**, 29, 325-9	8
1027	Uric acid metabolism in patients with primary gout and the metabolic syndrome. **2010**, 29, 330-4	18
1026	Association of a cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like 1 (CDKAL1) polymorphism with elevated hemoglobin Aâ[c) levels and the prevalence of metabolic syndrome in Japanese men: interaction with dietary energy intake. **2010**, 172, 985-91	16
1025	Age and sex differences in the clustering of metabolic syndrome factors: association with mortality risk. **2010**, 33, 2457-61	113
1024	Heart rate recovery after exercise is associated with renal function in patients with a homogenous chronic renal disease. **2010**, 25, 509-13	8
1023	Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesity-related metabolic syndrome. **2010**, 299, E947-52	48
1022	Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. **2010**, 26, 445-54	57
1021	Bayesian methods for instrumental variable analysis with genetic instruments ('Mendelian randomization'): example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome. **2010**, 39, 907-18	37
1020	Breaking patterns of environmentally influenced disease for health risk reduction: immune perspectives. **2010**, 118, 1091-9	72
1019	Enhanced glycogen metabolism in adipose tissue decreases triglyceride mobilization. **2010**, 299, E117-25	9
1018	Aging and HIV infection: a comparison between older HIV-infected persons and the general population. **2010**, 11, 100-9	128
1017	Evaluation of left ventricular rotation in obese subjects by velocity vector imaging. **2010**, 11, 424-8	17
1016	Procedure and outcomes of Roux-en-Y gastric bypass. **2010**, 19, 307-13	7
1015	The metabolic syndrome following kidney transplantation. **2010**, S8-14	16
1014	Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse. **2010**, 151, 2117-27	182
1013	Metabolic syndrome in Cushing's syndrome. **2010**, 92 Suppl 1, 96-101	73
1012	Metabolic syndrome is a low-grade systemic inflammatory condition. **2010**, 5, 577-592	17

1011	Essen zum Genusserlebnis machen. **2010**, 16, 249-255	
1010	The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. **2010**, 170, 478-84	94
1009	Adipokines and cardiometabolic profile in primary hyperaldosteronism. **2010**, 95, 2391-8	74
1008	Sequential changes of serum aminotransferase levels in severely obese patients after losing weight through enrollment in a behavioral weight loss program. **2010**, 122, 206-12	3
1007	Herbals used for diabetes, obesity, and metabolic syndrome. **2010**, 37, 237-54	32
1006	Symposia du 27e congrès de la SFE. **2010**, 71, 326-337	
1005	Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART. **2010**, 14, 158-166	40
1004	Reply. **2010**, 56, 743-744	
1003	Implications de la thrombose in situ et de l'embolisation distale durant les interventions endoluminales sur l'artère fémorale superficielle. **2010**, 24, 14-23	
1002	Implications of in situ thrombosis and distal embolization during superficial femoral artery endoluminal intervention. **2010**, 24, 14-22	22
1001	Association of hematological parameters and uric acid with clustered components of metabolic syndrome among Japanese male workers. **2010**, 4, 165-167	1
1000	Effects of obesity and weight loss on the functional properties of early outgrowth endothelial progenitor cells. **2010**, 55, 357-67	50
999	Pulse pressure amplification as a predictor of cardiovascular risk. **2010**, 56, 744; author reply 744-5	4
998	Reply. **2010**, 56, 744-745	
997	The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. **2010**, 56, 1113-32	1634
996	Subjects with elevated LDL cholesterol and metabolic syndrome benefit from supplementation with soy protein, phytosterols, hops rho iso-alpha acids, and Acacia nilotica proanthocyanidins. **2010**, 4, 59-68	33
995	"Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. **2010**, 4, 89-98	170
994	Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. **2010**, 118, 211-7	60

993	Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. **2010**, 120, 204-9	27
992	Impact of metabolic syndrome on the outcomes of percutaneous renal angioplasty and stenting. **2010**, 51, 926-32	21
991	Renal parenchymal preservation after percutaneous renal angioplasty and stenting. **2010**, 51, 1222-9; discussion 1229	10
990	Outcomes of interventions for recurrent disease after endoluminal intervention for superficial femoral artery disease. **2010**, 52, 331-9.e1-2	11
989	Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome. **2010**, 53, 1076-85	28
988	Effects of whey protein isolate on body composition, lipids, insulin and glucose in overweight and obese individuals. **2010**, 104, 716-23	188
987	Metabolic syndrome, brain magnetic resonance imaging, and cognition. **2010**, 33, 2489-95	59
986	Implications of the Glycemic Index in Obesity. **2010**, 219-230	
985	Pharmacophore-based virtual screening: a review of recent applications. **2010**, 5, 205-22	58
984	Metabolic syndrome and left ventricular dysfunction: new player of the game. **2010**, 138, 209-11	2
983	The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. **2010**, 142, 72-9	48
982	Joint effect of self-reported sleep problems and three components of the metabolic syndrome on risk of coronary heart disease. **2010**, 68, 149-58	19
981	Autonomic function and change in insulin for exercising postmenopausal women. **2010**, 65, 284-91	12
980	The metabolic syndrome: prevalence, main characteristics and association with socio-economic status in adults living in Great Tunis. **2010**, 36, 204-8	26
979	Renin angiotensin system polymorphisms in patients with metabolic syndrome (MetS). **2010**, 21, 414-8	25
978	Long-term consequences of hematopoietic stem cell transplantation: current state of the science. **2010**, 16, S90-6	25
977	Factors affecting sexual function in premenopausal age women with type 2 diabetes: a comprehensive study. **2010**, 94, 1840-3	18
976	Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults. **2010**, 411, 1496-501	50

975 Regulation of hepatic gene expression by saturated fatty acids. **2010**, 82, 211-8 55

974 Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. **2010**, 91, 275-99 175

973 Association of coronary artery calcification with obstructive sleep apnea and obesity in middle-aged men. **2010**, 20, 575-82 28

972 Carbohydrate restriction favorably alters lipoprotein metabolism in Emirati subjects classified with the metabolic syndrome. **2010**, 20, 720-6 12

971 Neonatal and fetal exposure to trans-fatty acids retards early growth and adiposity while adversely affecting glucose in mice. **2010**, 30, 418-26 18

970 [Comorbidities in psoriasis]. **2010**, 101 Suppl 1, 55-61 2

969 Metabolic syndrome and risk of pulmonary involvement. **2010**, 104, 47-51 15

968 Reduced vascular responsiveness to adiponectin in hyperlipidemic rats--mechanisms and significance. **2010**, 49, 508-15 27

967 Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005-2006. **2010**, 51, 18-23 86

966 Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses. **2010**, 2, 50-69 13

965 Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. **2010**, 159, 385-91 16

964 Physician diagnosis of overweight status predicts attempted and successful weight loss in patients with cardiovascular disease and central obesity. **2010**, 160, 934-42 29

963 Enfermedad del h□gado graso no alcoh□ico y riesgo cardiovascular. **2010**, 22, 259-271

962 Diabetes and 15-year cardiovascular mortality in a Chinese population: Differential impact of hypertension and metabolic syndrome. **2010**, 73, 234-40 5

961 The association of uncarboxylated matrix Gla protein with mitral annular calcification differs by diabetes status: The Heart and Soul study. **2010**, 210, 320-5 21

960 Metabolic syndrome is an independent predictor of cardiovascular events in high-risk patients with occlusive and aneurysmatic peripheral arterial disease. **2010**, 210, 596-601 28

959 Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. **2010**, 211, 182-6 70

958 Cardiovascular and metabolic characteristics of infertile Chinese women with PCOS diagnosed according to the Rotterdam consensus criteria. **2010**, 21, 572-80 30

957	The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. **2010**, 30, 273-90	83
956	Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. **2010**, 30, 1474-8	150
955	Metabolic syndrome and physical fitness in a sample of Azorean adolescents. **2010**, 8, 443-9	15
954	Anesthesia Student Survival Guide. **2010**,	1
953	Maximal exercise electrocardiographic responses and coronary heart disease mortality among men with metabolic syndrome. **2010**, 85, 239-46	8
952	Predictive performances of lipid accumulation product vs. adiposity measures for cardiovascular diseases and all-cause mortality, 8.6-year follow-up: Tehran lipid and glucose study. **2010**, 9, 100	39
951	Healthcare resource utilization, adherence and persistence with antipsychotic therapy among schizophrenia patients with vs. without pre-existing metabolic syndrome. **2010**, 26, 2499-506	4
950	The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. **2010**, 10, 59-76	210
949	Epidemiology of gout. **2010**, 12, 223	238
948	Development of a RP-HPLC method for the simultaneous analysis of diltiazem and statin: Application in pharmaceuticals and human serum. **2010**, 2, 1571	11
947	Protective effect of Clerodendron glandulosum extract against experimentally induced metabolic syndrome in rats. **2010**, 48, 1312-9	13
946	The National Niemann-Pick Type C1 Disease Database: correlation of lipid profiles, mutations, and biochemical phenotypes. **2010**, 51, 406-15	76
945	Characterization of systemic metabolic phenotypes associated with subclinical atherosclerosis. **2011**, 7, 385-93	26
944	Effects of vitamin D supplementation on 25-hydroxyvitamin D, high-density lipoprotein cholesterol, and other cardiovascular disease risk markers in subjects with elevated waist circumference. **2011**, 62, 318-27	39
943	An analysis of the management of cardiovascular risk factors in routine clinical practice in Italy: an overview of the main findings of the EFFECTUS study. **2011**, 18, 19-30	7
942	Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. **2011**, 164, 559-67	72
941	Shift work and chronic disease: the epidemiological evidence. **2011**, 61, 78-89	382
940	Predictors for metabolic syndrome in perimenopausal and postmenopausal Thai women. **2011**, 14, 58-65	27

939	Thrombophilia mediates lowering cardiovascular risk factors in women with a history of preeclampsia. **2011**, 30, 421-32	2
938	Hip circumference and incident metabolic risk factors in Chinese men and women: the People's Republic of China study. **2011**, 9, 55-62	18
937	Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. **2011**, 71, 631-6	29
936	Immune and neuroimmune alterations in mood disorders and schizophrenia. **2011**, 101, 169-201	53
935	Disease Prevention in Heart Failure. **2011**, 610-625	
934	Associations between levels of serum perfluorinated chemicals and adiponectin in a young hypertension cohort in Taiwan. **2011**, 45, 10691-8	47
933	Adiposity and aerobic fitness are associated with metabolic disease risk in children. **2011**, 36, 72-9	19
932	Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. **2011**, 46, 91-7	89
931	The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD without co-morbidities. **2011**, 8, 414-20	34
930	Obesity in rheumatoid arthritis. **2011**, 50, 450-62	144
929	BPCO, obesit^, sindrome metabolica e diabete. **2011**, 5, 75-80	
928	Diets for successful aging. **2011**, 27, 577-89	5
927	Update: metabolic and cardiovascular consequences of bariatric surgery. **2011**, 40, 81-96, viii	6
926	Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. **2011**, 58, 131-7	38
925	A Mediterranean-style low-glycemic-load diet improves variables of metabolic syndrome in women, and addition of a phytochemical-rich medical food enhances benefits on lipoprotein metabolism. **2011**, 5, 188-196	45
924	Metabolic syndrome--psycho neuropathogenesis and human brain evolution. **2011**, 5, 38-40	
923	Prevalence of metabolic syndrome among obese school students. **2011**, 6, e248-e252	7
922	Clinical Nutrition University. The place of nutrition in the prevention of´cardiovascular diseases (CVDs). **2011**, 6, e272-e282	4

921	The effect of a fibre supplement compared to a healthy diet on body composition, lipids, glucose, insulin and other metabolic syndrome risk factors in overweight and obese individuals. **2011**, 105, 90-100	78
920	The prevalence of metabolic syndrome in Latin America: a systematic review. **2011**, 14, 1702-13	104
919	Factors associated with prevalence, awareness, treatment and control of hypertension in urban adults from 33 communities in China: the CHPSNE Study. **2011**, 34, 1087-92	36
918	Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. **2011**, 126, 110-6	57
917	Med25 is required for RNA polymerase II recruitment to specific promoters, thus regulating xenobiotic and lipid metabolism in human liver. **2011**, 31, 466-81	50
916	Hot Topics in Infection and Immunity in Children VIII. **2011**,	
915	Metabolic syndrome in the elderly living in marginal peri-urban communities in Quito, Ecuador. **2011**, 14, 758-67	28
914	Physical activity, metabolic syndrome, and coronary risk: the EPIC-Norfolk prospective population study. **2011**, 18, 209-17	39
913	The metabolic syndrome--from insulin resistance to obesity and diabetes. **2011**, 95, 855-73	78
912	Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. **2011**, 15, 281-96, vii-x	40
911	ST-T Abnormalities on ECG in Relation to Cardiovascular Risk Factors. **2011**, 27, 202-207	2
910	Estudio gentico de la implicaci del gen USF1 en el desarrollo del sndrome metablico. **2011**, 23, 78-87	
909	Elevated oxidized low-density lipoprotein concentrations in postmenopausal women with the metabolic syndrome. **2011**, 412, 435-40	12
908	Serum carcinoembryonic antigen is associated with metabolic syndrome in female Korean non-smokers. **2011**, 412, 527-30	25
907	Complement C3 and cleavage products in cardiometabolic risk. **2011**, 412, 1171-9	86
906	The role of oxidative stress in non-alcoholic steatohepatitis. **2011**, 412, 1297-305	233
905	Persistent elevation of paraoxonase-1 specific enzyme activity after weight reduction in obese non-diabetic men with metabolic syndrome. **2011**, 412, 1835-41	18
904	Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. **2011**, 412, 2296-9	11

903	Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). **2011**, 27, 124-31	41
902	Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. **2011**, 14, 804-10	396
901	Diabetes and sleep: a complex cause-and-effect relationship. **2011**, 91, 129-37	111
900	Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. **2011**, 91, 159-63	58
899	The rs1801278 G>A polymorphism of IRS-1 is associated with metabolic syndrome in healthy nondiabetic men. Modulation by cigarette smoking status. **2011**, 93, e95-7	2
898	Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications. **2011**, 1812, 842-50	67
897	Obesity, metabolic dysregulation and oxidative stress in asthma. **2011**, 1810, 1120-6	39
896	Association between adolescent emotional problems and metabolic syndrome: the modifying effect of C-reactive protein gene (CRP) polymorphisms. **2011**, 25, 750-8	22
895	National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction. **2011**, 17, 1573-84	63
894	High fat diet induced downregulation of microRNA-467b increased lipoprotein lipase in hepatic steatosis. **2011**, 414, 664-9	57
893	Inhibitors of 11□hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. **2011**, 127-46	17
892	Hyperinsulinemia is a predictor of new cardiovascular events in Colombian patients with a first myocardial infarction. **2011**, 148, 85-90	21
891	Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. **2011**, 25, 326-30	50
890	Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. **2011**, 21, 783-91	19
889	Few favorable associations between fruit and vegetable intake and biomarkers for chronic disease risk in American adults. **2011**, 31, 616-24	8
888	Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. **2011**, 189, 200-7	14
887	[Cardiovascular risk factors in Spain in the first decade of the 21st Century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study]. **2011**, 64, 295-304	174
886	Daô renal en pacientes con s□ndrome metab□co que consultan en atenci□ primaria. **2011**, 37, 119-124	

885	Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease. **2011**, 105 Suppl 1, S12-9	14
884	Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome. **2011**, 218, 499-506	23
883	Cardiovascular Risk Factors in Spain in the First Decade of the 21st Century, a Pooled Analysis With Individual Data From 11 Population-Based Studies: the DARIOS Study. **2011**, 64, 295-304	4
882	Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. **2011**, 217, 125-9	45
881	Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. **2011**, 219, 596-602	30
880	Revised waist circumference cut-off points for the criteria of abdominal obesity in the Spanish population: Multicenter nationwide Spanish population based study. **2011**, 27, 168-174	15
879	A cross-sectional study of the association between heat shock protein 27 antibody titers, pro-oxidant-antioxidant balance and metabolic syndrome in patients with angiographically-defined coronary artery disease. **2011**, 44, 1390-5	18
878	Associations of psychological distress with metabolic syndrome among Japanese urban residents. **2011**, 18, 396-402	25
877	Gluco-lipidic indices in treated hypothyroidism associated with nonalcoholic fatty liver disease. **2011**, 48, 186-9	27
876	[Metabolic syndrome in children and adolescents: doubts about terminology but not about cardiometabolic risks]. **2011**, 55, 576-82	16
875	Evaluation of metabolic syndrome in patients with chronic low back pain: using the fourth Korea national health and nutrition examination survey data. **2011**, 47, 160-4	6
874	Rising Gout, Life Threatening Public Enemy. **2011**, 18, 234	1
873	Prevalence of metabolic syndrome and its association with educational inequalities among Brazilian adults: a population-based study. **2011**, 44, 713-9	23
872	Perfil de riesgo cardiovascular en adultos jóvenes asintomáticos con grosor íntima media carotídeo elevado. **2011**, 139, 1322-1329	8
871	HIV and HAART-Associated Dyslipidemia. **2011**, 5, 49-63	99
870	Unit 2. Giving dietary advice. **2011**, 22, 1-4	
869	Síndrome metabólico y antipsicóticos de segunda generación. **2011**, 31, 303-320	4
868	Are all criteria of metabolic syndrome equally harmful?. **2011**, 66, 189-96	5

867	Is the metabolic syndrome caused by a high fructose, and relatively low fat, low cholesterol diet?. **2011**, 7, 8-20	34
866	Increase in metabolic syndrome-related hospitalizations in relation to environmental sources of persistent organic pollutants. **2011**, 8, 762-76	5
865	Carotid intima media thickness and cardiometabolic risk associates in Turkish adults. **2011**, 66, 759-64	
864	Prevalence of metabolic syndrome and risks of abnormal serum alanine aminotransferase in Hispanics: a population-based study. **2011**, 6, e21515	35
863	The relationship between psychosocial stress, age, BMI, CRP, lifestyle, and the metabolic syndrome in apparently healthy subjects. **2011**, 30, 15-22	30
862	A health outcome assessment of the Cardio Metabolic Mission Health Program at Novartis. **2011**, 53, 647-52	5
861	Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. **2011**, 17, 100-9	14
860	Prevalence, awareness, treatment, control, and risk factors associated with hypertension in urban adults from 33 communities of China: the CHPSNE study. **2011**, 29, 1303-10	69
859	Time course of endothelial adaptation after acute and chronic exercise in patients with metabolic syndrome. **2011**, 25, 2552-8	37
858	The metabolic fitness program: lifestyle modification for the metabolic syndrome using the resources of cardiac rehabilitation. **2011**, 31, 282-9	21
857	Metabolic syndrome is associated with gastric dysplasia. **2011**, 23, 871-5	9
856	Early possible risk factors for overt diabetes after gestational diabetes mellitus. **2011**, 118, 71-78	36
855	Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. **2011**, 32, 218-25	60
854	Obesity in China: what are the causes?. **2011**, 17, 1132-9	15
853	Norlichexanthone isolated from fungus P16 promotes the secretion and expression of adiponectin in cultured ST-13 adipocytes. **2011**, 7, 250-6	10
852	Effects of insulin on the vasculature. **2011**, 9, 321-32	24
851	Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. **2011**, 25, 2133-42	39
850	Improving monitoring for metabolic syndrome using audit. **2011**, 28, i-iv	4

849	Cardiorespiratory fitness, obesity, and functional limitation in older adults. **2011**, 19, 336-46	4
848	Telmisartan improves insulin resistance in patients with low cytokine levels. **2011**, 59, 602-5	2
847	Mechanisms and Complications of Metabolic Syndrome. **2011**, 177-197	
846	Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance. **2011**, 75, 964-9	17
845	11β-Hydroxysteroid Dehydrogenase Type 1 as a Therapeutic Target for Type 2 Diabetes. **2011**, 423-458	
844	[Incidence of metabolic syndrome and associated lifestyle factors in a worksite male population]. **2011**, 53, 78-86	14
843	Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients. **2011**, 16, 85-92	3
842	Dyslipidemia intervention in metabolic syndrome: emphasis on improving lipids and clinical event reduction. **2011**, 341, 388-93	22
841	Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease. **2011**, 342, 383-7	15
840	Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach. **2011**, 28, 941-7	19
839	Obesity, metabolic syndrome, adipocytes and vascular function: A holistic viewpoint. **2011**, 38, 1-10	73
838	Androgenetic alopecia and insulin resistance: are they truly associated?. **2011**, 50, 417-22	30
837	Metabolic syndrome and hepatic resection: improving outcome. **2011**, 13, 846-59	9
836	Impact of physicians' age on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation Educational Programme. **2011**, 65, 649-57	0
835	Mechanisms of cerebrovascular protection: oestrogen, inflammation and mitochondria. **2011**, 203, 149-54	30
834	Obesity, blood vessels and metabolic syndrome. **2011**, 203, 279-86	60
833	Association between the leptin gene 2548G/A polymorphism, the plasma leptin and the metabolic syndrome with psoriasis. **2011**, 20, 715-9	38
832	Hypertriglyceridemic waist: an alternative to the metabolic syndrome? Results of the IMAP Study (multidisciplinary intervention in primary care). **2011**, 35, 292-9	60

831	Obesity-related non-communicable diseases: South Asians vs White Caucasians. **2011**, 35, 167-87	251
830	Metabolic normality in overweight and obese subjects. Which parameters? Which risks?. **2011**, 35, 1208-15	32
829	The relationship between periodontitis and metabolic syndrome among a Korean nationally representative sample of adults. **2011**, 38, 781-6	75
828	Effect of hydroxypropyl methylcellulose on obesity and glucose metabolism in a diet-induced obesity mouse model. **2011**, 3, 158-67	17
827	Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating Ēblockers. **2011**, 13, 52-9	47
826	Autonomic nervous system dysfunction in obesity and Prader-Willi syndrome: current evidence and implications for future obesity therapies. **2011**, 1, 175-83	11
825	Metabolic syndrome in transplant patients: an academic or a health burden?. **2011**, 43, 313-7	5
824	Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfunction in patients with dilated cardiomyopathy without overt heart failure. **2011**, 60, 227-33	20
823	Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. **2011**, 60, 544-9	53
822	Intensive practical lifestyle intervention improves endothelial function in metabolic syndrome independent of weight loss: a randomized controlled trial. **2011**, 60, 1736-40	32
821	Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. **2011**, 25, 143-50	16
820	Non-high-density lipoprotein cholesterol concentration is associated with the metabolic syndrome among US youth aged 12-19 years. **2011**, 158, 201-7	36
819	Paradoxically high adiponectin in obese 16-year-old girls protects against appearance of the metabolic syndrome and its components seven years later. **2011**, 158, 208-14.e1	16
818	Racial/ethnic and sex differences in the ability of metabolic syndrome criteria to predict elevations in fasting insulin levels in adolescents. **2011**, 159, 975-81.e3	37
817	[Prevalence of metabolic syndrome in patients with stable coronary disease: therapeutic objectives and utilization of cardiovascular drugs]. **2011**, 211, 1-8	3
816	Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. **2011**, 11, 29-35	1
815	The effect of family-based multidisciplinary cognitive behavioral treatment in children with obesity: study protocol for a randomized controlled trial. **2011**, 12, 110	16
814	Predicting cardiovascular risk in young adulthood from the metabolic syndrome, its component risk factors, and a cluster score in childhood. **2011**, 6, e283-9	71

813	The association between physical activity, physical fitness and development of metabolic disorders. **2011**, 6 Suppl 1, 29-34	46
812	Dietary fiber and nutrient density are inversely associated with the metabolic syndrome in US adolescents. **2011**, 111, 1688-95	67
811	Metabolic syndrome in adolescents: issues and opportunities. **2011**, 111, 1674-9	8
810	Soluble CD40 ligand, interleukin (IL)-6, and hemostatic parameters in metabolic syndrome patients with and without overt ischemic heart disease. **2011**, 63, 131-135	3
809	Could maternal perinatal atypical antipsychotic treatments program later metabolic diseases in the offspring?. **2011**, 667, 13-6	3
808	Triglyceride to HDL ratio is a reliable predictor of adverse outcomes in risk stratification for candidates undergoing abdominal aortic surgery. **2011**, 41, 249-55	2
807	Macrovascular effects and safety issues of therapies for type 2 diabetes. **2011**, 108, 25B-32B	25
806	Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study). **2011**, 108, 367-73	32
805	Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. **2011**, 108, 1129-35	18
804	Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease. **2011**, 42, 38-43	12
803	Contribution of serum leptin to metabolic syndrome in obese and nonobese subjects. **2011**, 42, 244-51	23
802	Impact of diabetes mellitus on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) educational program. **2011**, 34, 560-6	10
801	Potential mechanisms by which polyphenol-rich grapes prevent obesity-mediated inflammation and metabolic diseases. **2011**, 31, 155-76	172
800	GWAS of butyrylcholinesterase activity identifies four novel loci, independent effects within BCHE and secondary associations with metabolic risk factors. **2011**, 20, 4504-14	35
799	Mitochondrial energy metabolism and redox responses to hypertriglyceridemia. **2011**, 43, 19-23	27
798	Cytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apnea. **2011**, 15, 3-11	22
797	Preliminary data on the association between waist circumference and insulin resistance in children without a previous diagnosis. **2011**, 170, 35-43	22
796	AKT1 polymorphisms are associated with risk for metabolic syndrome. **2011**, 129, 129-39	22

795	Monitoring der künstlichen Ernährung bei kritisch kranken Patienten. **2011**, 48, 99-108	
794	The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. **2011**, 261, 69-78	28
793	Obesity and coronary risk in patients treated with second-generation antipsychotics. **2011**, 261, 417-23	24
792	Familial Mediterranean fever: an association with non-alcoholic fatty liver disease. **2011**, 30, 987-91	12
791	Distinct hepatic lipid profile of hypertriglyceridemic mice determined by easy ambient sonic-spray ionization mass spectrometry. **2011**, 401, 1651-9	22
790	Prolonged Sitting and the Risk of Cardiovascular Disease and Mortality. **2011**, 5, 350-357	9
789	Prevalence of coronary artery calcium scores and silent myocardial ischaemia was similar in Indian Asians and European whites in a cross-sectional study of asymptomatic subjects from a U.K. population (LOLIPOP-IPC). **2011**, 18, 435-42	5
788	Metabolic Syndrome and Breast Cancer Risk: Is There a Role for Metformin?. **2011**, 3, 142-150	9
787	Prévalence du syndrome métabolique chez des enfants obèses tunisiens âgés de 6 à 12 ans. **2011**, 6, 235-241	
786	NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis. **2011**, 21, 310-5	26
785	Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. **2011**, 46, 209-28	329
784	High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. **2011**, 46, 521-8	20
783	Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?. **2011**, 11, 91-8	8
782	Awareness, treatment and control of hypertension among the elderly living in their home in Tunisia. **2011**, 11, 65	26
781	Can body mass index, waist circumference, waist-hip ratio and waist-height ratio predict the presence of multiple metabolic risk factors in Chinese subjects?. **2011**, 11, 35	97
780	Associations of cardiovascular risk factors, carotid intima-media thickness and manifest atherosclerotic vascular disease with carpal tunnel syndrome. **2011**, 12, 80	30
779	Association of inflammation and endothelial dysfunction with metabolic syndrome, prediabetes and diabetes in adults from Inner Mongolia, China. **2011**, 11, 16	18
778	Serum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality study. **2011**, 10, 46	24

777	Association between metabolic abnormalities and HBV related hepatocelluar carcinoma in Chinese: a cross-sectional study. **2011**, 10, 49	29
776	Drinking carrot juice increases total antioxidant status and decreases lipid peroxidation in adults. **2011**, 10, 96	42
775	Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis. **2011**, 10, 13	21
774	Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome. **2011**, 10, 82	40
773	Predictive performance of the visceral adiposity index for a visceral adiposity-related risk: type 2 diabetes. **2011**, 10, 88	55
772	Metabolic syndrome and dietary components are associated with coronary artery disease risk score in free-living adults: a cross-sectional study. **2011**, 3, 7	18
771	Prevalence of metabolic syndrome in bus and truck drivers in Kashan, Iran. **2011**, 3, 8	38
770	Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. **2011**, 71, 1492-8	51
769	Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. **2011**, 63, 512-21	62
768	Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. **2011**, 63, 3216-25	69
767	Ischemia-modified albumin as an oxidative stress biomarker in obesity. **2011**, 44, 345-7	48
766	Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. **2011**, 44, 955-8	9
765	Development of an LC-MS/MS method for the quantitation of 55 compounds prescribed in combined cardiovascular therapy. **2011**, 879, 243-52	47
764	Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up. **2011**, 12, 1481-9	11
763	Dairy attentuates oxidative and inflammatory stress in metabolic syndrome. **2011**, 94, 422-30	142
762	Dairy constituents and neurocognitive health in ageing. **2011**, 106, 159-74	90
761	Chronic dietary n-3 PUFA intervention improves dyslipidaemia and subsequent cardiovascular complications in the JCR:LA- cp rat model of the metabolic syndrome. **2011**, 105, 1572-82	46
760	Reduction of monocyte chemoattractant protein 1 and macrophage migration inhibitory factor by a polyphenol-rich extract in subjects with clustered cardiometabolic risk factors. **2011**, 106, 1416-22	15

759	Adolescent BMI and risk of diabetes versus coronary disease. **2011**, 364, 2558-9; author reply 2559	1
758	Epicardial adipose tissue and metabolic syndrome in hypertensive patients with normal body weight and waist circumference. **2011**, 24, 1245-9	18
757	Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity: National Health and Nutrition Examination Survey 2001-2004. **2011**, 34, 1642-7	59
756	Obstructive sleep apnea and cardiovascular disease. **2011**, 19, 279-90	30
755	Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. **2011**, 26, 565-76	78
754	Ethnic disparities in metabolic syndrome in malaysia: an analysis by risk factors. **2011**, 9, 441-51	29
753	Higher aldosterone and lower N-terminal proatrial natriuretic peptide as biomarkers of salt sensitivity in the community. **2011**, 18, 664-73	10
752	Cardiovascular Risk Is Increased in Miner's Chronic Intermittent Hypobaric Hypoxia Exposure From 0 to 2,500 m?. **2021**, 12, 647976	1
751	Non-alcoholic fatty liver disease in polycystic ovary syndrome women. **2021**, 11, 7085	6
750	Role of dietary calcium and its possible mechanism against metabolic disorders: A concise review. **2021**, 45, e13697	2
749	Hypothyroidism and its influence in the development of Metabolic Syndrome (MetS).	
748	Anthropometric cut-points for discriminating diabetes and the metabolic syndrome among Arabs and Asians: the Kuwait Diabetes Epidemiology Program. **2021**, 1-11	1
747	Ambient air pollution and risk of respiratory infection among adults: evidence from the multiethnic study of atherosclerosis (MESA). **2021**, 8,	2
746	Which diagnostic criteria of metabolic syndrome are predictors of cardiovascular diseases in elderly populations?. **2021**, 23, 100248	
745	Late adverse effects and quality of life in survivors of testicular germ cell tumour. **2021**, 18, 227-245	9
744	Multi-Target Approaches in Metabolic Syndrome. **2020**, 11, 554961	11
743	Association of metabolic syndrome with mobility in the older adults: a Korean nationwide representative cross-sectional study. **2021**, 11, 6605	0
742	The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases. **2021**, 23, 89	

741	Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study. **2020**, 11, 560958	1
740	Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials. **2021**, 166, 105512	12
739	Differences in Several Factors in the Development of Erosive Esophagitis Among Patients at Various Stages of Metabolic Syndrome: A Cross-Sectional Study. **2021**, 14, 1589-1600	
738	Cardiac MRI for Patients with Increased Cardiometabolic Risk. **2021**, 3, e200575	
737	Mitochondria-DNA copy-number and incident venous thromboembolism among middle-aged women: a population-based cohort study. **2021**, 52, 148-157	0
736	Dietary isoflavones intake is inversely associated with non-alcoholic fatty liver disease, hyperlipidaemia and hypertension. **2021**, 1-11	3
735	Role of exercise on visceral adiposity after spinal cord injury: a cardiometabolic risk factor. **2021**, 121, 2143-2163	2
734	Validation of a continuous measure of cardiometabolic risk among adolescents. **2021**, 34, 763-770	
733	Dietary Strategies for Management of Metabolic Syndrome: Role of Gut Microbiota Metabolites. **2021**, 13,	14
732	Very High Coronary Artery Calcium (â1000) and Association With Cardiovascular Disease Events, Non-Cardiovascular Disease Outcomes, and Mortality: Results From MESA. *Circulation*, **2021**, 143, 1571-1583 1667	13
731	Saroglitazar, a novel dual PPAR-Â agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL/6J male mice. **2021**, 271, 119191	1
730	Metabolic syndrome and lifestyle-associated factors in the ethnically diverse population of Khuzestan, Iran: a cross-sectional study. **2021**, 20, 747-756	2
729	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. **2021**, 397, 2385-2438	80
728	Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes. **2021**, 41,	2
727	Role of Metabolic Syndrome in Prostate Cancer Development. **2021**, 7, 508-512	0
726	Coronary Collateral Flow Index Is Correlated With the Palmar Collateral Flow Index: Indicating Systemic Collateral Coherence in Individual Patients-Brief Report. **2021**, 41, 1830-1836	1
725	Divergent trajectories of cellular bioenergetics, intermediary metabolism and systemic redox status in survivors and non-survivors of critical illness. **2021**, 41, 101907	6
724	Extent of heel ulceration influences the outcomes in patients with isolated infrapopliteal limb threatening critical ischemia. **2021**, 73, 1731-1740.e2	

723	Associations between urinary hydration markers and metabolic dysfunction: a cross-sectional analysis of NHANES data, 2008-2010. **2021**, 60, 4229-4241	1
722	The role of mitochondria in metabolic disease: a special emphasis on heart dysfunction. **2021**, 599, 3477-3493	4
721	Association of Oxidative Balance Score with the Metabolic Syndrome in a Sample of Iranian Adults. **2021**, 2021, 5593919	3
720	Machine and Deep Learning Applied to Predict Metabolic Syndrome without a Blood Screening. **2021**, 11, 4334	0
719	An Empirically Derived Definition of Metabolically Healthy Obesity Based on Risk of Cardiovascular and Total Mortality. **2021**, 4, e218505	15
718	Mitochondrial genome copy number measured by DNA sequencing in human blood is strongly associated with metabolic traits via cell-type composition differences. **2021**, 15, 34	2
717	Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. **2021**, 17, 747-765	0
716	Enhanced solubility and biopharmaceutical performance of atorvastatin and metformin via electrospun polyvinylpyrrolidone-hyaluronic acid composite nanoparticles. **2021**, 161, 105817	0
715	Mapping pleiotropic loci using a fast-sequential testing algorithm. **2021**, 29, 1762-1773	0
714	Association between Visceral Adipose Tissue and Non-Alcoholic Steatohepatitis Histology in Patients with Known or Suspected Non-Alcoholic Fatty Liver Disease. **2021**, 10,	0
713	Integrated transcriptome and proteome analysis reveals potential mechanisms for differential abdominal fat deposition between divergently selected chicken lines. **2021**, 241, 104242	0
712	Racial and Sex Differences between Urinary Phthalates and Metabolic Syndrome among U.S. Adults: NHANES 2005-2014. **2021**, 18,	3
711	Insulin resistance, metabolic syndrome, and blood pressure progression among Blacks: the Jackson Heart Study. **2021**, 39, 2200-2209	0
710	Metabolic syndrome and bladder cancer. **2021**, 128, 1-2	1
709	The prevalence and correlates of pre-diabetes in middle- to older-aged Irish adults using three diagnostic methods. **2021**, 16, e0253537	1
708	Childhood maltreatment predicts physical health in college students. **2021**, 1-10	
707	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. **2021**, 10,	2
706	Circulating extracellular DNA is in association with continuous metabolic syndrome score in healthy adolescents. **2021**, 53, 309-318	0

705	Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC. **2021**,	3
704	Metabolic syndrome and the risk of colorectal cancer: a systematic review and meta-analysis. **2021**, 36, 2215-2225	3
703	Plasma Bile Acid Profile in Patients with and without Type 2 Diabetes. **2021**, 11,	3
702	Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health. **2021**, 11, 99-108	0
701	Expression of Jejunal Taste Receptors in Women with Morbid Obesity. **2021**, 13,	0
700	Dietary sugar intake and risk of Alzheimer's disease in older women. **2021**, 1-12	
699	Risk of Death in Colorectal Cancer Patients with Multi-morbidities of Metabolic Syndrome: A Retrospective Multicohort Analysis. **2021**, 53, 714-723	2
698	A novel inflammatory signaling pathway in patients with slow coronary flow: NF-B/IL-1/nitric oxide. **2021**, 143, 155511	3
697	Temporal correlation of morphological and biochemical changes with the recruitment of different mechanisms of reactive oxygen species formation during human SW872 cell adipogenic differentiation. **2021**, 47, 837-851	1
696	Adipose tissue biomarkers and type 2 diabetes incidence in normoglycemic participants in the MESArthritis Ancillary Study: A cohort study. **2021**, 18, e1003700	1
695	Effects of probiotic supplementation on anthropometric and metabolic characteristics in adults with metabolic syndrome: A systematic review and meta-analysis of randomized clinical trials. **2021**, 40, 4662-4673	8
694	Sudden Sensorineural Hearing Loss and Metabolic Syndrome: A Systematic Review and Meta-analysis. **2021**, 42, 1308-1313	0
693	Adiposity and cancer: a Mendelian randomization analysis in the UK biobank. **2021**, 45, 2657-2665	0
692	Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic. **2021**, 32, 466-472	0
691	CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes. **2021**, 321, C201-C213	2
690	Dietary Sugar Intake and Its Association with Obesity in Children and Adolescents. **2021**, 8,	4
689	Association of long-term exposure to ambient particulate pollution with stage 1 hypertension defined by the 2017 ACC/AHA Hypertension Guideline and cardiovascular disease: The CHCN-BTH cohort study. **2021**, 199, 111356	2
688	Variable Changes of Circulating ANGPTL3 and ANGPTL4 in Different Obese Phenotypes: Relationship with Vasodilator Dysfunction. **2021**, 9,	2

687	The Effect of Laparoscopic Sleeve Gastrectomy on Glycemic Control in Type 2 Diabetic Patients. **2021**, 13, e16986	
686	Mechanistically acting anti-obesity compositions/formulations of natural origin: a patent review (2010-2021). **2021**, 1-18	1
685	Association of the metabolic syndrome with mortality and major adverse cardiac events: A large chronic kidney disease cohort. **2021**, 290, 1219-1232	5
684	Effects of Tai Chi on health outcomes among community-dwelling adults with or at risk of metabolic syndrome: A systematic review. **2021**, 44, 101445	0
683	Metabolic Comorbidities in Vitiligo: A Brief Review and Report of New Data from a Single-Center Experience. **2021**, 22,	1
682	Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. **2021**, 43, 1505-1522	0
681	Physical inactivity and headache disorders: Cross-sectional analysis in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). **2021**, 41, 1467-1485	0
680	The Relationship and Gender Disparity Between Thyroid Nodules and Metabolic Syndrome Components Based on a Recent Nationwide Cross-Sectional Study and Meta-Analysis. **2021**, 12, 736972	3
679	ADA gene haplotype is associated with coronary-in-stent-restenosis. **2021**, 48, 6665-6671	
678	Obesity, metabolic syndrome, and inflammation: An update for anaesthetists caring for patients with obesity. **2021**, 40, 100947	2
677	The role of body mass index or metabolic syndrome components causing depression in women: An observation from weight reduction clinical trial. **2021**, 46, 1757-1763	1
676	Effects of different definitions of low muscle mass on its association with metabolic syndrome in older adults: A Korean nationwide study. **2021**, 21, 1003-1009	2
675	Changes in Cardiometabolic Risk Among Older Adults with Obesity: An Ancillary Analysis of a Randomized Controlled Trial Investigating Exercise Plus Weight Maintenance and Exercise Plus Intentional Weight Loss by Caloric Restriction. **2021**,	1
674	Live Monitoring of Inflammation Reveals Tissue and Sex-specific Responses to Western Diet and Butyrate treatment.	
673	Inflammatory Biomarkers and Components of Metabolic Syndrome in Adolescents: a Systematic Review. **2021**, 1	3
672	Microvessel Density: Integrating Sex-Based Differences and Elevated Cardiovascular Risks in Metabolic Syndrome. **2021**, 1-15	1
671	Alternative Dietary Patterns for Americans: Low-Carbohydrate Diets. **2021**, 13,	2
670	Effects of Caffeinated and Decaffeinated Coffee Consumption on Metabolic Syndrome Parameters: A Systematic Review and Meta-Analysis of Data from Randomised Controlled Trials. **2021**, 57,	3

669	Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease. **2021**, 54, 101342	0
668	Cohort study evaluation of New Chinese Diabetes Risk Score: A new non-invasive indicator for predicting metabolic syndrome. **2021**, 15, 825-831	
667	Dietary fibers extracted from Saccharina japonica can improve metabolic syndrome and ameliorate gut microbiota dysbiosis induced by high fat diet. **2021**, 85, 104642	0
666	Association between mesenteric panniculitis and non-neoplastic disorders. **2021**, 79, 219-224	0
665	Cladosporols A and B, two natural peroxisome proliferator-activated receptor gamma (PPARγ) agonists, inhibit adipogenesis in 3T3-L1 preadipocytes and cause a conditioned-culture-medium-dependent arrest of HT-29 cell proliferation. **2021**, 1865, 129973	2
664	Associations between metabolic syndrome and anthropogenic heat emissions in northeastern China. **2022**, 204, 111974	1
663	Prevalence of different comorbidities in chronic obstructive pulmonary disease among Shahrekord PERSIAN´cohort study in southwest Iran. **2021**, 11, 1548	5
662	Anthropometric Prediction of Visceral Adiposity in Persons With Spinal Cord Injury. **2021**, 27, 23-35	3
661	Metabolic Syndrome Fact Sheet 2021: Executive Report. **2021**, 1, 125	5
660	Meeting the challenge of physical comorbidity and unhealthy lifestyles. 114-130	1
659	Lipids, Atherogenic Dyslipidemia, and Therapy. 347-408	1
658	Principles of Pharmacological Treatment in Schizophrenia. 515-524	1
657	Correction of insulin resistance and the metabolic syndrome. **2005**, 591-617	2
656	Laparoscopic Roux-en-Y Gastric Bypass: Outcomes. **2007**, 271-280	1
655	Imprinted genes, postnatal adaptations and enduring effects on energy homeostasis. **2008**, 626, 41-61	28
654	Economic Burden of the Components of the Metabolic Syndrome. **2010**, 1135-1149	6
653	The Metabolic Syndrome. **2011**, 1-26	2
652	Triglyceride-Rich Lipoproteins. **2011**, 59-91	2

651	Mechanisms Linking Obesity to Cancer Risk. **2011**, 99-142	2
650	Obesity, Metabolic Syndrome and Type 2 Diabetes. **2014**, 499-507	1
649	Olive Oil as a Functional Food: Nutritional and Health Benefits. **2013**, 677-714	12
648	Nutraceutical Approaches in the Management of Cardiovascular Dysfunctions Associated with Diabetes Mellitus. **2014**, 377-396	1
647	Management of Medication-Related Adverse Effects. **2014**, 225-262	1
646	Dietary Calcium and the Metabolic Syndrome. **2006**, 401-409	3
645	Diagnosing Obesity, Diabetes Mellitus, and Insulin Resistance Syndrome. **2006**, 129-153	1
644	Metabolic Syndrome. **2006**, 155-168	1
643	Fatty Acids in the Causation and Therapy of Metabolic Syndrome. **2008**, 263-284	3
642	Systemic first-line phenotyping. **2009**, 530, 463-509	67
641	Chronomics of the Metabolic Syndrome. **2008**, 373-386	2
640	Cardiovascular Risk Assessment and Summary of Guidelines for the Management of Hypertension. **2011**, 97-113	1
639	Adipocytes as Target Cells for Endocrine Disruption. **2012**, 255-271	1
638	Nutritional Counseling for Overweight Patients and Patients with Metabolic Syndrome. **2007**, 201-211	1
637	Role of Perfluoroalkyl Substances as EDCs in Metabolic Disorders. **2021**, 301-322	1
636	Metabolic Syndrome, Obesity, and Osteoarthritis. **2015**, 27-42	1
635	Adipose Tissue and Cutaneous Inflammation. **2017**, 219-238	3
634	Objective and Subjective Aspects of the Drive to Eat in Obesogenic Environments. **2016**, 195-230	1

633	Differentiation Potential of Adult Human Mesenchymal Stem Cells. **2011**, 61-77	3
632	Sphingolipids in obesity, type 2 diabetes, and metabolic disease. **2013**, 373-401	64
631	Evolution of Metabolic Syndrome from Childhood. **2011**, 35-52	1
630	Mechanosensitivity of Pancreatic □cells, Adipocytes, and Skeletal Muscle Cells: The Therapeutic Targets of Metabolic Syndrome. **2012**, 379-404	2
629	Anesthesia for Bariatric Surgery. **2010**, 2089-2104	2
628	The Metabolic Syndrome. **2010**, 822-839	2
627	Primary and Secondary Hypertension. **2012**, 1670-1751	1
626	Complications of Diabetes Mellitus. **2011**, 1462-1551	7
625	Special Patient Populations: Diabetes and Metabolic Syndrome. **2009**, 443-462	1
624	Pre-treatment allostatic load and metabolic dysregulation predict SSRI response in major depressive disorder: a preliminary report. **2020**, 1-9	2
623	Threshold Values of High-risk Echocardiographic Epicardial Fat Thickness.	1
622	Metabolic Syndrome in Healthy Obese, Overweight, and Normal Weight Individuals: The Atherosclerosis Risk in Communities Study.	3
621	Metabolites in visceral fat: useful signals of metabolic syndrome?. **2018**, 475, 1789-1791	1
620	Microvascular dysfunction: causative role in the association between hypertension, insulin resistance and the metabolic syndrome?. **2006**, 42, 163-76	21
619	Associations of dietary vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12 and folate equivalent intakes with metabolic syndrome. **2020**, 71, 738-749	6
618	Diabetes Mellitus and Metabolic Syndrome. **2009**, 465-496	4
617	The prevalence of metabolic syndrome in Chinese postmenopausal women and the optimum body composition indices to predict it. **2010**, 17, 566-70	34
616	Metabolic Syndrome, Disease Activity, and Adipokines in Patients With Newly Diagnosed Inflammatory Joint Diseases. **2021**, 27, e349-e356	4

615	The Postprandial Phase as a Link Between Systemic Lipid Peroxidation and Liver Injury in NASH This article has been retracted. **2006**, 061113084836024-???	2
614	Microbial Flavonoid Metabolism: A Cardiometabolic Disease Perspective. **2021**, 41, 433-454	1
613	Usefulness of the epicardial fat tissue thickness as a diagnostic criterion for geriatric patients with metabolic syndrome. **2015**, 12, 373-7	5
612	FABP4 plasma levels are increased in familial combined hyperlipidemia. **2010**, 51, 1173-8	17
611	Glycemic Index and Diabetes Mellitus. **2016**, 45-77	1
610	Dyslipidemia and Atherosclerosis. **2014**, 137-159	1
609	Toxicology. **2015**, 434-457	4
608	Physical Activity Levels in a Community Lifestyle Intervention. **2016**, 1, 45-51	3
607	Diversity of metabolic syndrome criteria in association with cardiovascular diseases--a family medicine-based investigation. **2013**, 19, 571-8	9
606	Anti-obesity effect of a hop-derived prenylflavonoid isoxanthohumol in a high-fat diet-induced obese mouse model. **2020**, 39, 175-182	3
605	Physical activity disparities by socioeconomic status among metabolic syndrome patients: The Fifth Korea National Health and Nutrition Examination Survey. **2016**, 12, 10-4	8
604	Metabolic biomarkers and long-term blood pressure variability in military young male adults. **2020**, 8, 2246-2254	1
603	Predictors of subclinical atherosclerosis in women with spinal cord injury. **2014**, 20, 90-5	4
602	Cardiometabolic changes and disparities among persons with spinal cord injury: a 17-year cohort study. **2014**, 20, 96-104	10
601	Nutritional Health Considerations for Persons with Spinal Cord Injury. **2017**, 23, 188-206	19
600	Identification and Management of Cardiometabolic Risk after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers. **2018**, 24, 379-423	41
599	The CAPN10 gene is associated with insulin resistance phenotypes in the Spanish population. **2008**, 3, e2953	33
598	The metabolic syndrome: prevalence, associated factors, and impact on survival among older persons in rural Bangladesh. **2011**, 6, e20259	39

597	Post-streptococcal antibodies are associated with metabolic syndrome in a population-based cohort. **2011**, 6, e25017	10
596	Maternal cigarette smoke exposure contributes to glucose intolerance and decreased brain insulin action in mice offspring independent of maternal diet. **2011**, 6, e27260	31
595	Decreased circulating endothelial progenitor cell levels and function in patients with nonalcoholic fatty liver disease. **2012**, 7, e31799	33
594	Common variants of the liver fatty acid binding protein gene influence the risk of type 2 diabetes and insulin resistance in Spanish population. **2012**, 7, e31853	32
593	Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. **2012**, 7, e41183	38
592	Characterisation of gut microbiota in Ossabaw and Göttingen minipigs as models of obesity and metabolic syndrome. **2013**, 8, e56612	86
591	The normal limits, subclinical significance, related metabolic derangements and distinct biological effects of body site-specific adiposity in relatively healthy population. **2013**, 8, e61997	17
590	Neighborhood disadvantage, neighborhood safety and cardiometabolic risk factors in African Americans: biosocial associations in the Jackson Heart study. **2013**, 8, e63254	53
589	Pre-pubertal children born post-term have reduced insulin sensitivity and other markers of the metabolic syndrome. **2013**, 8, e67966	17
588	HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. **2013**, 8, e77138	13
587	Monocytes expand with immune dysregulation and is associated with insulin resistance in older individuals with chronic HIV. **2014**, 9, e90330	27
586	Hypertriglyceridemia influences the degree of postprandial lipemic response in patients with metabolic syndrome and coronary artery disease: from the CORDIOPREV study. **2014**, 9, e96297	24
585	Chronic glucocorticoid exposure-induced epididymal adiposity is associated with mitochondrial dysfunction in white adipose tissue of male C57BL/6J mice. **2014**, 9, e112628	15
584	Optimal central obesity measurement site for assessing cardiometabolic and type 2 diabetes risk in middle-aged adults. **2015**, 10, e0129088	13
583	Metabolic Syndrome Is Associated with Increased Oxo-Nitrative Stress and Asthma-Like Changes in Lungs. **2015**, 10, e0129850	45
582	Neuronal and Endothelial Nitric Oxide Synthases in the Paraventricular Nucleus Modulate Sympathetic Overdrive in Insulin-Resistant Rats. **2015**, 10, e0140762	5
581	Association of DNA Methylation at CPT1A Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study. **2016**, 11, e0145789	40
580	Workplace Health Promotion: Assessing the Cardiopulmonary Risks of the Construction Workforce in Hong Kong. **2016**, 11, e0146286	3

579	Metabolic Syndrome Components Are Associated with Intervertebral Disc Degeneration: The Wakayama Spine Study. **2016**, 11, e0147565	25
578	Peritoneal Dialysate Glucose Load and Systemic Glucose Metabolism in Non-Diabetics: Results from the GLOBAL Fluid Cohort Study. **2016**, 11, e0155564	7
577	Incremental Predictive Value of Serum AST-to-ALT Ratio for Incident Metabolic Syndrome: The ARIRANG Study. **2016**, 11, e0161304	16
576	Dual Energy X-Ray Absorptiometry Compared with Anthropometry in Relation to Cardio-Metabolic Risk Factors in a Young Adult Population: Is the 'Gold Standard' Tarnished?. **2016**, 11, e0162164	5
575	Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study. **2016**, 11, e0162753	30
574	Clustering of four major lifestyle risk factors among Korean adults with metabolic syndrome. **2017**, 12, e0174567	27
573	Parathyroid hormone and vitamin D are associated with the risk of metabolic obesity in a middle-aged and older Korean population with preserved renal function: A cross-sectional study. **2017**, 12, e0175132	8
572	Cardiometabolic risk factors and health behaviors in family caregivers. **2017**, 12, e0176408	5
571	The dynamic behaviour of metabolic syndrome and its components in an eight-year population-based cohort from the Mediterranean. **2017**, 12, e0176665	10
570	Subclinical thyroid dysfunction and risk of carotid atherosclerosis. **2017**, 12, e0182090	8
569	Metabolically healthy obese individuals present similar chronic inflammation level but less insulin-resistance than obese individuals with metabolic syndrome. **2017**, 12, e0190528	22
568	The associations between plasma phytoestrogens concentration and metabolic syndrome risks in Chinese population. **2018**, 13, e0194639	3
567	A STUDY OF NON ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME. **2013**, 2, 375-382	1
566	Metabolic aspects of the relationship of asthma and obesity. **2018**, 15, 9-14	12
565	Similarities and Distinctions in the Effects of Metformin and Carbon Monoxide in Immunometabolism. **2019**, 42, 292-300	8
564	Prevalence of Metabolic Syndrome and Its Clinical and Angiographic Profile in Patients With Naive Acute Coronary Syndrome in North Indian Population. **2016**, 8, 667-73	7
563	Low acylation stimulating protein levels are associated with cardiometabolic disorders-secondary to autoimmune activation?. **2017**, 17, 97-106	0
562	Dispersive Solid Phase Extraction Using Magnetic Nanoparticles Performed in a Narrow-Bored Tube for Extraction of Atorvastatin, Losartan, and Valsartan in Plasma. **2019**, 9, 138-146	4

561	Does long sleep duration increase risk of metabolic syndrome in Azar cohort study population?. **2018**, 8, 290-295	6
560	Interaction between Shift Work and Established Coronary Risk Factors. **2019**, 10, 57-65	5
559	Association between food insecurity and metabolic syndrome in North West of Iran: Azar Cohort study. **2019**, 11, 196-202	6
558	Review of Clinical Spectrum of Gastroesophageal Reflux Disease in a General Population; A Study from South-East Iran. **2016**, 8, 310-317	3
557	Prevalence of Metabolic Syndrome and Associated Risk Factors among Men in a Rural Health Centre Area in Tamil Nadu. **2019**, 9, 44-51	6
556	Sexual dimorphism in insulin resistance in a metabolic syndrome rat model. **2020**, 9, 890-902	4
555	Obstructive Sleep Apnea Risk and Stroke among Blacks with Metabolic Syndrome: Results from Metabolic Syndrome Outcome (MetSO) Registry. **2020**, 5,	3
554	Abdominal Obesity and Cardiovascular Disease. **2015**, 3,	2
553	The Metabolic Syndrome in Children and Adolescents: Shifting the Focus to Cardiometabolic Risk Factor Clustering. **2017**, 140,	151
552	RISK OF TYPE 2 DIABETES AMONG US AND FOREIGN BORN NON-HISPANIC ASIANS: EVIDENCE FROM NHANES´. **2015**, 2, 1-4	2
551	[Metabolic syndrome after pregnancy complicated with gestational diabetes: four-year follow-up]. **2008**, 149, 831-8	5
550	Fatores de risco para sÍndrome metabÓlica em cadeirantes: jogadores de basquetebol e nÃo praticantes. **2008**, 14, 188-191	2
549	Plants with potential use on obesity and its complications. **2015**, 14, 809-31	42
548	Role of Gender in the Prevalence of Metabolic Syndrome and Its Related Risk Factors in Shiraz Healthy Heart Center Population. **2015**, 9, 231-237	6
547	Peroxisome ProliferatorâActivated Receptors and The Metabolic Syndrome. **2009**, 1, 4	1
546	Metabolic syndrome: new aspects of old problem. **2007**, 13, 113-118	4
545	Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes. **2020**, 8, 1583	2
544	Prevalence and Trends of Metabolic Syndrome in Slovakia during the Period of 2003-2012. **2017**, 25, 313-320	14

543	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. **2010**, 3, 373-85	38
542	Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. **2010**, 3, 197-213	7
541	Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. **2007**, 3, 181-90	6
540	Healthy Diet and Reduction of Chronic Disease Risks of Night Shift Workers. **2019**, 26, 3521-3541	3
539	The Relevance of Single-nucleotide Polymorphism +62 G>A to the Expression of Resistin Gene Affecting Serum Resistin Levels in Metabolic Syndrome in the Egyptian Population. **2020**, 21, 626-634	2
538	Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances. **2017**, 10, 207-225	46
537	AdipoRon: A Novel Insulin Sensitizer in Various Complications and the Underlying Mechanisms: A Review. **2020**, 13, 94-107	8
536	Activity Tracker-Based Metrics as Digital Markers of Cardiometabolic Health in Working Adults: Cross-Sectional Study. **2020**, 8, e16409	6
535	A Feasible and Efficacious Mobile-Phone Based Lifestyle Intervention for Filipino Americans with Type 2 Diabetes: Randomized Controlled Trial. **2017**, 2, e30	22
534	Development of a Mobile Phone-Based Weight Loss Lifestyle Intervention for Filipino Americans with Type 2 Diabetes: Protocol and Early Results From the PilAm Go4Health Randomized Controlled Trial. **2016**, 5, e178	11
533	Association of -c.894G>T transversion with susceptibility to metabolic syndrome in Azar-cohort population: A case-control study and analysis of the SNP molecular effects. **2021**, 24, 408-419	3
532	Triglyceride to high-density lipoprotein cholesterol and low-density lipoprotein cholestrol to high-density lipoprotein cholesterol ratios are predictors of cardiovascular risk in Iranian adults: Evidence from a population-based cross-sectional study. **2020**, 11, 53-61	4
531	Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications. **2020**, 11, 310-314	1
530	Does the low-density lipoprotein cholesterol play a key role in predicting metabolic syndrome in the Iranian adult population?. **2017**, 8, 289-295	4
529	Myocardial hypertrophy in hypertensive patients with and without metabolic syndrome. **2008**, 65, 830-4	2
528	Challenges and future developments in liver transplantation. **2019**, 65, 136-152	5
527	Working in Shifts and the Metabolic Syndrome: Epidemiological Evidence and Physiopathological Mechanisms. **2018**, 24, 144-151	1
526	Waist circumference can predict the occurrence of multiple metabolic risk factors in middle-aged Japanese subjects. **2010**, 48, 447-51	2

525	MELEN Study: Rationale, Methodology and Basic Results. **2011**, 8,	2
524	Free Fatty Acid Metabolism in Visceral Obesity. **2008**, 83-88	2
523	Regional differences in the prevalence of the metabolic syndrome in primary care practices in Germany. **2008**, 105, 207-13	25
522	An inter-state comparison of cardiovascular risk factors in Germany: towards an explanation of high ischemic heart disease mortality in Saxony-Anhalt. **2014**, 111, 530-6	24
521	Adipokine expression in brown and white adipocytes in response to hypoxia. **2012**, 35, 522-7	18
520	Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B. **2016**, 22, 339-349	13
519	Insulin resistance and vitamin D deficiency in patients with chronic kidney disease stage 2-3. **2011**, 60, 149-55	16
518	Serum nesfatin-1 levels in patients with different glucose tolerance levels. **2016**, 65, 979-985	23
517	Correlation of uric acid levels and parameters of metabolic syndrome. **2017**, 66, 481-487	27
516	An Archival, Follow-Forward Exploration of the Metabolic Syndrome in Randomly Selected, Clozapine-Treated Patients. **2009**, 3, 87-96	5
515	Perfil de indiv□duos com excesso de peso metabolicamente saud□veis e metabolicamente n□ saud□veis. **2019**, 43, 317-323	1
514	Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease. **2015**, 21, 8096-102	5
513	Outcomes of a multidisciplinary approach to the management of the metabolic syndrome. **2008**, 141, 42-47	2
512	Association between Myeloperoxidase Levels and Risk of Insulin Resistance in Egyptian Obese Women. **2018**, 6, 629-633	2
511	Impact of the metabolic syndrome and its components on pulse wave velocity. **2006**, 21, 109-15	31
510	Maximal pericoronary adipose tissue thickness is associated with hypertension in nonobese patients with acute or chronic illness. **2017**, 32, 668-674	4
509	Predictive costs in medical care for Koreans with metabolic syndrome from 2009 to 2013 based on the National Health Insurance claims dataset. **2020**, 35, 936-945	4
508	The association between circulating inflammatory markers and metabolic syndrome in Korean rural adults. **2008**, 41, 413-8	13

507	Association between C-Reactive Protein and Metabolic Syndrome in Korean Adults. **2019**, 40, 116-123	15
506	Impact of Visceral Obesity on the Risk of Incident Metabolic Syndrome in Metabolically Healthy Normal Weight and Overweight Groups: A Longitudinal Cohort Study in Korea. **2020**, 41, 229-236	3
505	Association between Self-Perceived Health Status and Health Related Behavior in Routine Health Examinees. **2010**, 31, 688	11
504	The Prevalence of Obesity, Abdominal Obesity and Metabolic Syndrome among Elderly in General Population. **2011**, 32, 128	22
503	Factors Associated with Serum Levels of Carcinoembryonic Antigen in Healthy Non-smokers. **2013**, 34, 413-9	12
502	The Relationship between Metabolic Syndrome and Childhood Maternal Education Level, Job Status Findings from the Korean National Health and Nutrition Examination, 2007-2009. **2014**, 35, 207-15	12
501	Medication Use and Metabolic Syndrome Among Overweight/Obese Patients With and Without Binge-Eating Disorder in a Primary Care Sample. **2015**, 17,	4
500	The Evaluation of the Impact of Age, Skin Tags, Metabolic Syndrome, Body Mass Index, and Smoking on Homocysteine, Endothelin-1, High-sensitive C-reactive Protein, and on the Heart. **2013**, 58, 326	6
499	Prevalence of metabolic syndrome among HIV-infected patients in Ghana: A cross-sectional study. **2016**, 57, 86-90	20
498	Association of chronic periodontitis with metabolic syndrome: A cross-sectional study. **2016**, 20, 324-9	13
497	Prevalence of metabolic syndrome in pre- and post-menopausal women: A prospective study from apex institute of North India. **2016**, 7, 169-174	16
496	Metabolic syndrome and cardiovascular risk. **2010**, 17, 73-8	38
495	The relationship between metabolic syndrome and chronic obstructive pulmonary disease. **2017**, 11, 11-15	6
494	Transcription factor 7-like 2 polymorphism and context-specific risk of metabolic syndrome, type 2 diabetes, and dyslipidemia. **2017**, 22, 40	11
493	Evaluation of N-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein relationship with features of metabolic syndrome in high-risk subgroups for cardiovascular disease. **2015**, 5, 190-4	3
492	Testosterone and metabolic syndrome: The link. **2012**, 16 Suppl 1, S12-9	20
491	Spleen size in patients with metabolic syndrome and its relation to metabolic and inflammatory parameters. **2018**, 30, 78-82	3
490	Prevalence of Metabolic Syndrome in Psoriasis and Levels of Interleukin-6 and Tumor Necrosis Factor-□n Psoriasis Patients with Metabolic Syndrome: Indian Tertiary Care Hospital Study. **2017**, 7, 169-175	8

489	Metabolic Syndrome among Adults of Surendranagar District of Saurashtra, Gujarat: A Cross-Sectional Study. **2018**, 43, 24-28	5
488	Randomized Placebo Control Study of Metformin in Psoriasis Patients with Metabolic Syndrome (Systemic Treatment Cohort). **2017**, 21, 581-587	11
487	Association of Androgenetic Alopecia with Metabolic Syndrome: A Case-control Study on 100 Patients in a Tertiary Care Hospital in South India. **2018**, 22, 196-199	6
486	Evaluation of obstructive sleep apnea in metabolic syndrome. **2019**, 8, 1580-1586	7
485	Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials. **2019**, 8, 2249-2257	1
484	Anxiety but not depression is associated with metabolic syndrome: The Isfahan Healthy Heart Program. **2017**, 22, 90	9
483	The role of the herbal medicines, Rehmanniae radix, Citrus unshiu peel, and Poria cocos wolf, in high-fat diet-induced obesity. **2019**, 15, 363	2
482	Peyronie's Disease is common in poorly controlled diabetics but is not associated with the Metabolic Syndrome. **2019**, 11, 252-256	3
481	Diabetes in the Elderly: Exercising Your Clinical Skills. **2010**, 25, 1-37	1
480	Is there any role of glucose-6-phosphate dehydrogenase in obesity induced metabolic disorder. **2012**, 04, 1530-1536	1
479	Effects of Statin Therapy on Endothelial Function in Asymptomatic Metabolic Syndrome. **2014**, 05, 149-156	1
478	Patient Adherence to a Cardiovascular Rehabilitation Program: What Factors Are Involved?. **2015**, 06, 605-614	6
477	Long Lasting Effects of Breastfeeding on Metabolism in Women with Prior Gestational Diabetes. **2014**, 04, 257-263	5
476	Metabolic Syndrome: Consensus and Controversy: State of the Art. **2015**, 05, 124-130	2
475	Metabolic Syndrome and Pregnancy, Its Prevalence, Obstetrical and Newborns Complications. **2015** , 05, 618-625	9
474	Prevalence of Metabolic Syndrome in HIV-Infected Cameroonian Patients. **2014**, 04, 85-92	14
473	Impaired fasting glucose: Pro-diabetic, "atheroprotective" and modified by metabolic syndrome. **2013**, 4, 210-8	11
472	High adiponectin levels fail to protect against the risk of hypertension and, in women, against coronary disease: involvement in autoimmunity?. **2013**, 4, 219-25	9

471	Pulmonary hypertension and metabolic syndrome: Possible connection, PPARand Caveolin-1. **2014**, 6, 692-705	10
470	Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. **2012**, 27, 27-30	6
469	Rheumatoid factor mediates excess serum lipoprotein(a) for independent association with type 2 diabetes in men. **2015**, 15, 782-8	2
468	Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. **2019**, 51, 280-284	6
467	Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study. **2019**, 30, 266-270	11
466	Obesity as a risk factor for coronary events in Japanese patients with hypercholesterolemia on low-dose simvastatin therapy. **2010**, 17, 270-7	7
465	BMI specific waist circumference for detecting clusters of cardiovascular risk factors in a Japanese population. **2010**, 17, 468-75	5
464	Potential protective effects of Nigella sativa and Allium sativum against fructose-induced metabolic syndrome in rats. **2014**, 63, 839-48	20
463	Factor Analysis of Metabolic Syndrome Components in an Iranian Non-Diabetic Adult Population: A Population-Based Study from the North of Iran. **2018**, 16, e14159	3
462	Evaluation oF Epicardial Fat and Carotid Intima-Media Thickness in Obese Children. **2016**, 26, e2968	9
461	Association of Helicobacter pylori infection with the metabolic syndrome among HIV-infected black Africans receiving highly active antiretroviral therapy. **2015**, 26, 52-6	2
460	The Influence of Metabolic Syndrome in Predicting Mortality Risk Among US Adults: Importance of Metabolic Syndrome Even in Adults With Normal Weight. **2020**, 17, E36	6
459	Combined Influence of Obesity and Metabolic Syndrome on Ischemic Heart Disease in Korean middle aged and older adults. **2015**, 29, 540-550	4
458	Serum adiponectin and cardiometabolic risk in patients with acute coronary syndromes. **2013**, 101, 399-409	6
457	Variations in the Prevalence of Risk Factors for Coronary Artery Disease in Rio Grande do Sul-Brazil: A Comparative Analysis between 2002 and 2014. **2015**, 105, 573-9	10
456	[Relationship between the criteria for metabolic syndrome and the evaluation of abdominal fat distribution measured by CT scan]. **2007**, 63, 276-84	3
455	Metabolic Syndrome in Children: Definition, Risk Factors, Prevention and Management-A Brief Overview. **2019**, 16,	1
454	Development of the Automated Diagnosis CT Screening System for Visceral Obesity. **2008**, 2, 31-38	5

453	Fetal exposure to arsenic results in hyperglycemia, hypercholesterolemia, and nonalcoholic fatty liver disease in adult mice. **2014**, 1, 1	14
452	Association of polymorphisms in stress-related TNF and NPY genes with the metabolic syndrome in Han and Hui ethnic groups. **2014**, 15, 5895-900	2
451	The Effects of a Combined Exercise Program on Obesity and Metabolic Syndrome Factors for Chronic Psychiatric Inpatients. **2014**, 16, 105-112	4
450	Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics. **2016**, 4, e2163	4
449	Carbohydrate-restricted Diet and Exercise Increase Brain-derived Neurotrophic Factor and Cognitive Function: A Randomized Crossover Trial. **2019**, 11, e5604	17
448	Prevalence of Metabolic Syndrome among Psychiatric Inpatients: A Hospital Based Study from Kashmir. **2017**, 11, VC05-VC08	10
447	Does Melatonin and Melatonin Agonists Improve the Metabolic Side Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of Randomized Controlled Trials. **2018**, 16, 235-245	14
446	Metabolic Changes at the Menopausal Transition. **2021**, 191-204	
445	Machine Learning-Based Prediction for 4-Year Risk of Metabolic Syndrome in Adults: A Retrospective Cohort Study. **2021**, 14, 4361-4368	0
444	1,25-dihydroxyvitamin D and cardiometabolic risk in healthy sedentary adults: The FIT-AGEING study. **2021**, 344, 192-198	
443	Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis. **2021**, e2821	1
442	Risk Factors and Prevention, Including Hyperlipidemias. **2005**, 419-437	
441	Genomic of Skeletal Muscle and its Implications in the Metabolic Syndrome. **2005**, 153-161	
440	Hoofdstuk 7 Afwijkingen van de koolhydraat- en vetstofwisseling. **2005**, 153-185	
439	Epidemiology of the Metabolic Syndrome. **2005**, 109-129	
438	[Relationship between C-reactive protein and features of the metabolic syndrome in military pilots in the Serbia and Montenegro]. **2005**, 62, 811-9	
437	Childhood Obesity. **2005**,	
436	Novel fats for the future. **2006**, 508-524	

435 Nutritional Strategies for Patients with Obesity and the Metabolic Syndrome. **2006**, 55-80

434 The Metabolic Syndrome: Time for a Critical Appraisal. **2006**, 12, 99-116 3

433 Angiotensin II antagonists, diabetes and metabolic syndrome. **2006**, 99-109

432 Diabetes, Obesity, and Metabolic Syndrome. **2006**, 1-30

431 Women and Coronary Heart Disease. **2006**, 689-720

430 Chronic Kidney Disease. **2006**, 463-500

429 Metabolic Syndrome and Type 2 Diabetes Mellitus. **2006**, 41-78

428 Steps for the Medical Evaluation of the Obese Patient. **2006**, 15-28

427 Insulin Resistance and Hypertension. **2007**, 175-186

426 The Medical Management of Obesity. **2007**, 7-15

425 Cardiovascular Complications of Obesity and the Metabolic Syndrome. **2007**, 2693-2720

424 Management of Cholesterol Disorders. **2007**, 2667-2691

423 Treatment of Cardiovascular Manifestations of HIV. **2007**, 842-851

422 Evaluation for Insulin Resistance and Comorbidities Related to Insulin Resistance in Polycystic Ovary Syndrome. **2007**, 1-13

421 Pathophysiology of Obesity Comorbidity: The Effects of Chronically Increased Intraabdominal Pressure. **2007**, 1-6

420 Obesity as an Occult Risk Factor for Drug and Chemical Toxicities. **2007**, 165-173

419 Oxidative Stress Status in Humans with Metabolic Syndrome. **2007**, 123-137

418 The Metabolic Syndrome and Type 2 Diabetes Mellitus. **2007**,

417 Insulin Resistance, Metabolic Syndrome, and Cardiovascular Disease. **2008**, 75-84

416 Pathogenesis of the Metabolic Syndrome. **2008**, 83-114

415 Components of Metabolic Syndrome. **2008**, 21-82

414 Clinical Diagnosis of the Metabolic Syndrome. **2008**, 115-130

413 The Association Between Serum □glutamyltransferase and the Metabolic Syndrome in Adolescence. **2008**, 12, 8-18

412 The impact of the metabolic syndrome on cardiovascular risk and disease in rheumatoid arthritis. **2008**, 3, 335-349 1

411 Cardiometabolic Syndrome, Diabetes and Oxidative Stress. **2008**, 91-102

410 Abdominal Obesity, Metabolic Syndrome and Risk of Cardiovascular Disease. **2008**, 1-9

409 Diet and Atherosclerosis. **2009**, 19, 307-319

408 Metabolic Syndrome, Hyperglycemia, and Type 2 Diabetes. **2009**, 373-387

407 Assessment of Nutritional Status. **2009**, 93-114

406 Metabolic Syndrome (MetS) and Nonalcoholic Steatohepatitis (NASH): Study of biochemical markers Free Fatty Acid (FFA), Total Antioxidant Status (TAOS), Adiponectin, Transforming Growth Factor (TGF-beta1), in occurence of NASH. **2009**, 1, 40

405 Effects of Gymball Exercise with Aerobic Exercise Training on Physical Fitness and Metabolic Syndrome Risk of Factors in Elderly Women with Educable Mental Patients. **2009**, 17, 183-199

404 The effects of a new plant mixture on lipid levels in patients with metabolic syndrome. **2010**, 62, 403-405

403 Evidence-Based Decisions in Human Immunodeficiency Virus Infection and Cardiac Disease. **2010**, 79-90

402 Metabolic Syndrome. **2010**, 316-320

401 Physiology and Anesthesia for General and Bariatric Surgery. **2010**, 325-340

400 The electrical skin resistance test. **2010**, 175-192

399 Metabolic Syndrome in Psoriasis. **2010**, 95-98

398 The Metabolic Syndrome, Obesity, and Insulin Resistance. **2010**, 705-721

397 âAnchor-LineâAbdominoplasty: A Comprehensive Approach to Abdominal Wall Reconstruction and Body Contouring. **2010**, 239-248

396 Obesity and Therapeutic Approaches to Weight Loss. **2011**, 91-106

395 Obesity and the Metabolic Syndrome. **2011**, 67-92

394 Metabolic Syndrome and Inflammation. **2011**, 69-92 1

393 Effects of Exercise Training Intensity on Abdominal Fat Losses in Obese Women.. **2010**, 19, 413-422

392 Correlation of Ferritin and Transferrin Serum with hsCRP and F2-Isoprostane in Metabolic Syndrome. **2010**, 2, 131

391 Diabetes Mellitus. **2011**, 731-755

390 Nutritional and Gastrointestinal Disease. **2011**, 463-475

389 Metabolic Syndrome as a Disorder of the Brain with Its Origins in the Perinatal Period. **2011**, 2597-2616

388 Insulin Resistance, Dyslipidemia, Type 2 Diabetes Mellitus and Metabolic Syndrome. **2011**, 277-332

387 Measures of Health Status, Functioning, and Use of Health Services. **2012**, 217-267

386 The Epidemiology of the Metabolic Syndrome and its Association with Diabetes, Cardiovascular Disease and Other Conditions. 1-18 0

385 Our time of pestilence: purchasing immunity and ignoring the misery of others. **2011**, 719, 1-9

384 Risk Markers for Atherothrombotic Disease. **2012**, 914-934 4

383 Cardiovascular Disease. **2012**, 478-549

382 Basic science. **2012**, 197-236

381 Medical Problems after Liver Transplantation. 345-360

380 Obesity and Arthritis. **2012**, 355-380

379 Obesity and the Metabolic Syndrome. **2012**, 311-342 2

378 In?ammation. **2012**, 266-279

377 Discovery of Novel 11ÐHSD1 Inhibitors by Pharmacophore-Based Virtual Screening. **2012**, 33, 2365-2368

376 Insulin Resistance, Metabolic Syndrome, and Therapy. 468-490

375 The Prevalence and Risk Factors for Gout. **2013**, 9-23

374 Metabolic Syndrome as a Risk Factor for Depression. **2013**, 343-378

373 Primary Hypothyroidism: Presence of Central Adiposity and Its Improvement on Attaining Euthyroid State with L-Thyroxine. **2013**, 03, 241-244

372 Retrospective self-reported weight changes during childhood and adolescence are not good predictors of metabolic syndrome risk factors in Mexican young adults. **2013**, 03, 479-486

371 Heartbreak Hotei: Spirituality and Metabolic Syndrome. **2013**, 183-198

370 Diet and Exercise Are Potent Modulators of Cardiovascular Disease in Women. **2013**, 175-204

369 Epidemiology of Cardiovascular Disease. **2013**, 3-18

368 Body Weight, Diet, and Periodontitis. 1-9

367 Impact of Diabetes Mellitus and the Metabolic Syndrome on the Female Heart. **2014**, 265-286

366 Drugs in the Primary and Secondary Prevention of Coronary Artery Disease. **2014**, 1-32

365 Metabolic syndrome, strain, and reduced myocardial function: multi-ethnic study of atherosclerosis. **2014**, 102, 327-35 18

364 Comparison of Changes in Body Weight and Serum Lipid Profile after Roux-en-Y Gastric Bypass between Non-obese Patients and Obese Patients. **2014**, 23, 164

363 Immunotoxicity in Autism Spectrum Disorders. **2014**, 1567-1584

362 Gamma-glutamyl Transferase in Diabetic Individuals with the Metabolic Syndrome in Calabar, Nigeria. **2014**, 14, 60-67

361 Cut-Off Values of Anthropometric Indices for the Prediction of Hypertension in a Sample of Egyptian Adults. **2014**, 2, 89-94 1

360 A Randomized Trial on the Effect of Razavi's Dietary Pattern on the Components of Metabolic Syndrome. **2014**, 16, e14601 3

359 Diabetes. **2014**, 101-132 1

358 An Overview of Metabolic Medicine. **2014**, 3-22

357 Metabolic Syndrome. **2014**, 69-114

356 A Study on the Prevalence and Influencing Factors of Metabolic Syndrome among Police Officers. **2014**, 24, 566-577 1

355 Non-alcoholic Fatty Liver Disease. **2015**, 1-21

354 Molecular Nutrition Study of Biomembrane Fatty Acid Regulation According to Nutritional Status. **2015**, 68, 265-269

353 Overview of Metabolic Syndrome. **2015**, 1-13

352 Afwijkingen van de koolhydraaten vetstofwisseling. **2015**, 229-274

351 The Serum Lipid Lowering Effect of Rugosa Rose Petal Extract Rich in Polyphenols in Adults with High Serum Triglyceride. **2015**, 12, 29-35 1

350 Discovering Association between Metabolic Syndrome and its Related Chronic Diseases Represented by ICD-10 Code. **2015**, 258-261

349 The Role of Metabolic Syndrome in the Development and Progression of Chronic Renal Failure.

348 Afwijkingen van de koolhydraaten vetstofwisseling. **2015**, 109-125

347 Drugs in the Primary and Secondary Prevention of Coronary Artery Disease. **2015**, 1665-1693

346 Metabolic Syndrome in South Asians. **2015**, 1-14

345	Afwijkingen van de koolhydraaten vetstofwisseling. **2015**, 161-196	
344	7. Metabolic syndrome in adolescents: role of cholesterol sources, eggs, and others. **2015**, 109-132	1
343	Association of Human Adenovirus-36 With Dyslipidemia in Tehranian Children and Adolescent; TLGS. **2015**, 3,	
342	Nutrition Therapy for the Obese Critically Ill Patient. **2015**, 619-632	
341	Mediterranean Diet and Metabolic Syndrome. **2015**, 405-418	
340	Olive Oil in Metabolic Syndrome. **2015**, 230-251	
339	Adiposity and metabolic syndrome. **2015**, 190-204	
338	Occurrence of metabolic syndrome with relation to job profile among mine employees. **2016**, 3, 32	
337	Cardiometabolic Syndrome in SCI: The Role of Physical Deconditioning and Evidence-Based Countermeasures. **2016**, 199-215	
336	Hypolactasia is associated with insulin resistance in nonalcoholic steatohepatitis. **2016**, 8, 1019-27	1
335	Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record. **2016**, 18,	2
334	[Influence of multimodal effect of cytoflavin in the acute brain stroke in patients with metabolic syndrome]. **2016**, 116, 44-47	0
333	7 Schizofreniespectrum- en andere psychotische stoornissen. **2016**, 195-233	
332	Anthropometrics and Body Composition. **2016**, 65-76	
331	Physical Activity, Stress, and Obesity. **2016**, 1-17	
330	Physiology and Anesthesia for General and Bariatric Surgery. **2016**, 357-373	
329	Study of factors influencing central corneal thickness among patients attending ophthalmology outpatient department at a tertiary care center in North Kerala. **2016**, 28, 193	0
328	The association of hematological parameters and metabolic syndrome in an older population: A cross-sectional and longitudinal study. **2016**, 36, 180	0

327 âAnchor-LineâAbdominoplasty in Post-Bariatric Abdominal Contouring. **2016**, 141-151

326 Relationship of Obstructive Sleep Apnoea and Metabolic Syndrome: A Study in a South Indian Population. **2016**, 11, 20-29

325 Hyperuricemia and its Association with the Presence of Metabolic Syndrome among Indonesian Obese Adolescents. **2016**, 15, 238-243

324 Antidiabetic, Antihypertensive and Statin Medication Use in Metabolic Syndrome. **2016**, 2, 006-011

323 A Case Report on the Effect of Short-term Intensive Fat Treatment on an Obese Patient with Metabolic Syndrome. **2016**, 37, 1051-1058 1

322 Obesity, Spermatogenesis, and Male Infertility. **2017**, 167-182

321 The Effects of 12 Weeks Resistance Exercise Intensity on the Metabolic Syndrome Risk Factors in Middle-Aged Women with Metabolic Syndrome. **2017**, 56, 541-552 1

320 A Feasible and Efficacious Mobile-Phone Based Lifestyle Intervention for Filipino Americans with Type 2 Diabetes: Randomized Controlled Trial (Preprint).

319 A New International Journal Targeting the Pathophysiology and Treatment of Obesity and Metabolic Syndrome. **2017**, 26, 81-83 1

318 Development and Validation of Korean Inflammtory Index(K-DII) for Metabolic Disease Patients: by Using the Health Examinee Cohort (2012-2014). **2017**, 26, 369-381 2

317 ASSOCIATION OF SERUM URIC ACID LEVELS AND THE COMPONENTS OF METABOLIC SYNDROME-A COMPARATIVE STUDY. **2017**, 4, 4382-4386

316 Physical Activity, Stress, and Obesity. **2018**, 311-323

315 3. Vitamin D and cardiovascular disease. **2017**, 49-75

314 Modern aspects of the treatment and prevention of diabetes type 2 in patients with metabolic syndrome. **2017**, 98, 770-774

313 The impact of metabolic syndrome on ventilatory pulmonary Functions. **2017**, 11, 293-300

312 Increased trunk fat along with decreased peripheral fat as an important predictor of hypertriglyceridaemia & hypercholesterolaemia in Indians with HIV infection. **2018**, 148, 411-421 1

311 Comparative analysis of different definitions of metabolic syndrome. **2018**, 15, 86-90

310 Gender Differences in Metabolic Syndrome. **2018**, 15-33

309	Obesities: Controversies in Diagnosis and Classification. **2018**, 173-192	
308	Emergence of Metabolic Syndrome Out of Menopausal Box!!!. **2018**, 6, 1-7	
307	Metabolic Status in Patients with Operable vs. Inoperable Left-to-Right Shunts. **2018**, 24, 2655-2660	
306	Adiponectin and tumor necrosis factor in psoriasis and their relation to the metabolic syndrome. **2018**, 15, 88-93	
305	Metabolic Syndrome in Rheumatoid Arthritis and Ankylosing Spondylitis.	
304	Health-Related Quality of Life in Tehran Lipid and Glucose Study. **2018**, 16, e84745	2
303	Metabolic Syndrome: An Indicator of Complicated Gall Stone Disease?. **2018**, 10, e3659	1
302	Customized BMI and waist circumference cut-off values are needed to identify metabolic syndrome among South Koreans according to their Sasang constitutional type. **2018**, 39, 51-61	
301	Depression, metabolisches Syndrom und kardiovaskuläre Erkrankungen. **2019**, e.6-e.13	
300	Changes in Metabolic Profile Over Time: Impact on the Risk of Diabetes. **2019**, 43, 407-409	
299	Mediating Effect of Stress on the Relationship between Illness Perception and Sleep in Patients at Risk of Metabolic Syndrome. **2019**, 31, 449	0
298	Silent Gallbladder Stone Associated with Nonalcoholic Fatty Liver Disease in a Scenario of Insulin Resistance in Young Adults. **2019**, 23, 226-229	
297	Metabolic Syndrome and Social Deprivation. **2019**, 381-408	
296	METABOLIC SYNDROME AND THE PHENOMENON OF INSULIN RESISTANCE. GERIATRIC ASPECTS OF THE PROBLEM. **2019**, 2, 53	2
295	Sedentary behavior, physical inactivity and body composition in relation to idiopathic infertility among men and women.	
294	12-year follow-up study of the c-reactive protein in Iranian middle-aged women: Isfahan cohort study. **2019**, 9, 129	
293	Is normal body mass index a good indicator of metabolic health in Azar cohort population?. **2019**, 11, 53-60	1
292	Avaliação do efeito da quercetina em ratos Wistar com Síndrome Metabólica. **2019**, 44, 149-155	

291	The effect of metabolic risk factors on cancer mortality among blacks and whites.. **2019**, 8, S389-S396	0
290	Genetic variants on chromosome 19 (rs439401 and rs4420638) are associated with obesity and high blood pressure in the Algerian population. **2019**, 23, 608-614	
289	Aort Kapak Kalsifikasyon Derecesi ile Epikardiyal Yağ Dokusu Kalınlığı Arasındaki İlişki.	
288	The association between coronary artery disease and nonalcoholic fatty liver disease and noninvasive imaging methods. **2019**, 16, em165	
287	Dietary Melatonin Protects Against Behavioural, Metabolic, Oxidative, and Organ Morphological Changes in Mice that are Fed High-Fat, High- Sugar Diet. **2020**, 20, 570-583	3
286	Relation of Visceral Adipose Tissue to Coronary Artery Calcium in Thai Patients. **2020**, 103, 434-441	
285	Coexistence of fibromyalgia and metabolic syndrome in females: The effects on fatigue, clinical features, pain sensitivity, urinary cortisol and norepinephrine levels: A cross-sectional study. **2021**, 36, 26-37	
284	Development and Validation of a Stability-indicating RP-HPLC Method for the Simultaneous Determination of Telmisartan and its Related Substances in Telmisartan Bulk Drug Substance. **2020**, 10, 577-589	0
283	Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study). **2021**, 22, 756	3
282	Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota. **2021**, 193, 789-798	4
281	Association between 25 Hydroxyvitamin D Concentrations and Lipid Profiles in Japanese with Type 2 Diabetes Mellitus. **2021**, 67, 266-272	
280	Recent Trends of Metabolic Syndrome and Its Components in Military Recruits from Saudi Arabia. **2021**, 8,	0
279	Association between sarcopenic obesity with insulin resistance and metabolic syndrome. **2021**,	1
278	The challenges of metabolic disorders in Indonesia: focus on metabolic syndrome, prediabetes, and diabetes. **2021**, 29, 350-3	2
277	Defective FXR-SHP Regulation in Obesity Aberrantly Increases Expression, Promoting Insulin Resistance and Fatty Liver. **2021**, 70, 733-744	5
276	Phytochemicals from the Leaves of Cyclocarya paliurus and their 11β-HSD1 Enzyme Inhibitory Effects. **2021**, 18, e2000772	3
275	Metabolic syndrome and kidney disease. **2022**, 763-777	
274	Nutritional and metabolic management of obesity and the metabolic syndrome in patients with chronic kidney disease. **2022**, 779-792	

273	ADIPQ gene polymorphism rs266729 (-11377 C>G) and metabolic syndrome risk in a Mexican population of western Mexico. **2021**, 38, 67-72	0
272	Obesity and schizophrenia: New drugs, new hopes. **2020**, 52, 113-130	
271	Systemic Inflammation in the Morbidly Obese Patient. **2020**, 125-132	
270	Different Faces of Obesity in Cardiovascular Diseases: Culprit or Protector. **2020**, 3-13	
269	Fetal-Neonatal Lifestyle Basis of the Adult Metabolic Syndrome Patients.	
268	Role of the Nox4/AMPK/mTOR signaling axe in adipose inflammation-induced kidney injury. **2020**, 134, 403-417	0
267	Tri-Ponderal Mass Index Reference Values for Screening Metabolic Syndrome in Children and Adolescents: Results From Two National-Representative Cross-Sectional Studies in China and America. **2021**, 12, 739277	0
266	Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. **2021**,	1
265	Inhibition of acid sphingomyelinase by imipramine abolishes the synergy between metabolic syndrome and periodontitis on alveolar bone loss. **2021**,	0
264	Prevalence of metabolic syndrome with international diabetes federation criteria and ATP III program in patients 65 years of age or older.	
263	Non Alcoholic Steathohepatitis (NASH). **2006**, 195-198	
262	Innovative Models for the Delivery Preventive Cardiovascular Care. **2006**, 325-338	
261	The Metabolic Syndrome: Definitions, Controversies and Clinical Utility. **2008**, 3-24	
260	Epidemiology of the Metabolic Syndrome and Related Disorders in Children and Adolescents. **2008**, 25-43	
259	Isoflavones. **2020**, 199-244	
258	Metabolic syndrome and lifestyle factors among type 2 diabetes mellitus patients in Dessie Referral Hospital, Amhara region, Ethiopia. **2020**, 15, e0241432	2
257	Predictors and prognostic role of low myocardial mechano-energetic efficiency in chronic inflammatory arthritis. **2021**, 39, 53-61	1
256	Cardiometabolic aspects of polycystic ovarian syndrome. **2007**, 3, 55-63	27

255	Metabolic syndrome and sleep apnea. **2008**, 12, 81-6	8
254	The metabolic syndrome - background and treatment. **2006**, 14, 301-308	2
253	Identifying adolescent metabolic syndrome using body mass index and waist circumference. **2008**, 5, A115	18
252	Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins. **2005**, 97, 1600-7	8
251	Assessing the prevalence of the Metabolic Syndrome according to NCEP ATP III in Germany: feasibility and quality aspects of a two step approach in 1550 randomly selected primary health care practices. **2006**, 4, Doc07	20
250	Effect of a multifaceted, church-based wellness program on metabolic syndrome in 41 overweight or obese congregants. **2010**, 7, A81	7
249	Metabolic syndrome and coronary artery disease in Ossabaw compared with Yucatan swine. **2010**, 60, 300-15	105
248	Cardiovascular risk factor variation within a Hispanic cohort: SWAN, the Study of Women's Health Across the Nation. **2010**, 20, 396-402	28
247	Identification of modifiable chronic kidney disease risk factors by gender in an African-American metabolic syndrome cohort. **2010**, 37, 133-41, 148; quiz 142	7
246	Identifying metabolic syndrome in African American children using fasting HOMA-IR in place of glucose. **2011**, 8, A64	19
245	The pathophysiology of obesity and its clinical manifestations. **2007**, 3, 856-63	34
244	Association between sleep duration and metabolic syndrome in a population-based study: Isfahan Healthy Heart Program. **2011**, 16, 801-6	18
243	Chronic diseases in captive geriatric female Chimpanzees (Pan troglodytes). **2012**, 62, 131-6	28
242	K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome. **2006**, 1, 169-80	
241	Heart rate recovery does not predict endothelial function in obese women. **2007**, 3, 101-105	1
240	Increased prevalence of subclinical atherosclerosis in rheumatoid arthritis patients of Indian descent. **2012**, 17, 20-5	9
239	Evaluation of heart rate reserve and high-sensitivity C-reactive protein in individuals with and without metabolic syndrome in Isfahan, Iran. **2012**, 8, 70-5	2
238	An exploratory analysis of dynamic change of metabolic syndrome in relation to the risk of developing cardiovascular disease in a chinese cohort. **2012**, 41, 26-34	2

237	Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on Highly Active Anti-Retroviral treatment in Jimma, South West Ethiopia. **2012**, 13, 43	32
236	Metabolic syndrome & Framingham Risk Score: observations from a coronary angiographic study in Indian patients. **2013**, 137, 295-301	12
235	High prevalence of subclinical thyroid dysfunction and the relationship between thyrotropin levels and cardiovascular risk factors in residents of the coastal area of China. **2013**, 18, e16-20	11
234	The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives. **2010**, 21, 280-5	16
233	Circuit resistance exercise improves glycemic control and adipokines in females with type 2 diabetes mellitus. **2009**, 8, 682-8	9
232	The prevalence of metabolic syndrome according to the Iranian Committee of Obesity and ATP III criteria in Babol, North of Iran. **2012**, 3, 410-6	8
231	Association between leptin gene G-2548A polymorphism with metabolic syndrome. **2013**, 18, 668-73	6
230	Chemerin regulation and role in host defense. **2014**, 3, 1-19	54
229	Valproic Acid as a potentiator of metabolic syndrome in institutionalized residents on concomitant antipsychotics: fat chance, or slim to none?. **2015**, 40, 126-32	10
228	Predictive Power for Type 2 Diabetes Mellitus using Dynamic Change of Metabolic Syndrome, Dynamic Change of Fasting Plasma Glucose, Metabolic Syndrome and Fasting Plasma Glucose. **2014** , 43, 432-40	1
227	Adiponectin: an adipokine with protective features against metabolic syndrome. **2015**, 18, 430-42	52
226	Metabolic syndrome and its associated risk factors in Iranian adults: A systematic review. **2015**, 6, 51-61	19
225	Adherence and Attrition in a Web-Based Lifestyle Intervention for People with Metabolic Syndrome. **2014**, 43, 1248-58	15
224	Applying the Framingham risk score for prediction of metabolic syndrome: The Kerman Coronary Artery Disease Risk Study, Iran. **2015**, 11, 179-85	17
223	Investigation of relationship of visceral body fat and inflammatory markers with metabolic syndrome and its components among apparently healthy individuals. **2015**, 8, 13067-77	7
222	Lipid Variables Related to the Extent and Severity of Coronary Artery Disease in Non-Diabetic Turkish Cypriots. **2015**, 44, 1196-203	1
221	Dietary Intake among American Indians with Metabolic Syndrome - Comparison to Dietary Recommendations: the Balance Study. **2013**, 4, 33-45	5
220	Weaknesses in the reporting of cross-sectional studies according to the STROBE statement: the case of metabolic syndrome in adults from Peru. **2015**, 46, 168-175	2

219	LDL Cholesterol Goal Attainment in Hypercholesterolemia: CEPHEUS Indonesian Survey. **2013**, 29, 71-81	5
218	Domain Analysis of Integrated Data to Reduce Cost Associated with Liver Disease. **2015**, 216, 414-8	
217	Effect of obesity on cardiovascular risk factors in urban population in South India. **2010**, 2, 145-9	10
216	Physical Activity Levels in a Community Lifestyle Intervention: A Randomized Trial. **2016**, 1, 45-51	5
215	Impact of Metabolic Syndrome on Ablation-Outcome in Patients with Atrial Fibrillation: A Systematic Review. **2013**, 5, 798	
214	Extra Atrial Disease in Patients with "Lone" Atrial Fibrillation. **2008**, 1, 107	
213	Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders. **2017**, 47, 8-21	11
212	Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome. **2017**, 3,	51
211	Sphingolipid regulators of cellular dysfunction in Type 2 diabetes mellitus: a systems overview. **2014**, 9, 553-569	5
210	Prevalence of Metabolic Syndrome in Patients with Lichen Planus: A Cross-sectional Study from a Tertiary Care Center. **2018**, 9, 304-308	4
209	Association between sleep duration and electrocardiographic ischemic changes in middle-aged population: Isfahan Healthy Heart Program. **2018**, 14, 115-121	1
208	Wild pistachio () oil improve metabolic syndrome features in rats with high fructose ingestion. **2018** , 21, 1255-1261	
207	Waist Circumference Cutoff Point Determination for Defining Metabolic Syndrome in Type 2 Diabetes Mellitus in Ethiopia. **2019**, 30, 48-58	
206	Chemerin stimulates aortic smooth muscle cell proliferation and migration via activation of autophagy in VSMCs of metabolic hypertension rats. **2019**, 11, 1327-1342	9
205	The Role of Insulin-Like Growth Factor-1 and Pregnancy-Associated Plasma Protein-A in Diagnosis of Acute Coronary Syndrome and Its Related Morbidities. **2020**, 4, e18	
204	Cardiovascular Disease Risk Assessment: Triglyceride/High-Density Lipoprotein versus Metabolic Syndrome Criteria. **2019**, 19, e00442	2
203	Prevalence and Risk Factors of High Blood Pressure among Adults in Banyuwangi Coastal Communities, Indonesia. **2020**, 30, 941-950	1
202	Is there an independent association between metabolic syndrome and smoking in Iranian adults? Results of a large multicenter national survey. **2021**, 12, 327-335	

201	Preventive Effect of Different Wild Pistachio Oils on Oxidative Stress Markers, Liver Enzymes, and Histopathological Findings in a Metabolic Syndrome Model. **2019**, 8, e1238	
200	Diet and exercise in the management of PCOS: Starting from the basics. **2022**, 97-115	
199	Increased odds of having the metabolic syndrome with greater fat-free mass: counterintuitive results from the National Health and Nutrition Examination Survey database. **2021**,	1
198	Fundamentals of Membrane Lipid Replacement: A Natural Medicine Approach to Repairing Cellular Membranes and Reducing Fatigue, Pain, and Other Symptoms While Restoring Function in Chronic Illnesses and Aging.. **2021**, 11,	2
197	Effects of antioxidant diet on the RBC indices in fructose-induced obesity rat model. **2021**, 8, 21-28	
196	Automated Whole-Liver MRI Segmentation to Assess Steatosis and Iron Quantification in Chronic Liver Disease. **2021**, 211027	2
195	The prognostic role of heart rate recovery after exercise and metabolic syndrome in IgA nephropathy. **2021**, 22, 390	
194	Enhanced prediction of renal function decline by replacing waist circumference with "A Body Shape Index (ABSI)" in diagnosing metabolic syndrome: a retrospective cohort study in Japan. **2021**,	0
193	Cardiometabolic risk in childhood cancer survivors: a report from the Children's Oncology Group. **2021**,	0
192	Association between metabolic syndrome and incidence of ocular motor nerve palsy. **2021**, 11, 23033	0
191	Ethnic disparity in metabolic syndrome and related obesity and health behavior: a community study in Taiwan. **2021**, 13, 134	0
190	A new phenotypic classification system for dyslipidemias based on the standard lipid panel. **2021**, 20, 170	1
189	The Double Burden of Malnutrition at the Individual Level Among Adults: A Nationwide Survey in the Philippines. **2021**, 8, 760437	1
188	Assessment of Serum Spexin Levels In Obese Adolescents with Metabolic Syndrome Antecedents: Preliminary Results. **2021**,	0
187	Effect of voluntary exercise upon the metabolic syndrome and gut microbiome composition in mice. **2021**, 9, e15068	1
186	Nonlinear Relationship Between AST-to-ALT Ratio and the Incidence of Type 2 Diabetes Mellitus: A Follow-Up Study. **2021**, 14, 8373-8382	1
185	Glucose metabolic disorder in Klinefelter syndrome: a retrospective analysis in a single Chinese hospital and literature review. **2021**, 21, 239	2
184	Food obesogens as emerging metabolic disruptors; a toxicological insight. **2021**, 217, 106042	0

183	Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. **2011**, 11, 29-35	
182	Prevalence and Risk Factors of High Blood Pressure among Adults in Banyuwangi Coastal Communities, Indonesia. **2020**, 30, 941-950	1
181	Prevalencia de Acantosis Nigricans y factores asociados a S□ndrome Metab□ico en Nobsa-Boyac□ **2021**, 8, 63-74	
180	An algorithm for the management of non-alcoholic fatty liver disease in primary care. **2021**, 12, 114-122	
179	Fat metabolism is associated with telomere length in six population-based studies. **2021**,	1
178	Association of Pericardial Fat with Cardiac Structure, Function and Mechanics: the Multi-Ethnic Study of Atherosclerosis.. **2022**,	1
177	Dietary approach to stop hypertension and obesity among Iranian adults: Yazd health study-TAMYZ and Shahedieh cohort. **2022**, ahead-of-print,	
176	Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort.. **2022**, 9612033211061481	0
175	A Noninvasive Risk Stratification Tool Build Using an Artificial Intelligence Approach for Colorectal Polyps Based on Annual Checkup Data.. **2022**, 10,	1
174	Association between Frequency of Toothbrushing and Metabolic Syndrome among Adolescents: A 5-Year Follow-Up Study.. **2022**, 19,	0
173	Issue of Waist Circumference for the Diagnosis of Metabolic Syndrome Regarding Arterial Stiffness: Possible Utility of a Body Shape Index in Middle-Aged Nonobese Japanese Urban Residents Receiving Health Screening.. **2022**, 1-10	0
172	Sphingolipid Profiling: A Promising Tool for Stratifying the Metabolic Syndrome-Associated Risk.. **2021**, 8, 785124	0
171	Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol.. **2022**, 11,	0
170	Metabolic syndrome components response to the conducted 16-week randomised-controlled training trial on an elliptical trainer. 1-7	
169	Correlates of cardiorespiratory fitness among overweight or obese individuals with type 2 diabetes.. **2022**, 10,	0
168	Personality traits at age 16 and risk of metabolic syndrome at age 46.. **2022**, 155, 110744	0
167	Left ventricular hypertrophy subtype and long-term mortality in those with subclinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA).	
166	Mild to moderate overweight in dogs: is there an impact on routine hematological and biochemical profiles, echocardiographic parameters and cardiac autonomic modulation?. **2022**, 1	1

165	Comparison of global definitions of metabolic syndrome in early pregnancy among the Rajarata Pregnancy Cohort participants in Sri Lanka.. **2022**, 12, 2009	0
164	Differential Glycemic Effects of Low- versus High-Glycemic Index Mediterranean-Style Eating Patterns in Adults at Risk for Type 2 Diabetes: The MEDGI-Carb Randomized Controlled Trial.. **2022**, 14,	2
163	Visceral Adiposity, Inflammation, and Testosterone Predict Skeletal Muscle Mitochondrial Mass and Activity in Chronic Spinal Cord Injury.. **2022**, 13, 809845	
162	Obesity-Associated Neuropathy: Recent Preclinical Studies and Proposed Mechanisms.. **2022**,	0
161	Analysis of gingival crevicular fluid biomarkers in patients with metabolic syndrome.. **2022**, 118, 104065	
160	Metabolic Syndrome, Obesity and Cancer Risk. **2022**, 95-119	
159	Frequency of Metabolic Syndrome in Type 2 Diabetes Mellitus in a Tertiary Care Hospital of Bangladesh.	
158	METABOLIC EFFECTS OF ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIA. **2022**, 14-16	
157	Association between preventable risk factors and metabolic syndrome.. **2022**, 17, 341-352	0
156	The Prevalence of Metabolic Syndrome, Scoring, and Comparison in People With and Without COPD: Evidence from Shahrekord PERSIAN Cohort Study.. **2022**,	
155	Health Behavior Profiles Among Midlife Women: Identifying At-Risk Subgroups for Metabolic Syndrome Using Latent Class Analysis.. **2022**,	
154	Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.. **2022**, 17, e0263931	2
153	The hypertriglyceridemic waist phenotype is associated with fatty liver and glycometabolic profiles in overweight and obese adults: a cross-sectional study.. **2022**, 12, 2410	0
152	Associations Between 25-Hydroxyvitamin D, Kidney Function, and Insulin Resistance Among Adults in the United States of America.. **2021**, 8, 716878	0
151	Potential of four definitions of metabolic syndrome to discriminate individuals with different 10-year cardiovascular disease risk scores: a cross-sectional analysis of an Iranian cohort.. **2022**, 12, e058333	0
150	Gut microbiota from Mexican patients with metabolic syndrome and HIV infection: an inflammatory profile.. **2022**,	2
149	Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. **2022**, 9, 812294	2
148	Trends in the Prevalence of Obesity and Its Phenotypes Based on the Korea National Health and Nutrition Examination Survey from 2007 to 2017 in Korea.. **2022**,	1

147	Metabolic syndrome and its relationship with shift work in petrochemical workers.. **2022**,	1
146	Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study.. **2022**, 17, e0264634	2
145	Intestinal Alkaline Phosphatase: A Review of This Enzyme Role in the Intestinal Barrier Function.. **2022**, 10,	3
144	Using noninvasive anthropometric indices to develop and validate a predictive model for metabolic syndrome in Chinese adults: a nationwide study.. **2022**, 22, 53	0
143	Feasibility of a Home-Based Exercise Program for Managing Posttransplant Metabolic Syndrome in Lung and Liver Transplant Recipients: Protocol for a Pilot Randomized Controlled Trial.. **2022**, 11, e35700	
142	The fundamentals of sex-based disparity in liver transplantation: Understanding can lead to change.. **2022**,	0
141	Food Insecurity and Cardiometabolic Markers: Results From the Study of Latino Youth.. **2022**,	0
140	Efficacy of cognitive-behavioural therapy for lifestyle modification in metabolic syndrome: a randomised controlled trial with a 18-months follow-up.. **2022**, 1-21	
139	Role of age, gender and ethnicity in the association between visceral adiposity index and non-alcoholic fatty liver disease among US adults (NHANES 2003-2018): cross-sectional study.. **2022**, 12, e058517	0
138	Impact of Obesity on Postprandial Triglyceride Contribution to Glucose Homeostasis, assessed with a semi-mechanistic model.. **2022**,	0
137	The Effect of Eight Weeks of Combined Training (Endurance-Intermittent Resistance and Endurance-Continuous Resistance) on Coagulation, Fibrinolytic and Lipid Profiles of Overweight Women. **2021**, 28, 3-9	
136	Feasibility of a Home-Based Exercise Program for Managing Posttransplant Metabolic Syndrome in Lung and Liver Transplant Recipients: Protocol for a Pilot Randomized Controlled Trial (Preprint).	
135	Physiological Changes and Pathological Pain Associated with Sedentary Lifestyle-Induced Body Systems Fat Accumulation and Their Modulation by Physical Exercise.. **2021**, 18,	1
134	Population study of the gut microbiome: associations with diet, lifestyle, and cardiometabolic disease.. **2021**, 13, 188	1
133	Epigenome-wide association study of serum urate reveals insights into urate co-regulation and the SLC2A9 locus. **2021**, 12, 7173	1
132	Role of Biomarkers as Prognostic Factors in Acute Peripheral Facial Palsy.. **2021**, 23,	
131	Metabolic comorbidities of psoriasis (Review).. **2022**, 23, 179	0
130	High-fat diet-induced metabolic syndrome increases ligature-induced alveolar bone loss in mice.. **2021**,	0

129	Combatting Sedentary Behaviors by Delivering Remote Physical Exercise in Children and Adolescents with Obesity in the COVID-19 Era: A Narrative Review.. **2021**, 13,	3
128	Abnormal glucose tolerance in women with prior gestational diabetes mellitus: a 4-year follow-up study.. **2022**, 1	0
127	Table_1.docx. **2020**,	
126	Data_Sheet_1.docx. **2018**,	
125	Presentation_1.PDF. **2018**,	
124	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.. **2022**, 101161HYPERTENSIONAHA12217982	7
123	Monitoring of inflammation using novel biosensor mouse model reveals tissue- and sex-specific responses to western diet.. **2022**,	
122	Prevalence of metabolic syndrome in patients with lichen planus: A cross-sectional study from a tertiary care center. **2018**, 9, 304	7
121	Nonalcoholic Fatty Liver Disease in Children.. **2021**, 17, 579-587	
120	Dietary Acid Load but Not Mediterranean Diet Adherence Score Is Associated With Metabolic and Cardiovascular Health State: A Population Observational Study From Northern Italy.. **2022**, 9, 828587	3
119	TLR4 mutation protects neurovascular function and cognitive decline in high-fat diet-fed mice.. **2022**, 19, 104	0
118	Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD.. **2022**, 11,	
117	Prevalence of overweight and obesity amongst patients with diabetes and their non-diabetic family members in Senwabarwana, Limpopo province, South Africa. **2022**, 64,	
116	Relation of Left Ventricular Hypertrophy Subtype to Long-Term Mortality in Those With Subclinical Cardiovascular Disease (from the Multiethnic Study of Atherosclerosis [MESA]).. **2022**,	
115	STUDY OF ASSOCIATION OF INFLAMMATORY MARKERS WITH METABOLIC SYNDROME IN PREDIABETIC PATIENTS AT TERTIARY CARE CENTER OF RAJASTHAN, INDIA. 103-106	
114	Lipid-Lowering Efficacy of Kuding Tea in Patients With Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. **2022**, 9, 802687	1
113	Metabolic syndrome, hyperglycemia, and type 2 diabetes. **2013**, 436-462	
112	Obesity and individual performance: the case of eSports.. **2022**,	

111	Cardiometabolic Syndrome and Effects of Yoga. **2022**, 167-195	
110	Inflammatory Diseases and Risk of Atherosclerotic Cardiovascular Disease: A New Focus on Prevention. **2022**, 247-270	1
109	Serum and glucocorticoid-regulated kinase 1: A potential target for anticancer therapy. **2022**, 223-238	
108	Eggs Improve Plasma Biomarkers in Patients with Metabolic Syndrome following a Plant-Based Dietâ A Randomized Crossover Study. **2022**, 14, 2138	0
107	Co-activating the AMPK signaling axis by low molecular weight fucoidan LF2 and fucoxanthin improves the HFD-induced metabolic syndrome in mice. **2022**, 94, 105119	
106	Associations of Cannabis Use across Adolescence and Early Adulthood With Health and Psychosocial Adjustment in Early Adulthood and Midadulthood in Men. **2022**, 16, 117822182210961	
105	Metabolic syndrome among patients with type 2 diabetes in Jordan: A cross-sectional study (Preprint).	
104	Antioxidant and Anti-Inflammatory Effect of the Consumption of Powdered Concentrate of Sechium edule var. nigrum spinosum in Mexican Older Adults with Metabolic Syndrome. **2022**, 11, 1076	
103	Psychological factors in relation to the 10-year Incidence of Metabolic Syndrome: the ATTICA Epidemiological Study (2002-2012). **2022**,	0
102	Risk of liver fibrosis in patients with prediabetes and diabetes mellitus. **2022**, 17, e0269070	0
101	The Relation Between Non-alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease. **2022**, 13,	
100	Metabolic syndrome among Nigerians with type 2 diabetes mellitus: A comparative study of the diagnostic criteria. **2021**, 1, 51	0
99	Melatonin Suppresses NLRP3 Inflammasome Activation via TLR4/NF-B and P2X7R Signaling in High-Fat Diet-Induced Murine NASH Model. Volume 15, 3235-3258	2
98	Normal fasting triglyceride levels and incident type 2 diabetes in the general population. **2022**, 21,	
97	The Effects of Eggs in a Plant-Based Diet on Oxidative Stress and Inflammation in Metabolic Syndrome. **2022**, 14, 2548	0
96	Relationship between Health Behaviors and Metabolic Syndrome in Cancer Survivors in Korea: Korean National Health and Nutrition Examination Survey, 2013â2018. **2022**, 12, 144-150	
95	Dissecting the clinical relevance of polygenic risk score for obesityâ cross-sectional, longitudinal analysis.	1
94	African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population. **2022**, 100728	0

93	The Association between Early-life Famine Exposure and Adulthood Obesity on the Risk of Dyslipidemia. **2022**,	
92	Huzurevinde Ya□yan 65 Ya□ve □erindeki Bireylerde Obezitenin Bili□sel Fonksiyonlar ile °li□kis. 367-375	
91	Atherogenic Index of Plasma is an Independent Risk Factor for Contrast Induced Nephropathy in Patients With Non-ST Elevation Myocardial Infarction. 000331972211107	0
90	The Diagnosis and Management of Cardiometabolic Risk and Cardiometabolic Syndrome after Spinal Cord Injury. **2022**, 12, 1088	0
89	Association between sarcopenic obesity with insulin resistance and metabolic syndrome. **2022**, 159, 1-5	
88	Activation of circulating monocytes by low-density lipoprotein□ risk factor for osteoarthritis?.	
87	The metabolic and molecular mechanisms of □mangostin in cardiometabolic disorders (Review). **2022**, 50,	1
86	Grape-seed proanthocyanidin extract (GSPE) modulates diurnal oscillations of key hepatic metabolic genes and metabolites alleviating hepatic lipid deposition in cafeteria-fed obese rats in a time-of-day-dependent manner.	0
85	Analysis of energy intakes, physical activities and metabolic syndrome according to the income level in Korean elderly people: Korean National Health and Nutrition Examination Survey 2016-2018. **2022**, 26, 028-035	
84	Narrative on Hydrogen Therapy and its Clinical Applications: Safety and Efficacy. **2022**, 28,	2
83	Early and Long-Term Effects of Abdominal Fat Reduction Using Ultrasound and Radiofrequency Treatments. **2022**, 14, 3498	
82	Risk assessment indicators and brachial-ankle pulse wave velocity to predict atherosclerotic cardiovascular disease. **2022**, 101, e29609	
81	Concordance between Different Criteria for Metabolic Syndrome in Peruvian Adults Undergoing Bariatric Surgery. **2022**, 11, 4692	
80	Anthropometric indices and cut-off points for screening of metabolic syndrome among South African taxi drivers. 9,	0
79	Sex Differences in Dietary Patterns of Adults and Their Associations with the Double Burden of Malnutrition: A Population-Based National Survey in the Philippines. **2022**, 14, 3495	
78	Saturated fats network identified using Gaussian graphical models is associated with metabolic syndrome in a sample of Iranian adults. **2022**, 14,	
77	Effects of daily functional acorn cake consumption on insulin resistance in individuals with obesity or overweight and the metabolic syndrome: a placebo-controlled randomised clinical trial. 1-9	
76	ASSOCIATION BETWEEN SERUM URIC ACID AND METABOLIC SYNDROME COMPONENTS AT TERTIARY CARE HOSPITAL, NORTH WEST RAJASTHAN. 175-178	

75	Reconsidering the role of glycemic control on cardiovascular disease risk in type 2 diabetes: A 21 st century assessment.	0
74	Processed meat consumption and associated factors in Chile: A cross-sectional study nested in the MAUCO cohort. 10,	
73	Longitudinal Trends, Determinants, and Cardiometabolic Impact of Adherence to the Mediterranean Diet among Greek Adults. **2022**, 11, 2389	1
72	Physical activity pattern and migraine according to aura symptoms in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) cohort: A cross-sectional study.	0
71	Identification of genetic variants related to metabolic syndrome by next-generation sequencing. **2022**, 14,	0
70	Disentangling Genetic Risks for Metabolic Syndrome.	
69	Down-regulating Interleukin-22/Interleukin-22 binding protein axis promotes inflammation and aggravates diet-induced metabolic disorders. **2022**, 557, 111776	0
68	Nutritional Epigenetics and Fetal Metabolic Programming. **2023**, 611-623	0
67	Helicobacter pylori and cardiovascular risk: Only a dead Helicobacter is a good Helicobacter ?.	0
66	Does metabolic syndrome increase the risk of fracture? A systematic review and meta-analysis. **2022**, 17,	0
65	The mediating function of obesity on endocrine-disrupting chemicals and insulin resistance in children. **2022**, 35, 1169-1176	0
64	Vitamin D status and prevalence of metabolic syndrome by race and Hispanic origin in US adults: findings from the 2007â2014 NHANES.	0
63	Depression and Sexual Stigma are Associated with Cardiometabolic Risk among Sexual and Gender Minorities Living with HIV in Nigeria. **2022**, Publish Ahead of Print,	0
62	Metabolic syndrome, obesity and cancer risk. **2022**, 32, 594-597	0
61	Synergism between the metabolic syndrome components and cancer incidence: results from a prospective nested caseâcontrol study based on the China Health and Retirement Longitudinal Study (CHARLS). **2022**, 12, e061362	0
60	Cross sectional descriptive study to study the prevalence of metabolic syndrome among patients with epilepsy on antiepileptic drugs in a tertiary care centre. **2022**, 8, 172-178	0
59	Positive or U-Shaped Association of Elevated Hemoglobin Concentration Levels with Metabolic Syndrome and Metabolic Components: Findings from Taiwan Biobank and UK Biobank. **2022**, 14, 4007	0
58	Insulin, Glucose, and the Metabolic Syndrome in Cardiovascular Behavioral Medicine. **2022**, 809-831	0

57	Physiology and Anesthesia for General and Bariatric Surgery. **2022**, 455-474	0
56	Overview of Neuroglia Activation, Chronic Neuroinflammation, Remodeling, and Impaired Cognition Due to Perivascular Adipose Tissue-Derived Extracellular Vesicle Exosomes in Obesity and Diabetes. **2022**, 3, 112-138	1
55	Association of serum secreted protein acidic and rich in cysteine-like protein 1 with metabolic measures and dyslipidemia among Chinese adults. 13,	0
54	Lifestage Sex-Specific Genetic Effects on Metabolic Disorders in an Adult Population in Korea: The Korean Genome and Epidemiology Study. **2022**, 23, 11889	0
53	Low-Dose Dioxin Reduced Glucose Uptake in C2C12 Myocytes: The Role of Mitochondrial Oxidative Stress and Insulin-Dependent Calcium Mobilization. **2022**, 11, 2109	0
52	Obesity and Metabolic Traits after High-Fat Diet in Iberian Pigs with Low Birth Weight of Placental Origin. **2022**, 11, 1533	0
51	Prognostic nutritional index as a risk factor for diabetic kidney disease and mortality in patients with type 2 diabetes mellitus.	0
50	Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer.	0
49	Prevalence of Metabolic Syndrome by the Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions and their Association with Coronary Heart Disease in an Elderly Iranian Population. **2009**, 38, 142-149	4
48	Loss of GPR40 in LDL receptor-deficient mice exacerbates high-fat diet-induced hyperlipidemia and nonalcoholic steatohepatitis. **2022**, 17, e0277251	0
47	Assessment of dietary quality in American adults and its association with sociodemographic and metabolic syndrome-related biomarkers: Comparison of two samples from Midlife in the United States (MIDUS) study (Preprint).	0
46	Anxiety, Insomnia, and Memory Impairment in Metabolic Syndrome Rats Are Alleviated by the Novel Functional Ingredients from Anacardium occidentale. **2022**, 11, 2203	0
45	Defining Preventive Cardiology: A Clinical Practice Statement from the American Society for Preventive Cardiology. **2022**, 100432	2
44	Metabolic Syndrome and Cardiometabolic Risk Factors in the Mixed Hypercholesterolemic Populations with Respect to Gender, Age, and Obesity in Asir, Saudi Arabia. **2022**, 19, 14985	2
43	The association between social jetlag and parameters of metabolic syndrome and type 2 diabetes: a systematic review and meta-analysis.	1
42	Identification of Novel Metabolic Subtypes Using Multi-Trait Limited Mixed Regression in the Chinese Population. **2022**, 10, 3093	0
41	Independent risk factors for an increased incidence of thromboembolism after lung transplantation.	0
40	Association between metabolic syndrome components and cardiac autonomic modulation in southern Indian adults with pre-metabolic syndrome: hyperglycemia is the major contributing factor. **1993**, 27, 49-59	0

39	Serum leptin and adiponectin in metabolic syndrome: A brief review. **2022**, 8, 95	0
38	Risk Factors for Acute Coronary Syndrome in Indians: A Reappraisal. 263246362211495	0
37	Effect of metabolic health and obesity on all-cause death and CVD incidence in Korean adults: a retrospective cohort study. **2023**, 13,	0
36	Metabolic disturbances during treatment with second generation antipsychotics. **2022**, 14,	0
35	Why Non-HDL Cholesterol is Preferred over Apolipoprotein B-100 (Apo B).	0
34	The Belgian Diabetes in Pregnancy Follow-Up Study (BEDIP-FUS): A Multi-Centric Prospective Cohort Study on the Long-Term Metabolic Risk across Different Degrees of Gestational Glucose Intolerance: Methodology and Design. **2023**, 12, 1025	0
33	Female-biased association of NOS2-c.1823C>T (rs2297518) with co-susceptibility to metabolic syndrome and asthma.	1
32	Association of Adiposity with Periodontitis and Metabolic Syndrome: From the Third National Health and Nutrition Examination Survey of United States. **2023**, 20, 2533	0
31	Association of the Toll-like receptor 4 and NOX4 gene and protein levels in asthmatic patients with metabolic syndrome: A caseâ□ontrol study. **2023**, 28, 11	0
30	A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia. **2023**, 13, 368	0
29	Subtypes of type 2 diabetes and their association with outcomes in Korean adults - A cluster analysis of community-based prospective cohort. **2023**, 141, 155514	0
28	The association between educational status and colorectal neoplasia: results from a screening cohort. **2023**, 38,	0
27	Pre- and postnatal exposure to secondhand tobacco smoke and cardiometabolic risk at 12´years: Periods of susceptibility. **2023**, 224, 115572	0
26	Individual and mixtures of polychlorinated biphenyls and organochlorine pesticides exposure in relation to metabolic syndrome among Chinese adults. **2023**, 877, 162935	0
25	Associations of perchlorate, nitrate, and thiocyanate with metabolic syndrome and its components among US adults: A cross-sectional study from NHANES. **2023**, 879, 163083	0
24	Associations of childhood adiposity with adult intimaâ□media thickness and inflammation: a 20-year longitudinal population-based cohort. **2023**, 41, 402-410	0
23	Identifying High-Risk Patients With Nonalcoholic Fatty Liver Disease. Publish Ahead of Print,	0
22	Association of obesity and cardiovascular disease and progress in pharmacotherapy: what is next for obesity?. **2023**, 46, 14-25	0

21	Association between sleep duration and metabolic syndrome: linear and nonlinear Mendelian randomization analyses. **2023**, 21,	0
20	The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review. **2023**, 2, 122-164	0
19	Effects of helminths and anthelmintic treatment on cardiometabolic diseases and risk factors: A systematic review. **2023**, 17, e0011022	0
18	Influence of enlarged waist circumference and hypertriglyceridemia in the severity of acute pancreatitis: A retrospective study. **2023**,	0
17	Cardiorespiratory Fitness and All-Cause Mortality in Women with Metabolic Syndrome.	0
16	Metabolic syndrome â cardiac structure and functional analysis by echocardiography; a cross sectional comparative study. **2022**,	0
15	The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. **2023**, 13, 929	0
14	Physical activity levels and energy intake according to the presence of metabolic syndrome among single-household elderly in Korea: Korean National Health and Nutrition Examination Survey 2016â2018. 11,	0
13	Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome. **2023**, 13, 376	0
12	Benefits of Whey Proteins on Type 2 Diabetes Mellitus Parameters and Prevention of Cardiovascular Diseases. **2023**, 15, 1294	0
11	Overview and New Insights into the Metabolic Syndrome: Risk Factors and Emerging Variables in the Development of Type 2 Diabetes and Cerebrocardiovascular Disease. **2023**, 59, 561	0
10	Identification of new co-diagnostic genes for sepsis and metabolic syndrome using single-cell data analysis and machine learning algorithms. 14,	0
9	Incident diabetes in course of antiretroviral therapy. Publish Ahead of Print,	0
8	Efficacy of traditional Chinese exercises in improving anthropometric and biochemical indicators in overweight and obese subjects: A systematic review and meta-analysis. **2023**, 102, e33051	0
7	Effect of propolis on mood, quality of life, and metabolic profiles in subjects with metabolic syndrome: a randomized clinical trial. **2023**, 13,	0
6	Prevalence of combined metabolic health and weight status by various diagnosis criteria and association with cardiometabolic disease in Korean adults. **2023**,	0
5	Gut Bacterial Communities in HIV-Infected Individuals with Metabolic Syndrome: Effects of the Therapy with Integrase Strand Transfer Inhibitor-Based and Protease Inhibitor-Based Regimens. **2023**, 11, 951	0
4	Variable dysregulation of circulating lipocalin-2 in different obese phenotypes: Association with vasodilator dysfunction. 1358863X2311616	0

3	Skeptical Look at the Clinical Implication of Metabolic Syndrome in Childhood Obesity. **2023**, 10, 735	0
2	Application of Machine Learning Algorithms to Predict Uncontrolled Diabetes Using the All of Us Research Program Data. **2023**, 11, 1138	0
1	The Metabolic Switch of Physical Activity in Non-Obese Insulin Resistant Individuals. **2023**, 24, 7816	0